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PHOSPHO1 is a skeletal specific phosphatase whose activity towards the lipid 
metabolites, phosphocholine (PCho) and phosphoethanolamine (PEth), results in the 
generation of inorganic phosphate (Pi) within matrix vesicles (MV). PHOSPHO1 
activity is essential for the initiation of biomineralisation. The genetic ablation of 
Phospho1 results in severe hypomineralisation of the skeleton and dentition. Neutral 
sphingomyelinase 2 (nSMase2, encoded by the Smpd3 gene) catalyses the breakdown 
of the membrane lipid sphingomyelin to generate ceramide and PCho. Similar 
hypomineralisation of the skeleton is noted in the Smpd3-/- mouse. This observation 
led to the hypothesis that nSMase2 and PHOSPHO1 work in tandem for the generation 
of Pi within MV.  
Despite knowledge of the phenotype associated with the absence of Phospho1 or 
Smpd3, little is known about the expression profiles of these genes during the initiation 
of extracellular matrix (ECM) mineralisation, or the regulation of these genes. This 
thesis characterised the expression of Phospho1, Smpd3 and other key genes associated 
with ECM mineralisation in in vitro models of mineralisation under exogenous 
phosphatase substrate-free conditions. Additionally, building on preliminary work in 
osteocytes, the regulation of Phospho1 and Smpd3 by parathyroid hormone (PTH) was 
investigated both in vitro and in vivo.  
Characterisation of MC3T3 osteoblast-like cell cultures, primary calvarial osteoblast 
and embryonic metatarsal organ cultures similarly revealed simultaneous and striking 
increases in the expression of PHOSPHO1 and nSMase2 prior to the onset of ECM 




mineralisation. In Phospho1-/- cell and organ cultures, ECM mineralisation was 
markedly diminished, and nSMase2 expression was notably reduced.  
The parathyroid hormone (PTH) regulation of Phospho1 and Smpd3 in osteocytes was 
confirmed in MC3T3 osteoblast-like cell cultures. Phospho1 and Smpd3 mRNA 
expression was strongly and rapidly (within 15 minutes) inhibited by PTH. 
Experiments with cycloheximide revealed that this was a direct effect not requiring 
protein synthesis. Further experimentation utilising the adenylyl cylase agonist, 
Forskolin and the PKA inhibitor, PKI (5-24), identified the cAMP-PKA signalling 
pathway as the mediator of the effects of PTH on Phospho1 and Smpd3 expression. In 
contrast, however, primary calvarial osteoblasts, human subchondral bone osteoblasts 
and murine embryonic metatarsal cultures all displayed an upregulation of Phospho1 
expression in response to a 24 h exposure to PTH. Although informative, these 
findings highlighted the need to investigate the PTH regulation of Phospho1 in vivo. 
The administration of PTH (80 µg/kg) enhanced the expression of Phospho1 and 
Smpd3 within 6 h and after 14 and 28-day intermittent exposure in the distal femur of 
male wild-type mice. The expression of the transcription factors, Runx2 and Trps1, 
which have been implicated in the regulation Phospho1 were similarly upregulated by 
these PTH exposures. I hypothesised that the upregulation of Phospho1 could provide 
a novel mechanism explaining the osteoanabolic effects of intermittent PTH (iPTH). 
Bone microarchitecture in response to iPTH was assessed in the tibiae of WT and 
Phospho1-/- mice by micro computed tomography. The absence of Phospho1 limited 
the anabolic effects of PTH in cortical bone but not in the metaphyseal trabecular bone.  




The work described within this thesis provides further evidence of the cooperative 
functions of nSMase2 and PHOSPHO1 in the initiation of skeletal mineralisation. The 
potent regulation of these enzymes in vivo by PTH offers an additional explanation of 
the anabolic effects of iPTH and forms part of an emerging body of evidence seeking 




















Despite appearances, the bone and cartilage which comprise the vertebrate skeleton 
are incredibly dynamic tissues. Bone is a composite material, comprising a flexible 
and durable collagenous scaffold onto which a calcium and phosphorous based mineral 
is deposited which provides strength and rigidity to the skeleton. This mineralisation 
of bone ensures that the skeleton can carry out its primary functions as a store of the 
essential minerals, calcium and phosphorous, as a protective armour to the vital organs 
and, as a resilient point of attachment for the body’s musculature.  
In 1999, an enzyme specific to the skeleton, named PHOSPHO1, was discovered. 
PHOSPHO1 is involved in the generation of a key component of the mineral phase of 
bone, phosphorous. As such, PHOSPHO1 is essential for successful mineralisation of 
the skeleton. Studies utilising genetically modified mice revealed that the absence of 
PHOSPHO1 gives rise to an inadequately mineralised skeleton which results in 
bowing of the long bones and greenstick fractures. Despite our understanding of the 
function of this enzyme, little is known about how and when, the gene which encodes 
the PHOSPHO1 enzyme is turned on and off (i.e. its expression).  
In this thesis, I have developed and characterised models of skeletal mineralisation, 
utilising cells and indeed whole bones derived from new born or embryonic mice. 
These models revealed that Phospho1 is expressed in advance of the mineralisation 
events, highlighting its importance in facilitating this process. In addition, this thesis 
provides the first evidence that parathyroid hormone, a major regulator of calcium 
levels in the body and important therapeutic in the treatment of osteoporosis, can 
potently regulate the expression of Phospho1 in the bones of mice. 
The findings of this thesis help to expand the knowledge surrounding the process of 
mineralisation. This knowledge helps not only our understanding of bone 
mineralisation pathologies, but also those of vascular mineralisation. In addition, my 
findings that parathyroid hormone enhances Phospho1 expression may provide a novel 
explanation for the therapeutic success of this agent in the treatment of low bone mass.    
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1.1. The structure and function of bone 
Bone is often considered to be a lifeless, inert structure. This could not be further from 
reality. Bone is in fact a composite tissue which, through the tightly choreographed 
actions of numerous cell types, undergoes dynamic reconstruction throughout life. The 
combination of organic and inorganic material properties produces a flexible and 
durable, yet resistant and robust material which is capable of serving its many 
functions, such as in the protection of the vital organs, as a site of attachment for the 
musculature of the body and as an adaptable store of mineral ions (Farquharson and 
Staines, 2011). More recently, bone has been shown to be a systemic regulator of 
energy metabolism and reproduction, highlighting its role as an endocrine organ 
(Oldknow et al., 2015). 
The mineralised extracellular matrix (ECM) of bone may take two distinct forms at 
the macro-level; cortical (compact), which forms the outer surface of flat bone and the 
shaft of the long bones, and trabecular (cancellous), found sandwiched between the 
compact bone of the flat bones and within the interior of the ends of long bones. 
Comprising around 80% of the total bone mass, cortical bone is composed or numerous 
osteons (Brandi, 2009). These osteons are formed from concentric rings of bone, or 
lamellae, surrounding a central Haversian canal through which vasculature, lymphatic 
and neural tissues penetrate to supply the bone. These microstructures afford cortical 
bone the ability to resist axial and torsional loads. Cancellous bone on the other hand, 
does not contain a Haversian system, but rather is composed of numerous thin 
trabeculae which exist in a highly organised 3D structure. The individual trabecular 
are arranged with respect to the prevailing mechanical loads acting on the bone 
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(Sommerfeldt and Rubin, 2001). The 3D structure of trabecular bone gives rise to a 
large surface area which allows cancellous bone to be more metabolically active than 
cortical bone. This results in a bone that is remodelled more quickly that compact bone.  
1.2. Bone formation 
1.2.1 Intramembranous ossification  
Much of the vertebrate skull, the sternum, scapula and clavicle are derived through the 
process of intramembranous ossification (Franz-Odendaal, 2011). The sesamoid bones 
(e.g. the patella) and bone formation following some fractures types are also mediated 
by this process (Schindeler et al., 2008). Intramembranous ossification occurs directly 
via the condensation and differentiation of neural-crest derived mesenchymal 
osteochondroprogenitor cells. Primarily under the control of Runx2, these cells 
differentiate into osteoblasts which secrete and mineralise a collagenous ECM 
(Komori, 2010). Occasionally, osteoblasts become entrapped in this mineralised ECM 
and develop into osteocytes, although the majority continue to secrete osteoid which 
separates them from the mineralising tissue. The mesenchymal cells on the perimeter 
of the ossifying bone remain and form the periosteum (Franz-Odendaal, 2011).  
1.2.2. Endochondral ossification 
In contrast to intramembranous ossification, endochondral ossification involves the 
progressive replacement of a cartilage anlage with bone ECM which is subsequently 
mineralised. Endochondral ossification is the process by which the majority of the 
vertebrate skeleton is formed. The cartilage model of the prospective bone initially 
arises through the condensation of lateral plate mesoderm-derived mesenchymal 
precursor cells at the future sites of skeletal development (Provot and Schipani, 2005). 
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Under the influence of the transcription factor Sox9, cells within these condensations 
differentiate into chondrocytes that proliferate and secrete a type II collagen and 
proteoglycan-rich ECM (Kronenberg, 2003). Chondrocyte proliferation within the 
cartilage model supports its expansion. Chondrocytes then progress through 
morphologically distinct zones, regulated by endocrine and paracrine factors. 
Parathyroid hormone related peptide (PTHrP) and Indian hedgehog (Ihh) are the key 
regulators of this progression of chondrocytes through the zones of the growth plate. 
In the developing bone, PTHrP is synthesised exclusively by perichondral cells and 
chondrocytes at the epiphyses of the prospective bone (Kronenberg, 2006). PTHrP, 
acting through the PTH 1 receptor (PTH1R), simultaneously maintains chondrocyte 
proliferation whilst delaying their further differentiation. Only those chondrocytes 
sufficiently distant to the source of PTHrP production are able to initiate further 
differentiation. The differentiation of proliferative chondrocytes to pre-hypertrophic 
chondrocytes brings about the synthesis of Ihh (Kronenberg, 2005). Ihh acts to 
maintain the  proliferative chondrocyte phenotype both directly, and indirectly through 
the upregulation of PTHrP in the epiphyseal chondrocytes. Furthermore, Ihh acts on 
the cells of the perichondrium stimulating their differentiation into osteoblasts 
(Kronenberg, 2003). These osteoblasts eventually form a bone collar extending around 
the cartilage anlage and ultimately form the periosteum. Thus, the PTHrP/Ihh feedback 
loop tightly controls the pool of proliferating chondrocytes in the growth plate and the 
site of formation of the bone collar. After cessation of proliferation, chondrocytes 
initiate a genetic program which stimulates a substantial volume expansion or 
hypertrophy. This hypertrophy is critical for longitudinal bone growth. In addition, 
hypertrophic chondrocytes direct the mineralisation of the surrounding ECM through 
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the release of specialised extracellular nano-structures, termed matrix vesicles 
(MVs)(Bonucci, 1967, Anderson, 1969) (see section 1.4.2.). Vascular invasion of the 
prospective bone is also regulated by hypertrophic chondrocytes which secrete 
vascular endothelial growth factor (Mackie et al., 2011). Blood vessel infiltration of 
the cartilaginous ECM allows the simultaneous invasion of osteoblasts, which secrete 
and mineralise a bone specific ECM utilising the existing  chondrocyte ECM as a 
scaffold, and haematopoetically derived osteoclasts which resorb the chondrocyte 
remnants and much of the cartilaginous matrix (Mackie et al., 2008). These processes 
establish the primary ossification centre (Figure 1.1). Secondary ossification centres 
are later established at the epiphyses of the bone, demarcating two cartilaginous 
growth plates, which are responsible for the linear growth of the bone during postnatal 
life (Farquharson and Jefferies, 2000).   
1.2.3. Appositional bone growth  
Appositional growth, whereby osteoblasts, primarily in the diaphysis of the bone, form 
new bone on the perimeter of existing bone, thus increasing its width, is an essential 
process which allows bone to respond to the increasing mechanical pressures during 
early foetal and postnatal life (Carter et al., 1996). Periosteal osteoblasts lay down new 
bone in successive laminae. This occurs in tandem with endosteal bone resorption by 
osteoclasts. The net effect of these actions is an increase in bone mass and marrow 
cavity diameter. In humans, unlike longitudinal bone growth which ceases upon sexual 
maturity through the ossification and fusion of the growth plate (Farquharson and 
Jefferies, 2000), appositional bone growth has been observed by tetracycline  
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Figure 1.1. The process of endochondral ossification.  
(A) Mesenchymal derived osteochondroprogenitor cells condense and aggregate at the 
site of the prospective bone, forming the cartilage anlage. (B) Endocrine and paracrine 
factors influence the development of morphologically distinct zones of chondrocytes 
at different stages of differentiation. Cells at the periphery of the condensations are 
directed to differentiate into osteoblasts, forming the bone collar and eventually the 
periosteum. (C) Hypertrophic chondrocyte mineralise their ECM through the release 
of MVs. Vascular invasion follows, bringing with it ECM resorbing osteoclasts. (D) 
The primary ossification centre is established through the resorbing actions of the 
osteoclasts and the formation and mineralisation of a bone ECM by osteoblasts. The 
founding of the secondary ossification centre, creates region of chondrocytes in the 
metaphysis which comprise the growth plate. Adapted from Kozhemyakina et al. 
(2015). 
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incorporation into newly mineralised bone in individuals in their 7th decade of life 
(Epker and Frost, 1966). 
1.3. Bone modelling and remodelling 
Maintenance of the mechanical and structural integrity of bone occurs throughout life 
by means of two processes; bone modelling and bone remodelling. Bone modelling, 
orchestrated by the independent actions of osteoblasts and osteoclasts, occurs 
primarily during growth, but also in the mature skeleton (Clarke, 2008). This process 
is essential for the adaptation of bone to variations in mechanical load, perhaps most 
strikingly exemplified in tennis players who display increased cortical thickness in the 
radius of their racket arm compared to the contralateral (and unloaded) arm (Calbet et 
al., 1998). The continued renewal of the skeleton occurs through the coupled and 
sequential actions of osteoclasts and osteoblasts. The process of remodelling occurs 
within temporary anatomical structures termed basic multicellular units (BMUs), 
comprising osteoclast resorption at its leading edge, followed by osteoid deposition 
and mineralisation by osteoblasts (Figure 1.2.) (Baron and Hesse, 2012). Remodelling 
may be either targeted (for the repair of micro-damage) or stochastic (for example in 
the procurement of calcium) and is tightly controlled at both an endocrine level and 
locally, by osteocytes (Hadjidakis and Androulakis, 2006). Disruption of bone 
remodelling can lead to pathologies of bone mass such as osteopetrosis, osteoporosis 
and Paget’s disease.  
1.3.1 Osteoblasts 
Multipotent, self-renewing mesenchymal stem cells (MSC) found within the stroma of 
several mesenchymal tissues are the source of a number of cell types including: 
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adipocytes, chondrocytes, fibroblasts, myoblasts and importantly, osteoblasts (James, 
2013). Despite their specialised role in the synthesis and subsequent mineralisation of 
the organic ECM of bone, osteoblasts possess only two transcripts which differentiate 
them from fibroblasts; Runx2 and Bglap (bone gamma-carboxylate protein, or 
Osteocalcin (OCN)) (Ducy et al., 2000). The expression of the Runx2 transcription 
factor is essential in triggering the osteogenic genetic program of MSCs. The absence 
of Runx2 results in the complete absence of osteoblasts (Komori et al., 1997, Komori, 
2010). Bone morphogenetic protein (BMP), transforming growth factor β (TGFβ), 
Wnt, and Ihh signalling are potent regulators of Runx2 expression (Ducy et al., 2000). 
After lineage commitment, the actions of Sp7 (encoding Osterix) and Wnt signalling 
advance the progression of precursors to the osteoblast phenotype, whilst 
simultaneously blocking the differentiation of chondrocytes (James, 2013). Maturation 
of osteoblasts is accompanied by significant production of ECM proteins (mainly type 
I collagen), tissue non-specific alkaline phosphatase (TNAP) and OCN. The secretory 
nature of osteoblasts is exemplified by their numerous mitochondria, Golgi, 
endoplasmic reticulum and ribosomes. Mature osteoblasts are cuboidal and reside on 
the surface of bone and are ultimately resigned to three different fates; apoptosis, 
quiescence or they become embedded in the bone matrix and differentiate into 
osteocytes (Maes et al., 2007, Kim et al., 2012). In addition to their role in bone 
formation, osteoblasts also orchestrate resorption through the expression of molecules 
which regulate osteoclast formation and activity (see section 1.3.2). 
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Figure 1.2. Bone remodelling and skeletal cell morphology 
(A) Physiological bone remodelling involves both bone resorption and subsequent 
bone formation carried out by osteoclasts (OCs) and osteoblasts (OBs) respectively 
and orchestrated by the osteocytes (OCYs). Bone lining cells (BLCs). Adapted from 
Baron and Hesse (2012). (B) Electron micrograph of actively resorbing osteoclast (C) 
Cuboidal osteoblasts lining the surface of a newly formed trabecula. Adapted from de 
la Rosa, (2014). (D) Electron micrographs showing the extensive dendritic processes 
of osteocytes within bone. B & D provided from the bone research society by kind 
permission of Alan Boyde and Kevin Mackenzie. 
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1.3.2. Osteoclasts 
Osteoclasts are large multinucleated cells which function to resorb mineralised bone 
and cartilage and together with osteoblasts are essential for remodelling of the 
skeleton. Partially committed, haematopoetically derived granulocyte-macrophage 
colony forming units are the precursors to osteoclasts (Zaidi et al., 2003, Yamashita et 
al., 2012). Osteoblasts and osteocytes, as well as stromal cells and T-lymphocytes 
secrete receptor activator of nuclear factor kappa B ligand (RANKL) which is a potent 
inducer of osteoclast activity and osteoclastogenesis. Binding of RANKL to the 
RANK receptor stimulates the recruitment of TNF receptor associated family 6 
(TRAF-6) which triggers a number of downstream signalling pathways to initiate the 
osteoclast genetic program (Zaidi et al., 2003). Osteoblasts additionally control 
osteoclastogenesis through secretion of the RANKL decoy receptor, osteoprotegerin 
(OPG) (Simonet et al., 1997). The expression of the osteoclast regulatory molecules is 
tightly controlled by endocrine factors such as oestrogen and PTH (Zaidi et al., 2003). 
Also, the binding of the αvβ3 Integrin to amino-acid motifs within the bone matrix 
stimulates osteoclasts resorption (Teitelbaum, 2000). Through filamentous actin 
remodelling, polarized osteoclasts seal their perimeter onto the bone surface enclosing 
a ruffled membrane within the resorption lacunae. Acidification of this 
microenvironment to aid dissolution of hydroxyapatite (HA) mineral, is achieved 
through the actions of vacuolar H+-ATPase and Cl- channels which subsequently 
generate hydrochloric acid (Zaidi et al., 2003). The demineralised ECM is 
subsequently degraded by matrix metalloproteinases, tartate resistant acid phosphatase 
and the lysosomal cysteine protease, cathepsin K (Charles and Aliprantis). Extensive 
endocytosis at the ruffled border, traffics bone breakdown products to the osteoclasts 
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opposing surface (Stenbeck and Horton, 2004). Whilst it is yet to be established 
whether osteoclasts resorb bone in a targeted or stochastic manner during bone 
remodelling, it is clear that any disturbance of osteoclast formation and function can 
have profound effects on bone mass (Teitelbaum, 2000).   
1.3.3. Osteocytes 
Comprising up to 95% of the cellular component of bone, and one of the longest lived 
cells of the body, osteocytes are essential orchestrators of bone mass and systemic 
phosphate homeostasis (Bonewald, 2011). Although the precise genetic and molecular 
mechanisms are yet to be elucidated, subpopulations of osteoblasts on the bone surface 
are the osteocyte’s precursor. The temporally regulated expression of key osteocyte 
markers leads to substantial morphological changes and embedding of the osteocyte 
within the mineralised ECM. The early osteocyte marker E11 (podoplanin) is believed 
to regulate these early morphological changes (Bonewald, 2011, Staines et al., 2016). 
Evidence is emerging that osteocytes actively invade the ECM, rather than being 
passively trapped (Prideaux et al., 2012). Residing in discrete lacunae, osteocytes use 
their dendritic processes to connect to adjacent osteocytes or the vasculature through 
so called canaliculi. Osteocytes transduce both mechanical and hormonal inputs into 
molecular signalling events which regulate bone remodelling by osteoblasts and 
osteoclasts (Dallas et al., 2013). Indeed, osteocytes as opposed to osteoblasts or 
stromal cells are the major source of RANKL and OPG, implicating a direct role in 
modulating bone resorption (Nakashima et al., 2011). The late osteocyte marker and 
potent Wnt signalling antagonist, sclerostin (SOST, encoded by the Sost gene) has 
attracted a lot of attention with regard to its role in regulating bone mass. SOST inhibits 
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low-density lipoprotein receptor-related protein 5  (LRP5) mediated increases in bone 
mass, and its expression in osteocytes is modulated by mechanical loading and 
endocrine signalling (Robling et al., 2008, Kramer et al., 2010). 
Osteocytes are powerful regulators of phosphate homeostasis and mineralisation 
through the expression of PHEX (phosphate-regulating gene with homologies to 
endopeptidases on the X chromosome), and the SIBLING proteins (see section 
1.5.1.1.), dentin matrix protein 1 (DMP-1) and matrix extracellular 
phosphoglycoprotein (MEPE) (Bonewald, 2011). The endocrine function of the 
osteocyte was confirmed in 2004 through characterisation of the fibroblast growth 
factor 23 (FGF-23) knockout mouse. Fgf23 is highly expressed by osteocytes and its 
ablation results in elevated serum Pi and increased renal Pi reabsorption and 25-
hydroxyvitamin D3-1α-hydroxylase activity (Shimada et al., 2004). Increased 
circulating FGF-23 levels has been linked with the progression of chronic kidney 
disease (particularly the bone wasting phenotype) and vascular calcification 
(Bonewald and Wacker, 2013).  
1.3.4. Endocrine regulation of bone remodelling. 
Hormones are powerful regulators of bone remodelling and mineral homeostasis 
through their direct and indirect actions on bone cells. Indeed, their actions on the 
skeleton are so varied that they are beyond the scope of this thesis. In brief however, 
it is well accepted that the gonadal sex steroids are the primary regulators of bone 
remodelling in adults. Oestrogen in particular, through the loss of bone mass associated 
with its deficiency in post-menopausal women has been identified as having an 
influential role. Oestrogen deficiency leads to increased remodelling, with a net 
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resorptive effect, as the action of oestrogen at the skeleton is primarily to inhibit 
osteoclastogenesis (via enhanced osteoblast expression of OPG) (Hadjidakis and 
Androulakis, 2006, Walsh, 2015).  
Glucocorticoids are catabolic to the skeleton, impairing the differentiation of 
osteoblasts through inhibition of Runx2 and BMP signalling. Furthermore, 
osteoclastogenesis and osteoclast survival are enhanced in part by an increase in 
RANKL expression (Canalis and Delany, 2002). Investigations into the precise role of 
dexamethasone on osteoblast differentiation have provided conflicting results and, 
thus, the mechanism of dexamethasone’s action in vitro are still to be fully elucidated. 
Leptin, originally classified as an energy regulating hormone, indirectly regulates bone 
remodelling via the sympathetic nervous system. Leptin knockout, or leptin receptor 
knockout mice are grossly obese and hypogonadal and yet they exhibit around three 
times more bone mass than control mice (Ducy et al., 2000). Further knockout studies 
revealed that the action of leptin on the sympathetic nervous system is transmitted to 
osteoblasts through the β2 adrenergic receptor. Receptor activation results in signalling 
cascades which ultimately result in the upregulation of RANKL expression and 
increased osteoclastogenesis and bone resorption (Karsenty, 2006).  
The active thyroid hormone, 3,5,3′-L-triiodothyronine (T3), increases bone 
remodelling primarily through its actions on osteoblasts where its stimulates their 
differentiation and activity through numerous pathways (Williams, 2013). Importantly 
however, T3 also increases the expression of RANKL by osteoblasts, and patients with 
hyperthyroidism exhibit reduced bone mass (Britto et al., 1994).  
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One of the best characterised regulators of bone remodelling is (PTH). As a major 
focus of this thesis, PTH is discussed in more detail below.  
1.3.5. Parathyroid hormone 
PTH is a peptide hormone synthesised and secreted by the chief cells of the parathyroid 
glands. PTH mRNA encodes a 115 amino acid PreProPTH protein, which through two 
successive proteolytic cleavages at the amino terminal, is converted to the 84 amino 
acid protein of PTH (Potts Jr et al., 1982). PTH acts to elevate serum Ca2+ 
concentrations.  A diverse range of cellular functions are mediated by Ca2+ and as such 
serum Ca2+ must be maintained within a very narrow range to prevent disturbance to 
these functions and pathophysiology (Brown, 2015). The calcium sensor receptor (a 
G-protein coupled receptor (GPCR)), expressed on the surface of the chief cells, 
detects perturbations in serum Ca2+ concentration and in response to hypocalcaemia 
induces the rapid release of secretory vesicles containing PTH (Brown, 2015). PTH 
acts on the target tissues of bone and kidney through interaction with the PTH1R, 
another GPCR. Ligand binding can induce either adenylate cyclase or phospholipase C 
directed signalling pathways (Figure 1.3.)(Gardella, 2015). It is generally recognised 
that only the first 34 amino acids are required for both the binding and signal inducing 
function of PTH (Pioszak and Xu, 2008). The classical actions of PTH are: i) increased 
reabsorption of Ca2+ in the thick ascending limb and distal convoluted tubule of the 
kidney, in part through the enhancement of transient receptor potential vanilloid 5 
(TRPV5) expression. ii) increased activity of 1α-hydroxylase enzyme which catalyses 
the conversion of 25(OH)VitD3 to the 100-fold more potent 1,25(OH)2Vitamin D3 
(Vitamin D) in the proximal tubule of the kidney. Vitamin D acts on the intestine to 
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increase reabsorption of Ca2+ and phosphate. iii) increased mobilisation of Ca2+ (and 
phosphate) from the mineral stores of bone by increasing bone remodelling (Potts, 
2005, Revollo and Civitelli, 2015). These actions of PTH are hierarchal in the response 
to low calcium levels. By far the fastest mechanism to restore serum Ca2+ levels is via 
increased reabsorption in the kidney whereas increased resorption and mobilisation of 
mineral from bone is the last line of defence against low circulating calcium levels 
(Revollo and Civitelli, 2015). 
Osteoblasts and osteocytes are regarded as the primary cell types eliciting the effects 
of PTH in bone. Osteoclasts have been shown to express the PTH1R in vitro, although 
a number of studies have failed to show their activation by PTH (Dempster et al., 
2005). The effects of PTH on bone are truly pleiotropic and depend, in part, on the 
duration of exposure. A greater understanding of these effects came in large through 
pre-clinical and clinical studies of PTH administration and pathologies of PTH 
secretion (Poole and Reeve, 2005, Silva and Kousteni, 2015). Indeed, the intermittent 
exposure to low doses of PTH is anabolic to the skeleton, whereas the continuous 
exposure to elevated serum PTH leads to osteocatabolic effects (Silva and Bilezikian, 
2015).  
The anabolic effects of PTH have been established over a number of years utilising 
various animal models and more recently, extensive clinical trials (Neer et al., 2001, 
Rubin et al., 2002, Langdahl and Harsløf, 2011). The evidence from these studies now 
favours the use of low-dose intermittent administration of PTH to induce the anabolic 
effects on the skeleton. The method of administration potently stimulates trabecular 
bone formation and significantly reduces the risk of non-vertebral fractures (Silva and 
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Bilezikian, 2015). These anabolic effects are enacted through signalling pathways 
which modulate osteoblasts and osteocytes. The result is a plethora of effects 
(discussed in more detail in Chapter 5) which include, but are not limited to, the 
increased recruitment, differentiation, activity and survival of osteoblasts alongside 
the inhibition of Sost expression by osteocytes. Indeed during the initial months of 
PTH therapy, there is a significant rise in bone formation markers (typically serum 
procollagen type I N-terminal propeptide (P1NP)) without an accompanying rise in 
bone resorption markers (Lindsay et al., 2016). This bone modelling phase is described 
as the anabolic window and is limited by a concomitant rise in bone resorption; the 
two processes eventually becoming more aligned and thus the expansion of bone mass 
is stemmed (Pazianas, 2015). 
The increases in BMD reported in the literature, highlight a role for the skeletal 
phosphatases which have been shown to be essential in the mineralisation process. 
1.4. Matrix mineralisation  
The material properties of bone are dictated by its two primary components, the 
collagenous ECM and the hydroxyapatite (HA) mineral deposited within and upon 
that. The interaction of these elements creates a rigid yet fracture resillient material. 
Alterations to the intricate structure of the collagen-mineral composite can have a 
harmful impact on bone strength, particularly in old age and disease. Mineralisation 
process is governed by physicochemical and biochemical factors which regulate the 
deposition of HA within the ECM (Millán, 2012). If the process is not properly 
regulated, the result can be too little of the mineral or too much - either of which can   
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Figure 1.3. Schematic representation of the classical downstream signalling 
pathways induced by PTH.  
Ligand binding to the PTH1R can activate either the cAMP/PKA signalling pathway 
(through stimulation of adenylyl cyclase (AC)) or the PKC signalling pathway 
(through the stimulation of phospholipase C β (PLCβ) and production of 
diacylglycerol (DAG) and inositol triphosphate (IP3)). PKA and PKC can 
phosphorylate a range of downstream effector proteins. These proteins can translocate 
to the nucleus and modulate the expression of target genes through interaction with the 
DNA. 
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compromise bone health. Unfortunately, many aspects of the mineralisation process 
remain poorly understood, however, through studying the molecular players in the 
mineralisation process, we have the opportunity to gain a better understanding of the 
mechanism of mineralisation and what happens when the process goes awry. 
Suchknowledge is imperative for the identification of therapeutic targets against 
disorders of this process. 
1.4.1. The role of collagen in matrix mineralisation 
Type I collagen is the principal component of the mineralised tissue of bone, dentin 
and cementum. It has long been accepted that the collagenous matrix not only provides 
a scaffolding for mineral propagation, but the stereochemistry of the collagen molecule 
and the fibrillary network is capable of nucleating HA (Glimcher, 1987, Landis and 
Jacquet, 2013). This is perhaps the most accepted mechanism explaining the initial 
nucleation of apatite crystals within the ECM and has been extensively examined. 
Type I collagen comprises around 85-90% of the ECM of mineralised tissues of 
mammals and is constructed from three peptide chains, stabilised in a triple helical 
collagen molecule by hydroxylation of proline and lysine residues (Landis and Silver, 
2008). These collagen molecules (300 nm in length) self-assemble in the extracellular 
space into microfibrils. In 2D, this assembly possess results in 40nm ‘hole’ regions 
between the ends of adjacent helices. Layers of these microfibrils are crosslinked in 
such a manner that the hole regions line up creating channels within the now 3D 
collagen fibril (Landis and Jacquet, 2013). The stereo-configuration of the collagen 
fibril results in charged amino acid residues flanking the hole regions which promotes 
the infiltration of Ca2+ and Pi from the extracellular fluids and which act as potential 
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nucleation sites (Landis and Silver, 2008, Nudelman et al., 2010). Newly formed, thin, 
plate-like crystals of HA are organised such that their c-axis is parallel with the 
associated collagen molecule. Growth of apatite crystals occurs preferentially along 
the axis of the collagen helices (Figure 1.4.) (Landis, 1999). Non-collagenous proteins, 
in particular negatively charged proteins are implicated as facilitators of amorphous 
calcium phosphate (ACP) movement into the collagen fibril prior to its nucleation 
within the hole sites (Landis et al., 1993, Nudelman et al., 2010). For example, in the 
absence of the negatively charged, aspartate rich region of Dentin Matrix Protein 1 
(DMP1), mineral formation of collagen matrices only occurs in the extrafibrillar 
environment (Nudelman et al., 2010). Other mechanisms for the initiation of ECM 
mineralisation may exist (see 1.4.2) and of note is the recent observation that mineral 
may be formed on the outside of the collagen fibrils where it forms elongated mineral 
plate structures (McNally et al., 2012).   
1.4.2. The role of matrix vesicles in matrix mineralisation  
Whilst many in the field of bone mineralisation see no alternative to the collagen 
mediated mechanisms of HA nucleation and propagation, others believe that the 
initiation of skeletal mineralisation occurs within membrane limited MVs. Ground 
breaking electron microscopy studies by Bonucci (1967) and Anderson (1967) were 
the first to identify and describe the presence of mineral crystals within ‘’roundish 
bodies’’ adjacent to collagen fibrils. We now know with hindsight, that the 
extracellular lipid staining at the mineralisation front of rat growth plates and foetal 
human mandibles described by Irving (1959), is the Ca2 +-binding, acidic 
phospholipids of the MV (Wuthier and Lipscomb, 2011). To date MVs have been  
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Figure 1.4. MV and collagen directed mineralisation observed by electron 
microscopy.  
(A-B) Nucleation of ACP within MVs derived from bovine and rat growth plates 
(adapted from Ali et al. (1970) and Anderson et al. (2005a) respectively) (C) Eruption 
of the needle-like crystal of immature HA from the MV to the ECM (Millán, 2012). 
White arrows indicate the location of the HA crystals. (D) Localisation of ACP to the 
hole zones of collagen fibrils (Nudelman et al., 2010) (E-F) Apatite crystals propagate 
along the axis of the collagen fibrils (adapted from Nudelman et al. (2010) and Millán 
(2012) respectively). White arrow indicates the axis of the collagen fibrils. Black arrow 
indicates the electron dense HA crystals. 
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shown to be involved in the initiation of HA formation during growth plate 
mineralisation (Anderson, 1969), intramembranous ossification (Bernard and Pease, 
1969), dentin mineralisation (Sisca and Provenza, 1972), antler calcification (Sayegh 
et al., 1974), and pathological calcifications of aortic valves, neoplasms and tendons 
(Kim, 1976, Sela and Bab, 1979). MVs are encapsulated by a trilaminar membrane 
and are typically around 100-400 nm in diameter. Their biogenesis from the parent cell 
is contested, with polarised budding and apoptotic cell membrane rearrangement both 
being offered as possible mechanisms (Cui et al., 2016). Although apoptotic bodies 
are capable of mineral accrual, morphological studies have shown that the osteoblast 
and growth plate chondrocyte membranes are intact post MV release. Furthermore, 
Kirsch et al. (2003) identified alizarin red staining in the chick growth plate, prior to 
any TUNEL staining, suggesting that MV release and mineralisation occurs prior to 
hypertrophic chondrocyte apoptosis. Proteomic characterisation of MVs from Saos-2 
human osteosarcoma cells revealed 93% of the proteins are also present on the apical 
membrane of microvilli of the parent cell (Thouverey et al., 2009). This study also 
identified a number of cytoskeletal remodelling and vesicle trafficking proteins within 
microvilli, implicating a coordinated and active mechanism governing MV 
manufacture and release. Of interest, MV formation and release also appears to be 
spatially regulated. In the growth plate, they are only released from the lateral edges 
of the hypertrophic chondrocytes and not the apical and basal surfaces, this is 
consistent with sites of cartilage ECM mineralisation i.e. within the longitudinal septae 
and not the transverse septae of the growth plate (Reinholt and Wernerson, 1988). 
Although MVs share many of the same proteins and lipids with their parent cells, the 
precise composition is notably different (Genge et al., 2003, Xiao et al., 2009). 
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The trilaminar lipid membrane of MVs undergoes dynamic changes throughout the 
mineralisation process. Pioneering studies by Wu et al. (2002), examining the temporal 
changes in lipid composition of chick growth plate cartilage derived MVs, showed that 
MV membrane lipids underwent catabolism during in vitro calcification. In particular, 
phosphatidylinositol (PI), phosphatidylethanolamine (PE) and sphingomyelin (SM) 
were rapidly degraded, whereas phosphatidylcholine was degraded more slowly. 
Furthermore, the inner leaflet of MV membranes shows selective enrichment in the 
anionic phospholipid, phosphatidylserine (PS) where it is typically found as PS-Ca2+-
Pi complexes (Wu et al., 2002). In vitro, formation of PS-Ca
2+-Pi complexes show a 
potent ability to induce HA precipitation when incubated in synthetic cartilage lymph 
(Wu et al., 2009). Gain of function mutations in the PS synthase 1 gene, which 
catalyses the exchange of choline with serine on phosphatidylcholine (PC), has been 
shown to cause the rare Lenz–Majewski syndrome, which is associated with 
hyperostosis of the cranium, vertebrae and diaphysis of tubular bones (Sousa et al., 
2014). As well as a particular lipid composition, MVs are also equipped with an arsenal 
of proteins which serve to aid the accumulation of calcium and modulation of Pi/ 
inorganic pyrophosphate (PPi) levels.  
The most abundant MV proteins are the Annexins (Anx), with particular enrichment 
in Anx A2, A5 and A6 (Golub, 2011). Their precise roles are yet to be fully elucidated, 
although clarification is coming from their 3D crystal structures. For example, Anx A5 
contains a hydrophilic pore formed by a cluster of alpha helices, suggestive of an ion 
(Ca2+) channelling role. Anx A6 on the other hand, possesses six Ca2+ binding sites 
(Wuthier and Lipscomb, 2011). To date, the primary role of Anx appears to be in the 
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nucleation of PS-Ca2+-Pi complexes, i.e. to initiate the formation of ACP (Balcerzak 
et al., 2003). Of course, Ca2+ is only one component of ACP; MVs are also powerful 
modulators of the local Pi concentrations. The major MV regulators of intra and 
extravesicular Pi and PPi are discussed in detail in section 1.5.2.  
1.5. Regulators of matrix mineralisation 
1.5.1. Extracellular matrix proteins 
1.5.1.1. SIBLING proteins 
Osteopontin (OPN), bone sialoprotein, MEPE, DMP-1 and dentin sialoprotein make 
up a group of non-collagenous extracellular mineralisation-regulating proteins termed 
SIBLING (small integrin-binding ligand N-linked glycoprotein) proteins (Staines et 
al., 2012). These proteins share a conserved arginine-glycine-aspartic acid (RGD) 
motif which mediates their cell attachment and signalling functions (Fisher and 
Fedarko, 2003). The conserved ASARM (acidic serine and aspirate rich motif) peptide 
region within this family of proteins appears to be the key determinant of their role in 
mineralisation (Rowe, 2012). In particular, it is the post-translational modifications of 
this motif, through enzymatic cleavage and phosphorylation, which dictates its 
function. Indeed, the ASARM peptide of OPN has been shown to inhibit the ECM 
mineralisation of osteoblast-like cells through the binding of HA (Addison et al., 
2010). This inhibition of mineralisation is dependent on the number of phosphorylated 
serine residues, with non-phosphorylated ASARM peptide showing no inhibition of 
mineralisation (Addison et al., 2010). OPN has also emerged as a potent inhibitor of 
ectopic, pathological mineralisation (Giachelli, 2005). This effect was most clearly 
demonstrated by a study which showed the exacerbation of vascular calcification in 
Chapter 1                                                                                                                                             Introduction                                                                                                    
   
 
~ 24 ~ 
 
the matrix gla protein (MGP) null mouse through the simultaneous ablation of OPN 
(Speer et al., 2002). The phosphorylated ASARM peptide of MEPE has also been  
shown to inhibit the mineralisation of osteoblast-like cells and bone marrow stromal 
cell cultures (Addison et al., 2008, Martin et al., 2008). More recently, inhibition of 
ECM mineralisation by the phosphorylated, but not non-phosphorylated, MEPE-
ASARM peptide in cultured murine embryonic metatarsals has been observed (Staines 
et al., 2012). To my knowledge, the ability of TNAP to dephosphorylate the OPN 
ASARM peptide as previously shown (Addison et al., 2007, Narisawa et al., 2013), 
has yet to be shown for other SIBLING protein derived ASARM peptides.  
1.5.1.2. Bone morphogenetic proteins 
Bone morphogenetic proteins (BMP), part of the TGFβ superfamily, are a group of 
multifunctional proteins which regulate osteo- and chondro-genesis as well as the self-
renewal of embryonic stem cells (Xiao et al., 2007). Osteoprogenitors, osteoblasts and 
chondrocytes produce and secrete BMPs into the ECM of bone. BMP-2, -4, -5, -6, -7 
and -9 display the greatest osteogenic capability, whereas BMP-3 strongly antagonises 
bone development (Hogan, 1996). Classically, BMPs induce the hetero-dimerisation 
of type I and type II BMP receptors (serine/threonine kinase receptors); 
phosphorylation of the type I component results in a downstream signalling cascade. 
Smads 1,5,8 are a common target of BMP signalling and their translocation to the 
nucleus, activates the transcription of target genes (Zhu et al., 2015). BMP signalling 
enforces differentiation of mesenchymal mutipotent stem cells to cells of either the 
osteogenic or chondrogenic lineage. Collagen synthesis and alkaline phosphatase and 
osteocalcin expression, markers of differentiated osteogenic cells, are all stimulated 
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by BMPs (Hogan, 1996). The osteogenic capacity of BMPs has now been harnessed 
in the clinic, in particular, for the acceleration of bone regeneration in fracture repair. 
For example, the delivery of recombinant human BMP-2 or BMP-7 significantly 
improves the quality and time to union of problematic non-union tibial fractures 
(Valentin-Opran et al., 2002, White et al., 2007). In recent years, the BMP coating of 
implants (for example, titanium femoral heads used in hip replacement surgery) has 
received attention in an attempt to improve their osseous integration (Agarwal and 
Garcia, 2015). 
1.5.2. Phosphatases and phosphate transport in matrix mineralisation 
The establishment, maintenance and management of the ratio between promoters and 
inhibitors of the biomineralisation process is central to physiological skeletal 
mineralisation. As a major component of the HA nanocrystals of vertebrate mineral, 
the regulation of Pi concentrations is vital. Contrastingly, PPi has long been recognised 
as a potent inhibitor of mineralisation, obstructing the nucleation and propagation of 
HA (Russell and Fleisch, 1975). Disruption of the Pi:PPi ratio leads to mineralisation 
pathologies characterised by hypo- or hyper- and ectopic- mineralisation phenotypes. 
Locally, during the initiation of skeletal mineralisation, phosphatase activity and Pi or 
PPi transportation, are crucial in developing intra- and extra- vescicular environments 
conducive to mineralisation. The major players in this process are introduced below. 
1.5.2.1. Tissue non-specific alkaline phosphatase 
In 1923, Robison described the hydrolysis of a phosphoric acid monoester by an 
enzyme abundant in ossifying rabbit cartilage (Robison, 1923). The enzyme in 
question would later be identified as an alkaline phosphatase isozyme, tissue non-
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specific alkaline phosphatase (TNAP). Encoded by the ALPL gene in humans, TNAP 
is preferentially expressed in bone, liver and kidney (Weiss et al., 1988). Osteoblasts, 
hypertrophic chondrocytes and odontoblasts express TNAP on their plasma 
membrane, and on the membrane of their shed MVs, by means of a 
glycosylphosphatidylinositol anchor (Millan, 2006). TNAP is the major extravesicular 
regulator of the PPi/Pi ratio through its hydrolysis of PPi and ATP (Ciancaglini et al., 
2010). More recently, TNAP was additionally shown to dephosphorylate, and thus 
prevent, the HA-binding properties of OPN, highlighting TNAPs multifactorial role in 
promoting skeletal mineralisation (Addison et al., 2010, Narisawa et al., 2013). Loss 
of function, primarily missense mutations in one or both ALPL alleles, leads to the 
human condition known as hypophosphatasia (HPP) (Henthorn and Whyte, 1992, 
Whyte et al., 2015). HPP can present with a spectrum of severity, in part dictated by 
the precise mutation involved. The infantile and childhood HPP forms are the most 
severe and are characterised by severe dental and skeletal defects associated with 
hypomineralisation, alongside vitamin B6-dependent seizures, nephrocalcinosis and 
muscle weakness (Whyte, 2010, Millán and Whyte, 2015). The Alpl-/- mouse 
developed by Narisawa et al. (1997), recapitulates the infantile HPP phenotype and 
has provided an essential model for the study of TNAP function in skeletal 
mineralisation. Correction of extracellular PPi levels in the Alpl
-/- mouse by 
concomitant ablation of either Enpp1 or ank (the major providers of extracellular PPi) 
restores the mineralisation defects and affirmed the accumulation of PPi as the 
causative agent for the hypomineralisation observed in the absence of functional 
TNAP (Harmey et al., 2004).  
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Accrual of PPi within the extracellular environment prevents the propagation of HA 
crystals formed within the confines of MVs. Alpl-/- mice are born with a normally 
mineralised skeleton, with hypomineralisation defects only becoming apparent around 
postnatal days 6-10 (Yadav et al., 2011). Furthermore, electron microscopy studies 
identified crystals of HA within MVs derived from patients with HPP and the Alpl-/- 
mouse (Anderson et al., 1997, Anderson et al., 2004). These findings highlight 
alternative mechanisms of generating a PPi/Pi ratio conducive to mineral formation 
within the interior of MVs. 
1.5.2.2. Nucleotide pyrophosphatase/ phosphodiesterase 1 
Physiological mineralisation is a tightly regulated process. Disruption of the fine 
balance between promoters and inhibitors of mineralisation leads to pathological 
mineralisation. Whereas as TNAP positively promotes the mineralisation process 
through the hydrolysis of PPi, the generation of PPi by nucleoside pyrophosphatase/ 
phosphodiesterase 1 (NPP1), provides vital control to unrestrained mineralisation. 
NPP1 is a transmembrane protein highly expressed in osteoblasts, chondrocytes and 
their shed MVs (Bollen et al., 2000, Terkeltaub, 2006). NPP1 generates PPi and Pi 
through cleavage of the pyrophosphate bonds in ATP and ADP respectively 
(Mackenzie et al., 2012a). As was the case for TNAP, the importance of NPP1 in 
regulating mineralisation was underlined through the study of human conditions, in 
this case, generalized arterial calcification of infancy (GACI) and pseudoxanthoma 
elasticum (PXE). Bi-allelic mutations in the ENPP1 gene which results in the loss of 
function of NPP1 and low systemic levels of PPi are the hallmark of GACI (Nitschke 
et al., 2012). The reduction in PPi levels results in the catastrophic calcification of 
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arteries, with most children affected by this rare autosomal recessive condition dying 
within 6 months of life (Rutsch et al., 2000). Characterisation of mutant (ttw/ttw) and 
knock-out (Enpp1-/-) mouse models emphasised the role of NPP1 in regulating skeletal 
and ectopic mineralisation. These mice exhibit intervertebral and peripheral joint 
hyperostosis, arterial and cartilage calcification alongside substantial changes to bone 
composition and structure (Okawa et al., 1998, Harmey et al., 2004). Interestingly, the 
calvariae of Enpp1-/- mice show hypermineralisation, whereas the long bones present 
with reduced trabecular and cortical bone mass, albeit with similarly reduced porosity, 
compared to WT animals (Anderson et al., 2005b, Hajjawi et al., 2014). These findings 
suggest a differential expression of Enpp1 between the axial and appendicular 
skeleton. Consistent with this observation, restoration of the hypomineralised 
phenotype of Alpl-/- mice by simultaneous ablation of Enpp1, was effective in the 
calvariae and verterbrae, but not in the long bones (Anderson et al., 2005b). Evidence 
is emerging that loss of Enpp1 may affect systemic regulators of skeletal 
mineralisation, as well as the classical local changes in PPi levels. Serum levels and 
calvarial mRNA expression of Fgf23 are increased in Enpp1-/- mice (Mackenzie et al., 
2012b). As a phosphaturic hormone, increased FGF-23 may be a compensatory 
response to reduce the extent of excessive mineralisation through the elimination of 
Pi. Interestingly, hypophosphataemic rickets resulting from increased FGF-23 levels, 
has been observed in patients with ENPP1 mutations (Lorenz-Depiereux et al., 2010). 
These findings highlight, the yet to be fully characterised, roles of skeletal 
mineralisation regulators in controlling whole body mineral homeostasis.  
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1.5.2.3. PHOSPHO1 
Originally identified as a phosphatase enriched in chick hypertrophic chondrocytes 
(Houston et al., 1999),  PHOSPHO1 provides a means of explaining the presence of 
HA within MVs lacking TNAP activity. PHOSPHO1 is a member of the functionally 
and evolutionary diverse, haloacid dehalogenase (HAD) superfamily of magnesium‐
dependent enzymes (Stewart et al., 2003). Amino acid sequence analysis of 
PHOSPHO1 from various organisms revealed the presence of two fully conserved 
aspartate residues at positions 43 and 123, which are proposed to be essential to the 
phosphohydrolase activity of this enzyme (Stewart et al., 2003). Early studies 
identified PHOSPHO1 in the mineralising regions of both embryonic and mature chick 
bone by immunohistochemistry and in situ hybridisation (Stewart et al., 2006). These 
findings were later established in the mouse, where PHOSPHO1 was again shown to 
be expressed in hypertrophic chondrocytes, metatphyseal trabecular bone, and the 
osteoblasts lining the bone forming surfaces of cortical bone (Roberts et al., 2007). In 
vitro recombinant human PHOSPHO1 exhibits high, specific activity towards two 
components of phospholipid metabolism, phosphocholine (PCho) and 
phosphoethanolamine (PEth). Sonicated, but not intact, Alpl-/- MVs are able to 
generate Pi during incubation with PCho or PEth, highlighting the localisation of 
PHOSPHO1 within MVs (Roberts et al., 2007). Also, analysis of the 267 amino acid 
long human PHOSPHO1 protein revealed the absence of a signal peptide. This 
suggests PHOSPHO1 to be a soluble cytoplasmic phosphatase (Stewart et al., 2003). 
To date, PHOSPHO1 has been identified in MVs derived from osteoblasts, 
chondrocytes, and odontoblasts (Houston et al., 2004, Roberts et al., 2007, McKee et 
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al., 2013), and a number of studies unequivocally provide evidence for its key role in 
intravesicular Pi generation.  
 
Importantly for its proposed role in the initiation of MV mineralisation, PHOSPHO1 
is expressed prior to the appearance of mineralisation. Small molecule compounds, 
such as lanzoprazole, that inhibit PHOSPHO1 activity reduce MV-mediated 
calcification and long bone mineralisation (Roberts et al., 2007, MacRae et al., 2010).  
Inhibition of ECM mineralisation has similarly been observed in vascular smooth 
muscle cell and embryonic metatarsal cultures treated with the potent and specific 
PHOSPHO1 inhibitor, MLS-0263839 (Kiffer-Moreira et al., 2013, Huesa et al., 2015). 
The pivotal role of PHOSPHO1 in bone mineralisation was recently highlighted by 
the generation and characterisation of the Phospho1−/− mouse. Phospho1−/− mice 
display severe bone and tooth abnormalities including hypomineralisation, bowed long 
bones, spontaneous fractures and scoliosis (Yadav et al., 2011, Huesa et al., 2011, 
Rodriguez-Florez et al., 2015, McKee et al., 2013). Javaheri et al. (2015) also detected 
raised numbers of osteocyte lacunae and Haversian canals in Phospho1-/- animals. 
Serum PPi and phosphorylated-OPN levels are raised in Phospho1
-/- mice, possibly 
explained through reduced Alpl expression. Despite this, the overexpression of Alpl 
does not significantly mitigate the skeletal pathologies of the Phospho1-/- mouse, in 
spite of the restored PPi levels (Yadav et al., 2011). In contrast, a significant 
improvement in the skeletal phenotype of Phospho1-/- mice is achieved through 
simultaneous ablation of Spp1 (which encodes OPN) (Yadav et al., 2014). 
Intriguingly, the double ablation of Phospho1 and Alpl in mice completely abolishes 
skeletal mineralisation in embryonic mice highlighting the critical role and 
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cooperativity of both phosphatases in the control of biomineralisation (Yadav et al., 
2011). From this work, the authors of this study proposed that MVs initiate 
mineralization by a dual mechanism: PHOSPHO1-mediated intravesicular generation 
of Pi and phosphate transporter-mediated influx of Pi via the Na/Pi co-transporter, 
Pit1. Mice that were double deficient in Phospho1 and PiT1 showed extensive 
hyperosteoidosis and displayed significantly decreases in BV/TV, trabecular  number 
and bone mineral density, as well as decreased stiffness and strength (Yadav et al., 
2016) 
Fascinatingly, atomic force microscopy studies revealed reduced numbers of MV from 
Phospho1-/- chondrocytes. Alongside its role in provision of intravesicular Pi, 
PHOSPHO1 activity may also act, by a yet undefined mechanism, to regulate MV 
formation and/or release (Yadav et al., 2016).  
Despite our understanding of the non-redundant role of PHOSPHO1 in the initiation 
of MV mineralisation, data surrounding the regulation of its expression are limited. 
Microarray analysis of murine embryonic limb bud cultures transfected with Runx2-
adenovirus, identified Phospho1 as one of the major upregulated genes (Nishimura et 
al., 2012). A more striking upregulation of Phospho1 was observed with the 
overexpression of Smad3 in MC3T3 cell cultures (Hisa et al., 2011). 
1.5.2.4. Ankylosis protein 
The multipass transmembrane protein, ANK (progressive ankyloses, ank), facilitates 
the intracellular to extracellular transport of the mineralisation inhibitor PPi (Ho et al., 
2000). Mice homozygous for the progressive ankyloses trait (ank/ank), develop 
debilitating ossification of the synovial joints and tendons (Hakim et al., 1984). The 
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trait is the result of a spontaneous recessive mutation, specifically, a nonsense mutation 
which results in the truncation of the ank gene), with homozygotic animals rarely 
surviving beyond 5 months of age and exhibiting reduced body size (Krug et al., 1989). 
Interestingly, despite its expression amongst many of the soft tissues, ectopic 
mineralisation within these tissues has yet to be extensively characterised. The 
hypomineralisation and high serum PPi levels exhibited by the Alpl
-/- mouse are 
corrected in the Alpl-/-:ank/ank double deficient mouse, thus providing confirmatory 
evidence of the role of ANK in regulating extracellular PPi levels (Harmey et al., 
2004). Decreased extracellular PPi levels in the ank/ank mouse also similarly decrease 
the expression of OPN, a well-known inhibitor of HA nucleation (Wang et al., 2005). 
Interestingly, although both NPP1 and ANK activity results in increased extracellular 
PPi levels, the simultaneous genetic ablation results in an additive effect with regard 
to the hypermineralisation phenotype. Protein localisation studies confirmed the 
presence of NPP1 and ANK in osteoblast protein lysates, but only NPP1 was found to 
be present in protein lysates from MV derived from osteoblasts (Harmey et al., 2004). 
These differences in subcellular localisation may go some way to explain the 
differences in the pathologies of the Enpp1-/- and ank/ank mice.  
1.5.2.5. Sodium dependent Pi cotransporters  
MV lacking the intravesicular phosphatase, PHOSPHO1, still possess HA mineral 
within their sheltered interior, as observed by electron and atomic force microscopy 
studies (Yadav et al., 2011, Yadav et al., 2016). The concomitant ablation of the 
primary extravesicular phosphatase, TNAP, results in MV devoid of any mineral and 
a complete lack of bone mineralisation in general (Yadav et al., 2011). Pi transporters 
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have therefore been implicated in the extra to intra-vesicular transport of Pi during 
skeletal mineralisation. The type III sodium/Pi cotransporters, Pit1 and Pit2 are 
expressed by osteoblasts and chondrocytes, with Pit1 identified as the major mediator 
of Pi transport within these cell types (Millán, 2012). The induction of Pit1 mRNA has 
been observed in vitro in response to established osteogenic factors such as PTH, 
BMP-2 and Ca2+ (Suzuki et al., 2006). Injection of foscarnet (a competitive inhibitor 
of sodium/Pi cotransporters) over the calvaria of neonatal rats inhibits the progression 
of mineralisation of the calvaria (Yoshiko et al., 2007). On the contrary, the 
chondrocyte-specific ablation of Pit1, or the hypomorphic expression of Pit1 in vivo, 
does not induce any abnormal skeletal phenotype (Bourgine et al., 2013, Yadav et al., 
2016). The authors noted that the expression of Pit2 was upregulated 2-fold in response 
to the reduced Pit1 expression (Bourgine et al., 2013). MVs derived from the Pit1
col1/col1 
mice are devoid of mineralisation, underscoring a non-redundant role for Pit1 in 
transporting extravesicularly generated Pi to MVs (Yadav et al., 2016). Unlike Pit1, 
where the global ablation is embryonic lethal (Beck et al., 2010), Pit2
-/- mice exhibit 
around a 50% survival rate. Although limited to a conference abstract, the 
characterisation of the skeletal phenotype of these mice revealed a marked impairment 
of growth plate mineralisation and bone formation (Beck-Cormier et al., 2015). The 
temporal-spatial expression of these Pi transporters requires further investigation to 
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1.5.3. Lipid metabolism in MVs: A new player linked to Pi generation and bone 
mineralisation? 
1.5.3.1. Sphingomyelin phosphodiesterase 3 
Sphingolipids are an extremely diverse and bioactive class of lipid compounds. 
Although historically, sphingolipids were believed to be inert structural molecules, 
they are now well recognised as potent signalling molecules regulating numerous 
cellular events for example; differentiation, proliferation, growth, apoptosis, 
membrane trafficking, autophagy and cell-cell and cell-matrix interactions (Merrill et 
al., 2005, Merrill, 2011). Importantly, there is a mounting body of evidence implicating 
sphingolipid metabolites (in particular, ceramide and sphingosine-1-phosphate) as 
regulators of osteoblast, osteoclast and chondrocyte survival and function (Oldknow 
et al., 2015). Exhibiting strong expression within bone, cartilage and neuronal tissues, 
the membrane bound neutral sphingomyelinase 2 (nSMase2, encoded by the Smpd3 
gene) hydrolyses SM to generate ceramide and PCho (Khavandgar and Murshed, 
2015). The vector targeted or mutagenic ablation of nSMase2 activity, as observed in 
the Smpd3-/- and fro/fro (fragilitas ossium) mouse strains respectively highlighted the 
essential role for this enzyme in skeletogenesis and mineralisation (Muriel et al., 1991, 
Stoffel et al., 2005).  
The phenotypic characterisation of the fro/fro mouse in particular, revealed marked 
hypomineralisation of the skeleton and dentition and deformed and retarded growth of 
the long bones. In vitro, osteoblasts from the fro/fro mouse display reduced ECM 
mineralisation. Correction of the bone and dentin mineralisation defects is achieved in 
the fro/fro mouse through a Col1a1 promoter driven expression of Smpd3 
(Khavandgar et al., 2011, Khavandgar et al., 2013). Local and cell-autonomous roles 
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of nSMase2 are further evident by the fact that frofro;Col1a1-Smpd3 mice still exhibit 
chondrocyte mineralisation defects. Smpd3-/- and fro/fro mice present with an 
increased zone of hypertrophic chondrocytes and poorly mineralised chondrocyte 
ECM (Stoffel et al., 2007, Khavandgar et al., 2011). Ceramide is known to induce the 
apoptosis of terminally differentiated chondrocytes (MacRae et al., 2006, Kakoi et al., 
2014). Although the mechanisms of hypertrophic chondrocyte mineralisation are 
debated, apoptosis is implicated and as such, the reduced ceramide levels in fro/fro 
mouse may explain the impairment of chondrocyte mineralisation (Khavandgar et al., 
2011). Recent studies were able to recapitulate the chondrocyte defects of the fro/fro 
mouse through the targeted deletion of Smpd3 in chondrocyte using the Col2a1-Cre 
(Li et al., 2016). Interestingly however, inactivation of the alternative de novo pathway 
of ceramide synthesis in dihydroceramide desaturase 1 -deficient (Des1-/-) mice does 
not produce any bone mineralisation defects (personal communication with Prof. 
Murshed, McGill University, Montreal). This observation raises the possibility that the 
other nSMase2 metabolite, PCho, might play a role in bone mineralisation. 
Importantly for the studies of this thesis, nSMase2 has been identified in proteomic 
studies of MV isolations (Thouverey et al., 2009, Thouverey et al., 2011). 
Furthermore, nSMase2 is implicated in mediating exosome release during the 
calcification of vascular smooth muscle cell cultures (Kapustin et al., 2015). It is 
evident therefore that the effects of nSMase2 during mineralisation are likely to be 
multifactorial. The generation of PCho through the hydrolysis of SM is of primary 
interest, as it provides a mechanism in combination with the activity of PHOSPHO1 
for the generation of Pi within MV. 
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1.5.3.2. Choline kinase enzymes 
The de novo synthesis of the major constituent of mammalian lipid bilayers, PC, occurs 
through two pathways: i) the methylation of PE by the PE-N-methyltransferase 
enzymes and ii) The CDP-choline (or Kennedy) pathway (Aoyama et al., 2004). The 
first reaction in the Kennedy pathway is the ATP-dependent conversion of choline to 
PCho, catalysed by the choline kinase (CK) enzymes. Cloning of cDNAs derived from 
rat liver lysates identified three isoforms of CK; CKα1 and CKα2 (obtained through 
alternative splicing of the Chkα gene) and CKβ (a product of the Chkβ gene) (Uchida, 
1994). The importance of PC as a structural and functional component of lipid 
membranes ensures the CK genes are ubiquitously expressed in mammalian tissues 
(Gibellini and Smith, 2010). The earliest investigations of CK in bone revealed the 
lack of induction of these enzymes in response to Vitamin D and calcitonin (Stern and 
Vance, 1987). However, it wasn’t until 2006, that the characterisation of a mouse 
possessing an intragenic deletion within the Chkβ gene, resulting in the ablation of 
CKβ protein, highlighted a role for CK enzymes in bone formation. The rmd/rmd 
mouse exhibits marked growth retardation and bowing of the forelimb bones alongside 
its pathological feature of severe muscular dystrophy (contrastingly, only affecting the 
hindlimbs) (Sher et al., 2006). This cranial-caudal anomaly was later explained by a 
differential expression of CK isoforms between the forelimbs and the hindlimbs (Wu 
et al., 2010). The flp/flp mouse (possessing an ENU-induced mutation of Chkβ gene) 
presents with reduced BMD and the disrupted activity of both osteoclasts and 
osteoblasts. Flp/flp osteoclasts are present in higher numbers and display increased 
Cathepsin K activity than their WT counterparts. On the contrary, osteoblasts from the 
flp/flp mice poorly mineralise their ECM in vitro (Kular et al., 2015). The genetic 
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ablation of Chkα is embryonic lethal (Wu et al., 2008). Small molecule inhibition of 
CKα activity in vitro however, results in reduced ECM mineralisation and TNAP 
activity (Li et al., 2014b). Silencing of Chkα expression in MG-63 cells reduces PCho 
levels by 80% (Li et al., 2014b). PCho is readily hydrolysed by PHOSPHO1 and as 
such these data surrounding CK enzymes provide further connection between lipid 
metabolism and mineralisation which are worthy of exploration.  
1.6. Aims 
The extensive characterisation of the skeletal phenotype of the Phospho1-/- mouse has 
confirmed the importance of this intravesicular enzyme during the initiation of 
mineralisation. Furthermore, emerging evidence, especially that gained from analysis 
of the fro/fro mouse, implicates MV lipid metabolism in the mineralisation process. In 
particular, it is hypothesised that nSMase2 and CK, work in tandem with PHOSPHO1 
during the initiation of skeletal mineralisation through the generation and processing 
of PCho respectively (Figure 1.5.). Unfortunately, currently used in vitro models of 
mineralisation in which to investigate these relationships rely on the use of β-
glycerophosphate (βGP), a substrate for TNAP. As the production of Pi from 
TNAP-mediated βGP catalysis may interfere with the endogenous mechanisms of Pi 
generation, new model systems are needed to study the relationship between 
PHOSPHO1 and nSMase2. Therefore, the aims of Chapter 3 are to: 
I. Establish phosphatase-substrate free conditions for the in vitro mineralisation 
of osteoblast-like cell cultures, primary calvarial osteoblast cell cultures and 
and embryonic metatarsal cultures. 
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II. Investigate the temporal mRNA and protein expression of key mineralisation 
dependent enzymes within these models. 
The development and characterisation of these model system will assist in studies 
seeking to understand the regulation of the key mineralisation genes. Indeed, it is 
apparent from the literature that there is a paucity of information surrounding the 
regulation of, in particular, Phospho1 and Smpd3. Interestingly, Phospho1 was 
recently identified as one of a number of genes regulated by PTH in osteocyte-like 
cells (St John et al., 2015)). As PTH can exert both anabolic and catabolic effects on 
the skeleton, I hypothesised that the regulation of Phospho1 by PTH could provide a 
novel mechanism to explain these effects. Therefore, the aims of Chapters 4 and 5 are 
to: 
III. Characterise the effects of PTH on osteoblasts in vitro. 
IV. Examine the skeletal expression of key mineralisation genes in response to 
intermittent PTH and continuous PTH exposure in vivo. 
V. Determine the role of Phospho1 in the osteoanabolic and osteocatabolic 
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Figure 1.5. Hypothetical Pi and Ca2+ accumulation within MVs.  
Pi generation within MVs is primarily carried out through the hydrolysis of PCho (or 
PEth) by PHOSPHO1. PCho may be derived from the breakdown of membrane 
sphingomyelin by nSMAse2 or through the de novo synthesis from choline by the 
action of the CK (choline kinase) enzymes. NPP1 and TNAP are the major 
extravesicular regulators of PPi and Pi. Extravesicular Pi, may be transported to the 
interior of MVs through the actions of Pit1. Calcium accumulation is primarily carried 
out by the actions of Annexins (Anx) and the acidic phospholipid, phosphatidylserine 
(PS). Anx and PS are also involved in the nucleation of ACP.  
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2.1. Reagents and solutions 
All chemicals were purchased from Sigma Aldrich (Poole, UK) unless otherwise 
stated. Tissue culture media, reagents and plastic ware were purchased from Thermo 
Fisher Scientific (Northumberland, UK) unless otherwise stated. The composition of 
media and buffers used are detailed in Appendix I.  
2.2. Cell culture 
2.2.1. Thawing frozen cell stocks 
Cryovials of frozen cell stocks were initially thawed in a beaker of 37°C water. The 
cryovial contents were next transferred to a universal and 5 mL of pre-warmed (37°C) 
maintenance media (Appendix I) was added dropwise. The cell suspension was gently 
agitated and spun at 1000 x g for 5 min. The supernatant was discarded and the 
resultant cell pellet was resuspended in the cell-type specific media and transferred to 
a T175 tissue culture flask and incubated in a humidified atmosphere (37°C, 5% CO2). 
2.2.2. Freezing cell stocks 
To maintain stocks of cell-lines, cultured cells in the log-phase of growth (i.e. sub-
confluent) were initially detached from the culture flask through the use of trypsin- 
ethylenediaminetetraacetic acid (EDTA). In brief, cell monolayers were rinsed in 
serum-free α-minimum essential medium (MEM) prior to incubation with trypsin-
EDTA for 5 min at 37°C to detach the cells. Maintenance media, which contains foetal 
bovine serum to inactivate the trypsin, was then added to the flasks and cells were 
harvested by centrifugation at 1000 x g for 5 min. Cells were resuspended in a 1:1 mix 
of maintenance media and freezing mix (Appendix I) to give a cell concentration of  
2-3 x 106 cells/mL. Cryovials containing 1 mL of cell suspension were stored at -70°C 
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in a polystyrene box lined with cotton wool for up to one week prior to their transfer 
to -150°C for long-term storage.  
2.2.3. MC3T3 cells 
The pre-osteoblast like cell-lines MC3T3-clone 14 and MC3T3-clone 24 (Wang et al., 
1999) (ATCC, Teddington, UK) were cultured in maintenance media at 37°C, 5% 
CO2. For experimentation, cells were trypsinised (as described in 2.2.2.), counted 
using a haemocytometer and then plated in multi-well plates at a density of 1 x 104 
cells/cm2. Upon confluency, maintenance media was replaced with MC3T3 
mineralisation media (Appendix I) to induce the differentiation and support ECM 
mineralisation of MC3T3 cell cultures. Cell cultures were maintained for up to 14 days 
and media was replaced every 2-3 days.  
2.2.4. IDG-SW3 cells 
IDG-SW3 cells (a kind gift from Prof. Bonewald, University of Missouri) were 
initially expanded through culture in IDG-SW3 proliferation media (containing 
recombinant mouse Interferon-γ which is required to induce expression of the SV40 
large tumor antigen and maintain proliferation of this cell line, Appendix I) at 33°C 
(Woo et al., 2011). For experimentation, cells were trypsinised (as described in 2.2.2.), 
counted using a haemocytometer and then plated in multi-well plates at a density of 4 
x 104 cells/cm2. Upon confluency, proliferation media was replaced with IDG-SW3 
mineralisation media (Appendix I) to induce the differentiation and support ECM 
mineralisation of IDG-SW3 cell cultures. Cell cultures were transferred to 37°C and 
maintained for up to 28 days with media changes every 2-3 days. The culture of IDG-
SW3 cells was carried out on type I collagen coated plasticware. 
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2.2.5. Murine calvarial osteoblast isolation and culture. 
The calvariae from 3-4 day old new born WT and Phospho1-/- mice were dissected 
under sterile conditions as previously described (Jonason and O’Keefe, 2014). Isolated 
calvariae were washed in Hank’s balanced salt solution (HBSS) and subjected to serial 
enzymatic and chemical digestions at 37°C with constant agitation. In brief, calvariae 
were initially subjected to a type II collagenase (10 mg/ml, Worthington, New Jersey, 
USA) digestion for 10 min after which the supernatant was discarded. Next, calvariae 
were again exposed to type II collagenase for 30 min, with the supernatant and 
subsequent phosphate buffered saline (PBS) wash were retained (fraction 1). 
Following this, calvariae were incubated with 4 mM EDTA for 10 min with the 
supernatant and subsequent HBSS wash were retained (fraction 2). A final 30 min, 
type II collagenase digestion was carried out and the supernatant was retained (fraction 
3). Primary osteoblasts were harvested, by combining all fractions and centrifuging 
them at 1000 x g for 5 min. The resultant cell pellet was resuspended in maintenance 
media and transferred to tissue culture flasks, where they were maintained in a 
humidified atmosphere (37°C, 5% CO2) until 70-80% confluent. For experimentation, 
cells were trypsinised (as described in 2.2.2.), counted using a haemocytometer and 
then plated in multi-well plates at a density of 1 x 104 cells/cm2. Upon confluency, 
maintenance media was replaced with primary osteoblast mineralisation media to 
induce the differentiation and support ECM mineralisation of primary osteoblast cell 
cultures. Cell cultures were maintained for up to 28 days and media was replaced every 
2-3 days.  
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2.2.6. Human subchondral bone osteoblast isolation and culture  
Human samples were obtained following ethical guidelines (Tissue Governance, NHS 
Lothian) and consent from patients undergoing total knee replacement for 
osteoarthritis in collaboration with Mr. Anish Amin (Orthopaedic surgeon, NHS 
Lothian). Upon advice from Mr. Amin, the non-osteoarthritic condyle of the tibia was 
subjected to the following protocol to isolate the subchondral osteoblasts. 
Articular cartilage was removed from the tibial condyle and the underlying bone cut 
into small fragments (2-3 mm3) using bone clippers. These fragments were washed 
briefly six times in PBS containing 10% v/v penicillin streptomycin (PenStrep 
solution). Bone fragments were then incubated for 10 min at 37°C in trypsin-EDTA. 
The bone fragments were subsequently washed in PBS and then incubated for 30 min 
at 37°C in 10 mg/mL type II collagenase. Next, the bone fragments were washed 3 x 
5 min in PenStrep solution. The processed bone fragments were then used to establish 
explant cultures in T75 flasks with human osteoblast culture media (Appendix I). 
Media was changed every three days and at 70-80% confluency, cells were trypsinised 
(as described in 2.2.2.), counted using a haemocytometer and then plated in multi-well 
plates at a density 3 x 104 cells/well.  Experiments utilising human subchondral 
osteoblast cell cultures were carried out upon confluency. 
2.3. Ex-vivo organ culture 
2.3.1. Murine embryonic metatarsal dissection and culture 
WT and Phospho1-/- embryos were culled by decapitation on embryonic day 15. The 
hind limbs of each embryo were dissected and placed into pre-warmed preparation 
media (Appendix I) under sterile conditions. Using a dissecting microscope the central 
three metatarsals from each hind limb were carefully isolated and maintained in 
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preparation media (Houston et al., 2016a). Metatarsals were cultured in 24-well tissue 
culture plates; each well contained one bone and 300 µL metatarsal media (Appendix 
I). Metatarsals were cultured in a humidified atmosphere (37°C, 5% CO2) for up to 7 
days. The culture media was not changed during the culture (Haaijman et al., 1997). 
The total length of the metatarsal and the length of the mineralisation zone were 
measured along the centre line using image analysis software (DS Camera Control 
Unit DS-L1, Nikon, Surrey, UK).  
2.3.2. Murine calvariae dissection and culture 
The calvariae from 4-day old, new born WT mice were dissected aseptically and 
transferred to pre-warmed calvariae culture media (Appendix I). Next, calvariae were 
halved along the sagittal suture, and hemi-calvariae were cultured in 24-well tissue 
culture plates with 350 µL of calvariae culture media for 24 hours (h) prior to 
experimentation. After 24 h, culture media was replaced with fresh media and 
supplemented with experimental reagents for up to 24 h.   
2.4. RNA Methods 
2.4.1. Isolation of RNA from cell cultures 
Cultured cells were scraped from individual wells in 1 mL of ice cold PBS, pelleted at 
12000 x g for 1 min and stored at -70°C. Total RNA was extracted using the RNeasy 
mini kit (Qiagen, West Sussex, UK) according to the manufacturer’s instructions. It is 
essential that cell pellets are fully homogenised in RLT buffer with 1% v/v β-
mecaptoethanol by vortexing before progressing with the remainder of the protocol. 
The concentration and quality (as assessed by the 260:280 nm wavelength absorbance 
ratio) was determined using a nanodrop spectrophotometer (ND-1000, Thermo Fisher 
Scientific).  
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2.4.2. Isolation of RNA from murine tissues 
Murine tissues obtained from animal dissection or ex vivo culture were snap frozen in 
liquid nitrogen and stored at -70°C. Total RNA was extracted using the RNeasy lipid 
tissue mini kit (Qiagen) as described herein. In brief, murine tissues were homogenised 
in 1 mL of Qiazol (Qiagen) using a T10 basic ULTRA-TURRAX homogeniser (IKA, 
Staufen, Germany). The homogenised samples were incubated for 5 min at room 
temperature prior to the addition of 200 µL of chloroform. Samples were shaken 
vigorously for 15 s and centrifuged at 12000 x g for 15 min at 4°C. Centrifugation of 
the sample induces a phase separation, consisting of an organic lower phase, an 
interphase and an aqueous upper phase; the aqueous phase was transferred to a 2 mL 
safelock Eppendorf (Sigma Aldrich) and care was taken not to transfer any of the 
interphase or organic phase. To the aqueous upper phase, 600 µL of 70% v/v ethanol 
was added to precipitate the RNA. The RNA was captured, processed and eluted in 
nuclease-free water (NFW) according to the manufacturer’s instructions. The 
concentration and quality (as assessed by the 260:280 nm wavelength absorbance 
ratio) was determined using a nanodrop spectrophotometer. 
2.4.3. Reverse transcription of RNA 
The reverse transcription of RNA to cDNA was carried out utilising the DNA 
polymerase, Superscript II. In brief, 2 µL of random hexamers (random hexamer 
diluted 1:60, Thermo Fisher Scientific) was added to 10 µL of diluted RNA from 
sections 2.4.1. and 2.4.2. and incubated at 70°C for 10 min in a Hybaid polymerase 
chain reaction (PCR) express thermal cycler (Thermo Fisher Scientific). The samples 
were immediately cooled on ice. A mastermix comprising, 4 µL 5X first-strand buffer, 
2 µL dithiothreitol (DTT, 0.1 M), 1 µL deoxyribonucleotide triphosphate mix (10 mM) 
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and 1 µL Superscript II enzyme (all Thermo Fisher Scientific) was prepared and 8 µL 
of the mastermix was added to each sample. The samples were run on the following 
programme in the Hybaid PCR machine: 25°C for 10 min, 42ºC for 50 min, 70°C for 
15 min and held at 4°C. The resulting cDNA samples were diluted to 5 ng/µL with 
NFW and stored at -20°C.  
2.4.4. Real-time quantitative polymerase chain reaction (RT-qPCR) and 
quantification of gene expression 
RT-qPCR reactions were carried out in a 96-well PCR plates and cycled in a Stratagene 
Mx3000P PCR cycler (Agilent Technologies, Santa Clara, USA). Each qPCR reaction 
was performed with 5 µL (25 ng) of diluted cDNA from section 2.4.3. and 15 µL of 
qPCR mastermix which comprised: 1µL primers (10µM, forward and reverse primer), 
10 µL 2X PrecisionPlus SYBR green mastermix (PrimerDesign, Southampton, UK) 
and 4µL NFW. The following program was used to perform the qPCR reaction: Initial 
hotstart enzyme activation (2 min at 95°C)  followed by 40 cycles of denaturation (15 
s at 95°C) and annealing (1 min at 60°C). A post-PCR melt curve analysis was carried 
out to ensure only one PCR product was formed during the qPCR reaction. Three 
technical replicates were performed for each sample and reactions analysing the 
expression of suitable housekeeping genes were similarly performed. The relative 
expression of the target genes was calculated using the 2-ΔΔCt method (Livak and 
Schmittgen, 2001). 
2.4.5. Primer validation  
Primers were tested for amplification efficiency by performing the qPCR reaction on 
serial dilutions of cDNA (known to express the target gene) and producing a standard 
curve from the amplification (Ct) results (Fig 2.1.A). Primers were considered 
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acceptable if the amplification efficiency was within the range of 90-110%, with an R2 
value between 0.90 and 1.00, and amplification curves were regularly spaced along 
the dilution series. Primer specificity was demonstrated both by the generation of a 
single peak in the melt curve (Fig 2.1.B) and by Sanger sequencing of the qPCR 
product. In brief, qPCR products were cleaned of salts and impurities using a 
QIAquick PCR purification kit (Qiagen). Purified PCR products were sent for Sanger 
sequencing at Edinburgh Genomics. The National Centre for Biotechnology 
Information (NCBI) Basic local Alignment Search Tool (BLAST) was used to 
compare the resulting sequences to the mouse genome (Fig 2.1.C).  
2.5. Protein methods 
2.5.1. Protein extraction from cell cultures 
Cultured cells were rinsed in ice cold PBS and scraped in 200 µL of radio-
immunoprecipitation assay (RIPA, Thermo Fisher Scientific) buffer containing 15% 
v/v complete protease inhibitor cocktail (Roche, West Sussex, UK) and 1% v/v 
phosphatase inhibitor cocktail 2. Samples were vortexed and stored at -20°C until 
further use. 
2.5.2. Protein extraction from murine tissues 
Murine tissues obtained from animal dissection or ex vivo culture were snap frozen in 
liquid nitrogen and stored at -70°C. Murine tissues were homogenised in 500 µL of 
RIPA buffer containing 15% v/v complete protease inhibitor cocktail and 1% v/v 
phosphatase inhibitor cocktail 2 using a T10 basic ULTRA-TURRAX homogeniser. 
Homogenised samples were stored at -20°C until further use. 
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Figure 2.1. Validation of qPCR primer efficiency and specificity. 
Representative image of (A) standard curve, (B) melt curve and (C) NCBI BLAST 
results confirming the identity of sequenced qPCR product. 
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2.5.3. Determination of protein concentration 
The Bio-Rad Detergent Compatible (DC) protein assay (Bio-Rad, Hertfordshire, UK) 
was used to determine the protein concentration of extractions from sections 2.5.1. and 
2.5.2. Serial dilutions of bovine γ-globulin (2 mg/mL, protein standard, Bio-Rad) were 
initially prepared to generate a standard curve. Next, 5 µL of protein standard or 
samples were pipetted in duplicate into a 96-well plate followed by 25 µL alkaline 
copper tartrate (reagent A’) and 200 µL Folin’s reagent (reagent B). The plate was 
shaken briefly and incubated for 15 min at room temperature. The absorbance at 
750 nm was assessed in each well using a Multiskan Ascent microplate reader 
(Thermo Fisher Scientific). The protein concentration of the samples was determined 
through extrapolation from the generated standard curve.   
2.5.4. Western blotting  
Following protein concentration determination (section 2.5.3.) the appropriate volume 
of protein lysate to provide between 10-20 µg was calculated and combined with 4X 
lithium dodecyl sulphate sample buffer (Thermo Fisher Scientific) and DTT reducing 
agent (Thermo Fisher Scientific) prior to denaturation at 70°C for 10 min. Denatured 
protein samples and a pre-stained molecular weight marker (All Blue, Bio-Rad) were 
chilled on ice prior to being loaded into 10% Bis-Tris polyacrylamide gels (Thermo 
Fisher Scientific). Proteins were separated by electrophoresis at 200 V for 50 min in a 
Novex gel tank (Thermo Fisher Scientific) containing 1X MOPS (3-(N-morpholino) 
propanesulfonic acid) running buffer (Appendix I). Antioxidant (2.5 µL/mL, Thermo 
Fisher Scientific) was added to the centre compartment of the tank to preserve reduced 
proteins. After separation, proteins within the polyacrylamide gels were transferred 
onto Hybond-enhanced chemoluminesence nitrocellulose membrane (GE Healthcare, 
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Buckinghamshire, UK). In brief, the nitrocellulose membrane was placed onto the 
polyacrylamide gel and sandwiched between transfer buffer (Appendix I) soaked filter 
paper and sponges within a transfer module (Thermo Fisher Scientific). The transfer 
of proteins was carried out on ice for 90 min at 30 V.  
Following transfer, nitrocellulose membranes were washed 5 x 5 min in PBS. 
Membranes were subsequently blocked in Odyssey blocking buffer (LI-COR 
Biosciences, Nebraska, USA) for 1 h at room temperature. The membranes were 
probed with primary antibodies diluted at the appropriate concentrations in Odyssey 
blocking buffer overnight at 4°C with constant agitation. Nitrocellulose membranes 
were next washed 3 x 5 min in PBS prior to incubation with the appropriate secondary 
antibodies (Appendix II) for 50 min at room temperature and protection from light. 
After extensive washing in PBS, antibodies were detected using the Odyssey CLx 
infrared scanner (LI-COR Biosciences) (Eaton et al., 2013). Scans were performed in 
either the 700 nm or 800 nm channels as appropriate with a scan resolution of 169 µm. 
In some experiments, quantification of the western blots was performed with Image 
Studio Lite (LI-COR Biosciences).  
To allow the probing of multiple protein targets on the same nitrocellulose membrane, 
antibodies were stripped from membranes using restore plus stripping buffer (Thermo 
Fisher Scientific) for 40 min at room temperature and with constant agitation. After 
extensive washing with PBS, membranes were re-probed with the appropriate 
secondary antibodies and visualised using the Odyssey CLx infrared scanner to 
confirm successful stripping.   
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2.6. Lipid methods 
2.6.1. Lipid extraction and quantification 
Cultured embryonic metatarsals from section 2.3.1. were snap frozen in liquid nitrogen 
and stored at -70°C until further processing. Next, metatarsals (20 bones per sample) 
were incubated with 200 µL type II collagenase (10 mg/ml) at 37°C for 4 h with 
constant agitation. After this incubation, the samples were again snap frozen in liquid 
nitrogen and stored at -70°C. Lipids were extracted from collagenase digested samples 
according to the method of  Folch et al., 1957. Samples were transferred to borosilicate 
glass tubes with PFTE lined caps (13 mm diameter, Thermo Fisher Scientific) and 
4 mL of chloroform/methanol (2:1, v/v) was added. Samples were vortexed 
extensively and incubated for 1 h in a sonicating water bath at room temperature. The 
mixture was partitioned through the addition of 1.25 mL of potassium chloride (0.1 
M), vortexed briefly, and centrifuged at 1500 x g for 10 min to induce phase separation. 
The organic, lower phase was transferred to a new borosilicate glass tube using a glass 
Pasteur pipette and subsequently dried under a stream of nitrogen gas. The dried lipid 
extract was reconstituted in 200 µL methanol containing 5 mM ammonium formate. 
Glycophospholipid analysis and quantification was performed by Professor Phillip 
Whitfield at the Lipidomics Research Facility, Inverness, UK using liquid 
chromatography (hydrophilic interaction chromatography column) mass spectrometry 
(Exactive Orbitrap mass spectrometer, Thermo Fisher Scientific). 
2.7. In vivo methods 
2.7.1. Animal welfare and generation 
All animal experiments were approved by the Roslin Institute’s Animal Users 
Committee and the animals were maintained in accordance with Home Office 
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guidelines for the care and use of laboratory animals. Animals were maintained under 
conventional housing conditions with a 12 h light/dark cycle and free access to food 
and water. Phospho1-/- mice, which possess a cytosine to thymidine mutation in codon 
74 of exon 2 (introducing a stop codon) of the Phospho1 gene, were generated as 
previously described (Ciancaglini et al., 2010).  Separate colonies of WT (C57BL/6J) 
and Phospho1-/- mice were maintained and genotyping of offspring was performed as 
described in section 2.7.2. 
2.7.2. DNA extraction and genotyping 
Ear snips from WT and Phospho1-/- mice were collected and the DNA was extracted 
using DNA extraction solutions I and II (Appendix IV). In brief, 75 µL of solution I 
was added to each ear snip and samples were incubated at 95°C for 30 min. The 
reaction was stopped by the addition of 75 µL of solution II. PCR was performed on 
extracted DNA using PCR primers targeted toward exon 3 of the murine Phospho1 
gene (Appendix IV). The resulting amplified DNA was subjected to restriction digest 
with BsrDI restriction enzyme (New England Biolabs, Massachusetts, USA) through 
the addition of 5 µL of restriction digest master mix (Appendix IV) to the DNA and 
incubation at 65°C for 1 h. Digested samples were electrophoresed on a 1.5% w/v 
agarose: Tris-borate-EDTA gel containing 0.01% v/v SYBRsafe (Thermo Fisher 
Scientific) and the gels were visualised using a Gel Doc XR+ System (Bio-Rad). 
HyperLadder 1kb (Bioline, London, UK) was used as a molecular weight marker.  
2.7.3 Parathyroid hormone administration 
Recombinant human parathyroid hormone 1-34 (rhPTH 1-34, BACHEM, Bubendorf, 
Switzerland) was reconstituted in sterile PBS and stored in aliquots at -70°C. Prior to 
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in vivo administration, rhPTH 1-34 was diluted to the appropriate concentration with 
0.9% w/v saline containing 0.2% w/v bovine serum albumin (vehicle solution). For 
single dose and intermittent studies, animals were weighed on the day of injection and 
50 µL injections containing 80 µg/kg rhPTH 1-34 or vehicle solution were 
administered subcutaneously. The continuous administration of rhPTH 1-34 was 
carried out using a subcutaneously implanted Alzet micro-osmotic pump (Model 1004, 
Durect Corp., California, USA). In brief, micro-osmotic pumps were filled with 
100 µL of rhPTH 1-34 (0.308 mg/ml) or vehicle solution and submerged in sterile 
0.9% w/v saline and incubated at 37°C for 48 h prior to surgical implantation. This 
priming step ensured the pumps released their contents at the defined rate immediately 
upon implantation. Pumps were implanted subcutaneously, posterior to the scapula in 
accordance with manufacturer’s guidelines.  
2.7.4. Processing of tissue to paraffin 
Murine tissues destined for histology or immunohistochemistry were dissected, and in 
the case of bone samples, freed from any soft tissues immediately following sacrifice 
of the animal. Dissected tissues were fixed in 4% w/v paraformaldehyde (PFA) for 
24 h. Soft tissues (kidney and thyroid) were then stored in 70% v/v ethanol until further 
processing. After 24 h in fixative, bone samples were transferred to 10% w/v EDTA 
(pH 7.4) and maintained at 4°C with constant agitation for up to four weeks. EDTA 
was changed every 2-3 days. Tissues were next dehydrated and processed to paraffin 
wax using a Leica ASP300S tissue processor (Leica Microsystems, Milton Keynes, 
UK) with the following steps applied: two 1 h incubations in 70% v/v ethanol, two 1 h 
incubations in 95% v/v ethanol, two 1 h incubations in absolute ethanol, two 1 h 
incubations in xylene, three 1 h incubations in paraffin wax (at 60°C and under 
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vacuum). Processed tissues were embedded in paraffin wax using plastic moulds and 
allowed to set at 4°C prior to storing at room temperature. Using a Leica RM2235 
microtome (Leica) equipped with MX35 Premier plus Microtome Blades (Thermo 
Fisher Scientific), wax blocks were trimmed to expose the sample surface. The paraffin 
embedded samples were then cooled and tissues were sectioned at  5 μm thickness. 
Sections were floated into a water bath at 40°C, before being transferred to poly-L-
lysine coated microscope slides (VWR International Ltd., Lutterworth, UK). Slides 
were stored at room temperature until required. 
2.7.5. Immunohistochemistry 
The spatial localisation of TNAP within paraffin embedded bone sections was assessed 
by immunohistochemistry. First, sections of paraffin embedded bone (section 2.7.4.) 
were de-waxed in xylene and rehydrated through a series of alcohols to dH2O. Next, 
an antigen retrieval process was carried to out to expose the antigenic site on proteins 
which are readily cross-linked by methylene bridges during PFA fixation. Antigen 
retrieval was carried out by immersing slides in either citrate buffer (Appendix I) for 
90 min at 70°C. Slides were next washed in PBS (3 x 5 min) before inactivation of 
endogenous tissue peroxidases by incubating the slides in 0.3% v/v hydrogen peroxide 
in methanol for 30 min at room temperature. Slides were washed in dH2O (5 min) and 
PBS (3 x 5 min). Being careful not to disturb the tissue sections, slides were blotted 
dry and a wax pen (Daido Sangyo Co. Ltd., Tokyo, Japan) was used to create a 
boundary around the section. Sections were incubated in a blocking solution (normal 
goat serum diluted 1:5 in 5% v/v foetal bovine serum in PBS) for 30 min at room 
temperature. The blocking solution was tipped off and again the sections were blotted 
dry before being incubated with the primary antibody (TNAP, diluted 1:200 in 5% v/v 
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foetal bovine serum in PBS) or control rat IgG overnight at 4°C in a humidity chamber 
so as to prevent evaporation. The following day, slides were washed in PBS (3 x 5 
min) and incubated with the goat anti-rat horseradish peroxidase-conjugated secondary 
antibody (diluted 1:100 in 5% v/v foetal bovine serum in PBS) for 1 h at room 
temperature. Slides were again washed in PBS (3 x 5 min) and subsequently incubated 
with 3,3’-diaminobenzidine for 15 s and washed thoroughly in dH2O. Slides were 
dehydrated through a series of alcohols and xylene and counterstained with 
haematoxylin using the Leica ST5010 Autostainer XL. Slides were mounted with 
DePeX (VWR International Ltd.) and visualised using a Nikon E600 microscope with 
a digital camera attachment. Images were obtained using Image Tool Version 3.00. 
2.7.6. Micro-computed tomography imaging 
Micro-computed tomography (µCT) imaging was used to assess trabecular and 
cortical bone architecture in the tibiae of experimental mice. Tibiae were dissected, 
freed from any surrounding soft tissues and stored in dH2O at -20°C prior to scanning. 
High resolution scans were performed by Dr Katherine Staines or Mr Mark 
Hopkinson, using a Skyscan 1172 (Skyscan, Kontich, Belgium) µCT system, with the 
X-ray tube operated at 50 kV and 200 μA, 1600 ms exposure time with a 0.5 mm 
aluminium filter and a voxel size of 5 μm. Scans were then reconstructed using 
NRecon 1.6.9.4 (Skyscan, Kontich, Belgium). All downstream processes were 
performed by myself. CTAn 1.13.5.1 + version software (Skyscan, Kontich, Belgium) 
was used to perform 2D/3D analysis of reconstructed scans including tibial length. 
Metaphyseal trabecular bone of the proximal tibia was assessed in a 250 slice stack, 
5% of the total bone length below the first appearance of a trabecular ‘bridge’ 
connecting the two primary spongiosa bone islands (Fig 2.2.A, (Javaheri et al., 2015)) 
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Cortical bone was assessed in 100 slice stacks at 37% and 50% of the total bone length 
(proximal-middle, Fig 2.2.B) from the reference starting slice (first appearance of the 
medial tibial condyles) (Sugiyama et al., 2008). To assess bone mineral density 
(BMD), BMD phantoms were used to calibrate the CTAn software. BMD phantoms 
of known calcium hydroxyapatite mineral densities of 0.25 and 0.75 g/cm3 were 
scanned and reconstructed using the same parameters as used for bone samples.   
2.7.7. Three point bending analysis 
Mechanical testing was performed on tibiae from the defined groups of male mice 
using an LXR material testing machine (Lloyd Instruments, West Sussex, UK) fitted 
with an 100 N load cell. The span was fixed at 10  mm, and the cross-head was lowered 
at 1 mm/min. Data were recorded after every 0.2 mm change in deflection. Each bone 
was tested to failure, with failure points being identified as the point of maximum load 
from the load–extension curve. The maximum stiffness was defined as the maximum 
gradient of the rising portion of this curve (Aspden, 2003).  
2.8. In vitro assays 
2.8.1. Alizarin red staining and quantification 
The calcium deposition within cell cultures was assessed by alizarin red staining. Cells 
were washed with PBS prior to fixing for 5 min in 4% w/v PFA. Alizarin red stain (2% 
w/v, pH 4.2) was used to stain the cell monolayers for 5 min at room temperature. 
Unbound stain was removed by repeated washing of the cell monolayers with dH2O. 
Stained monolayers were imaged with a digital camera by Mr Norrie Russell of The 
Roslin Institute. Quantification of the bound alizarin red stain was carried out by 
initially leaching the dye through the addition of 10% w/v cetylpyridinium chloride 
for 1 h. The absorbance of the resultant solution was determined at a wavelength of  
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Figure 2.2. Analysis of bone microarchitecture by µCT.  
(A) Representative image showing the trabecular ‘bridge’ connecting the two 
primary spongiosa bone islands. Metaphyseal trabecular bone was assessed in a 
1.25 mm section, beginning 5% below this reference point (B) Representative images 
of metaphyseal trabecular bone and cortical bone at 37% and 50% of the total bone 
length. 
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570 nm using a Multiskan Ascent microplate reader. Each biological replicate was 
tested in duplicate, and 10% w/v cetylpyridinium chloride was used as a blank.   
2.8.2. Calcium assay 
To assess serum calcium, serum from experimental mice was prepared from a terminal 
blood sample. Whole blood was allowed to clot on ice for 30 min prior to 
centrifugation at 1000 x g for 10 min. The resultant supernatant (serum) was aliquoted 
and stored at -70°C. Serum calcium was assessed by a colorimetric assay (Randox 
calcium assay, Randox Laboratories Ltd., County Antrim, UK). In brief, 6.25 µL of 
calcium standard and serum samples were pipetted in duplicate into a 96-well plate. 
Equal volumes of buffer R1 and buffer R2 (containing O-Cresophthalein, which forms 
a violet complex with calcium ions under alkaline conditions) were combined and 
250 µL of the buffer mixture was pipetted into wells containing standard and samples. 
The plate was gently vortexed and the absorbance of each well was determined at a 
wavelength of 570 nm using a Multiskan Ascent microplate reader. 
2.8.3. Bone formation and resorption marker assays 
The concentrations of P1NP and CTX-1 were assessed in the serum of experimental 
mice using a rat/mouse P1NP or rat/mouse CTX-1 enzyme immunoassay 
(Immunodiagnostic Systems, Newcastle, UK) respectively. The assays were 
performed by Ms Elaine Seawright. Quantification of serum concentration was 
achieved through extrapolation from the generated standard curves.  
2.9. Statistical methods 
Data were analysed with appropriate statistical tests using Graphpad Prism 6 
(Graphpad Software, California, USA). All data were initially assessed for normality 
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and equal variance to determine whether parametric or non-parametric tests should be 
used. Student’s t-test, one-way analysis of variance (ANOVA) and two-way ANOVA 
(with post hoc Holm-Sidak pairwise multiple comparison tests between individual 
groups) were applied where appropriate on parametric data sets. The Kruskal-Wallis 
test (with post hoc Dunn’s tests between individual groups) was used when comparing 
multiple data sets which were not normally distributed. Data are presented as mean ± 
standard error of the mean (S.E.M.) and ‘N’ refers to the number of individual samples 
assessed in the study.  
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3.1. Introduction 
Biomineralisation of vertebrate tissues, i.e. the deposition and propagation of HA 
within the ECM is an essential prerequisite in the provision of functional bone, dentin 
and growth plate cartilage (Anderson, 1995). This complex process depends on the 
coordination of both biochemical and physicochemical processes, mediated, in part, 
through a tightly controlled balance of promoters and inhibitors of mineralisation 
(Millán, 2012, Giachelli, 2005). During the initiation of skeletal mineralisation, 
amorphous calcium phosphate nucleates within the sheltered interior of MVs 
(Anderson, 2003, Cui et al., 2016). Believed to bud from the apical membrane of 
osteoblasts and hypertrophic chondrocytes in bone and growth plate cartilage 
respectively (Thouverey et al., 2009, Wuthier and Lipscomb, 2011), MV composition 
is directly related to their function. In particular, the inner leaflet of the MV membrane 
shows selective enrichment in PS, which alongside Anx, serve to accumulate calcium 
and aid the nucleation of calcium-phosphate complexes (Cotmore et al., 1971, Wu et 
al., 2002). Phosphatases too are essential regulators of ECM mineralisation, modifying 
local levels of Pi, PPi and indeed, the phosphorylation status of OPN, a key regulator 
of ECM mineralisation (Narisawa et al., 2013).  
The glycosylphosphatidylinositol anchored ectozyme, TNAP, is perhaps the most well 
established promoter of ECM mineralisation, catalysing the breakdown of PPi to Pi in 
the extra-vesicular environment to generate a Pi/PPi ratio conducive to HA propagation 
within the ECM (Register et al., 1986, Millan, 2006). Defective TNAP activity 
resulting from missense mutations in the ALPL gene, as observed in the human 
condition HPP (Henthorn and Whyte, 1992), or the complete genetic ablation of the 
Alpl gene in mice, results in severe hypomineralisation of the skeleton and teeth 
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ensuing after birth (Harmey et al., 2004, Yadav et al., 2012). Contrastingly, NPP1, is 
a plasma membrane glycoprotein generating PPi in the extra-vesicular environment 
from nucleoside triphosphates (Mackenzie et al., 2012b). Concomitant ablation of 
Enpp1 on a Alpl-/- genetic background partially restores the serum PPi levels and 
normalises skeletal mineralisation (Harmey et al., 2004), highlighting the antagonistic 
roles of these two MV enzymes. Intriguingly however, pioneering studies utilising 
electron microscopy revealed that MVs from patients with hypophosphatasia and Alpl-
/- mice possess crystals of HA within their interiors (Anderson et al., 1997, Anderson 
et al., 2004). These findings highlight alternative mechanisms of generating a 
PPi:Pi ratio conducive to mineral formation within the interior of MV. 
Active within chondrocyte- and osteoblast- derived MV (Roberts et al., 2004, Stewart 
et al., 2006) and expressed exclusively in mineralising bone, cartilage and dentin 
(Houston et al., 2004, Roberts et al., 2007, McKee et al., 2013), PHOSPHO1, is 
essential for the initiation of MV mediated mineralisation. Small molecule inhibition 
of PHOSPHO1 in MV’s derived from Alpl-/- mice significantly affects their ability to 
calcify in vitro (Roberts et al., 2007). The genetic ablation of Phospho1 results in 
severely hypomineralised skeletal and dental tissues with resulting bowing of the long 
bones, spontaneous fractures and scoliosis (Huesa et al., 2011, Yadav et al., 2011, 
McKee et al., 2013, Rodriguez-Florez et al., 2015). This phenotype may be 
underpinned by the recent observation that MV-mediated initiation of mineralization 
was impaired in chondrocytes from Phospho1 deficient mice (Yadav et al., 2016). 
Complete ablation of skeletal mineralisation is observed in Phospho1-/-;Alpl-/- double 
knockout embryos and in metatarsals cultured in the presence of both PHOSPHO1 and 
TNAP inhibitors (Yadav et al., 2011, Huesa et al., 2015). In vitro, PHOSPHO1 shows 
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high phosphohydrolase activity towards PCho and PEth, two metabolites derived from 
lipid metabolism (Roberts et al., 2004).  
More recently, hypomineralisation of skeletal and dental tissues was observed in the 
fro/fro mouse, a mouse containing a major deletion in the sphingomyelinase 
phosphodiesterase 3 (Smpd3) gene (Khavandgar et al., 2011, Khavandgar et al., 2013). 
Smpd3 encodes for neutral sphingomyelinase 2 (nSMase2) which catalyses the 
breakdown of the membrane lipid SM to ceramide and PCho. Through their role in the 
generation and processing of PCho, nSMase2 and PHOSPHO1 respectively, may 
function together to liberate Pi for skeletal mineralisation (Khavandgar and Murshed, 
2015). The links between lipid metabolism and skeletal mineralisation have been 
bolstered through investigation CK enzymes, which phosphorylate choline to produce 
PCho. Flp/flp mice, which possess a mutation  in exon 1 of the choline kinase β (Chkβ) 
gene, exhibit low bone mass and reduced osteoblast ECM mineralisation in vitro 
(Kular et al., 2015). Similarly, the pharmacological inhibition of choline kinase alpha 
(Chkα) in human osteosarcoma MG-63 cells leads to a diminished mineralisation 
capacity and a reduction in TNAP activity (Li et al., 2014b). The essential role of 
phosphate manipulation in the initiation of skeletal mineralisation, has, as highlighted 
above, been confirmed through the use of transgenic mouse models and in vitro models 
of mineralisation. To date however, these enzymes have been studied in isolation. To 
investigate whether any interplay exists between these enzymes, they must be studied 
simultaneously. Despite this, the examination of this potential interplay is hampered 
by the currently accepted in vitro models of mineralisation.  
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ECM mineralisation has been studied in vitro in a number of clonal cell lines, primary 
cell cultures and organ culture model systems. Well-established methodologies for 
inducing ECM mineralisation in these models requires the addition of phosphate 
sources with βGP the most common choice amongst most researchers. The use of βGP 
to induce ECM mineralisation however, has a number of limitations, particularly when 
seeking to investigate the regulation and control of enzymes essential for ECM 
mineralisation. For example, Alpl expression and activity is enhanced in the presence 
of βGP (Orimo and Shimada, 2006). Furthermore, the presence of matrix 
mineralisation in βGP supplemented cultures is considered by many, to merely 
indicate the presence of alkaline phosphatase activity, as was observed by Khouja et 
al. (1990), in which human trabecular osteoblasts mineralised their ECM to the same 
extent as human skin fibroblasts. The authors of this latter study additionally observed 
significant amounts of calcium and phosphate deposits in cell-free cultures (Khouja et 
al., 1990). This stimulation of alkaline phosphatase activity is a hindrance to the study 
of additional mineralisation regulators as it may modulate the requirement of 
underlying physiological processes in the production of Pi for HA formation. It is 
therefore crucial that exogenous phosphatase-substrate free models of ECM 
mineralisation are developed to allow the investigation of the expression and 
regulation of essential regulators of MV-mediated ECM mineralisation.  
3.2. Hypothesis 
ECM mineralisation can be achieved in vitro without the use of exogenous 
phosphatase substrates. ECM mineralisation involves the co-ordinated expression of 
key regulators of Pi generation. 
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3.3. Aims 
I) Identify suitable phosphatase-substrate free conditions for the in vitro 
mineralisation of MC3T3 osteoblast-like cell lines, primary calvarial 
osteoblasts and cultured embryonic metatarsals. 
II) Examine the temporal mineralisation of these in vitro models under 
phosphatase-substrate free conditions. 
III) Determine the temporal expression patterns of PHOSPHO1, TNAP and 
nSMase2 during mineralisation in the in vitro models developed in Aim I. 
3.4. Materials and methods 
3.4.1. MC3T3 cell culture 
The MC3T3-C24 control empty-vector transfected (EV) and MC3T3-C24 FLAG-
tagged PHOSPHO1 transfected (FP1) cells were previously generated by Dr Carmen 
Huesa (Huesa et al., 2015). MC3T3-C14, MC3T3-C24, MC3T3-C24 EV and MC3T3-
C24 FP1 cell lines  were seeded in multi-well plates at 1 x 104 cells/cm2 in maintenance 
medium and cultured as described in section 2.2.3 (see Table 1 for review of the 
characteristics of these and other cell lines used in this thesis). To investigate the 
mineralisation of MC3T3-C24 EV and MC3T3-C24 FP1 cell cultures in exogenous 
phosphatase-substrate free conditions (section 3.5.1.), cells were cultured for 14 days 
in maintenance media containing either: 50 µg/mL ascorbic acid (AA), 50 µg/mL AA 
and 1.5 mM calcium chloride, 50 µg/mL AA and 3.0 mM calcium chloride or 
50 µg/mL AA and 6 mM calcium chloride. To provide a comparison, MC3T-C24 EV 
and MC3T3-C24 FP1 cell cultures were cultured with maintenance media containing: 
50 µg/mL AA plus 5 mM βGP or 50 µg/mL AA plus 3 mM PCho (i.e. phosphatase-
substrate containing media). MC3T3- 
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Table 1. Characteristics of cell lines used.  
 
C14 and MC3T3-C24 cultures were supplemented with MC3T3 mineralisation media 
from day 0 for up to 10 days. 
3.4.2. Primary calvarial osteoblast cell culture 
Primary osteoblasts from the calvaria of new born wild-type (WT) and Phospho1-/- 
mice were extracted and seeded in multi-well plates at 1 x 104 cells/cm2 with 
maintenance medium as described in section 2.2.5. To investigate the mineralisation 
of primary osteoblast cultures in exogenous phosphatase-substrate free conditions 
(section 3.5.2.), cells were cultured for 28 days in maintenance media containing 
either: 50 µg/mL AA, 50 µg/mL AA and 1.5 mM calcium chloride, 50 µg/mL AA and 
3.0 mM calcium chloride or 50 µg/mL AA and 6 mM calcium chloride. To provide a 
comparison, WT and Phospho1-/- cell cultures were cultured with maintenance media 
containing: 50 µg/mL AA plus 5 mM βGP or 50 µg/mL AA plus 3 mM PCho. For the 
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assessment of temporal mineralisation and gene expression, primary osteoblast 
cultures from WT and Phospho1-/- mice were supplemented with primary osteoblast 
mineralisation media from day 0 for up to 28 days. 
3.4.3. Metatarsal organ culture 
The middle three metatarsals from WT and Phospho1-/- E15 mice were isolated 
aseptically as detailed in section 2.3.1. To investigate the validity of pooling the middle 
three metatarsals, the anatomical location of the dissected metatarsal was recorded and 
metatarsals were described as either the 2nd (medial of the three metatarsals), 3rd or 4th 
(lateral of the three metatarsals). Metatarsals were cultured for 7 days in metatarsal 
medium supplemented with 1 mM βGP.  
To investigate the mineralisation of cultured E15 metatarsals in exogenous 
phosphatase-substrate free conditions (section 3.5.4.), groups of between 5-10 
metatarsals were cultured in 300 µL of the following media for up to 7 days: metatarsal 
medium (i.e. AA only) alone, or metatarsal medium supplemented with 1.5 mM 
calcium chloride, 3 mM calcium chloride or 6 mM calcium chloride. The total length, 
and length of the mineralised zone were measured daily as described in section 2.3.1. 
To provide a comparison, metatarsals were similarly cultured in metatarsal media 
supplemented with either 1 mM βGP or 3 mM PCho. 
3.4.4. Assessment of ECM mineralisation 
The ECM mineralisation of MC3T3 and primary osteoblast cell cultures was assessed 
by alizarin red staining. Cell monolayers were fixed in 4% PFA on the specified day 
of culture and alizarin red staining and quantification was carried out as described in 
section 2.8.1. 
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3.4.5. Gene expression analysis 
MC3T3 and primary osteoblast cell cultures were scraped from the culture plastic-
ware on the specified day of culture and RNA was extracted as described in 2.4.1. E15 
metatarsals were snap frozen in liquid nitrogen (LN2) at the relevant time point in 
culture and RNA was extracted according to section 2.4.2. Five metatarsals were 
pooled for each sample to provide sufficient RNA. RNA from cell and organ cultures 
was reverse transcribed according to 2.4.3.  RT-qPCR was performed on three 
technical replicates per sample and the results for each gene of interest were 
normalised to the housekeeping gene Atp5b. Relative gene expression was calculated 
using the ΔΔCt method (section 2.4.4.) and expressed as a fold change against control 
cultures. 
3.4.6. Protein analysis  
Protein was extracted from cells and cultured E15 metatarsal samples (5 bones per 
sample) at the specified day of culture as described in sections 2.5.1. and 2.5.2. 
respectively. The concentration of the protein lysate was determined by DC assay as 
described in section 2.5.3. Fifteen micrograms of protein was loaded and the resultant 
nitrocellulose were probed by western blotting for PHOSPHO1, nSMase2, TNAP and 
β-actin as described in section 2.5.4.  
3.5. Results 
3.5.1. Establishing suitable exogenous phosphatase-substrate free conditions for 
the mineralisation of MC3T3-C24 EV and MC3T3-C24 FP1 cell cultures. 
The expression of Phospho1 and Alpl mRNA in MC3T3-C24 EV and MC3T3-C24 
FP1 cell cultures was assessed at day 0 (i.e. upon confluency) by RT-qPCR. Phospho1 
expression was significantly increased in MC3T3-C24 FP1 cell cultures compared to 
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MC3T3-C24 EV cell cultures (P<0.01, Fig. 3.1.A). There was no difference in Alpl 
expression observed between the two cell lines (Fig. 3.1.B).  
The ECM mineralisation of MC3T3-C24 EV and MC3T3-C24 FP1 cell cultures, 
cultured in the presence of various mineralisation promoting supplements was 
assessed on day 14 of culture by alizarin red staining and subsequent 
spectrophotometric quantification of the leached stain. Cultures supplemented with 
ascorbic acid only displayed no signs of mineral deposition by 
day 14 (Fig. 3.1. C & D). MC3T3-C24 FP1 cells cultured in the presence of 5 mM 
βGP displayed extensive ECM mineralisation which was significantly greater 
(P<0.001) than in βGP supplemented MC3T3-C24 EV cultures. Comparable, 
pronounced ECM mineralisation was observed in MC3T3-C24 FP1 cultures 
supplemented with 3 mM PCho, which was, again, significantly greater (P<0.001) than 
in 3 mM PCho supplemented MC3T3-C24 EV cultures. The ECM mineralisation of 
cell cultures was next determined in the presence of varying concentrations of calcium 
chloride; a molecule which is not cleaved by phosphatases. The addition of 1.5 mM 
calcium chloride to MC3T3-C24 FP1 cultures induced ECM mineralisation to around 
70% of that seen in 5 mM βGP treated cultures. The ECM mineralisation of MC3T3-
C24 FP1 cultures treated with 1.5 mM calcium chloride was also significantly greater 
than similarly treated MC3T3-C24 EV cultures (P<0.01). Furthermore, ECM 
mineralisation was completely absent in MC3T3-C24 EV cultures treated with 3 mM 
and 6 mM calcium chloride. In MC3T3-C24 FP1 cultures, 3 mM calcium chloride 
induced very low levels of ECM mineralisation, whilst in the presence of 6mM 
calcium chloride, there was a complete absence of ECM mineralisation 
(Fig. 3.1.C & D).  
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3.5.2. Establishing suitable exogenous phosphatase-substrate free conditions for 
the mineralisation of WT and Phospho1-/- primary calvarial osteoblast cell 
cultures. 
In a similar experiment, ECM mineralisation was assessed in WT and Phospho1-/- 
primary osteoblast cultures, cultured in the presence of differing mineralisation media. 
After 28 days in cultures, ascorbic acid only treated cultures (both WT and Phospho1-
/-) displayed no evidence of ECM mineralisation as assessed by alizarin red staining 
(Fig. 3.2.). The addition of 5 mM βGP induced ECM mineralisation of primary 
osteoblast cultures with WT cultures showing a significantly greater extent of 
mineralisation compared to Phospho1-/- cultures (P<0.001). Extensive ECM 
mineralisation was likewise observed with the addition of  3mM PCho to WT and 
Phospho1-/- primary osteoblast cell cultures. WT primary osteoblast cultures treated 
with calcium chloride displayed ECM mineralisation in a dose dependent manner. 
ECM mineralisation was completely absent in the presence of 1.5 mM calcium 
chloride whereas mineralisation in the presence of 6 mM calcium chloride was 
comparable to that observed with 5 mM βGP treated cultures. In Phospho1-/- primary 
osteoblast cultures the trend was similar, although ECM mineralisation in the presence 
of 1.5, 3.0 and 6 mM calcium chloride was significantly less than that observed in 
corresponding WT cultures (P<0.01, Fig. 3.2.).  
3.5.3. Comparison of the in vitro growth and mineralisation capacity of 
anatomically distinct E15 metatarsals 
The growth and mineralisation capacity of the 2nd, 3rd and 4th metatarsals from E15 
mice was assessed to confirm the validity of the practice of pooling these metatarsals 
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Figure 3.1. Establishing suitable exogenous phosphatase-substrate free 
conditions for the mineralisation of  MC3T3-C24 EV and MC3T3-C24 FP1 cell 
cultures.  
RT-qPCR analysis of (A) Phospho1 (B) Alpl mRNA expression in MC3T3-C24 EV 
and MC3T3-C24 FP1 cell cultures upon confluency. (C) Representative images of 
alizarin red staining and (D) relative quantification of cetylpyridinium chloride 
leached bound dye from MC3T3-C24 EV and MC3T3-C24 FP1 cell cultures at day 
14. Data are represented as mean ± S.E.M. (N=3 replicates). ** P<0.01 and *** 
P<0.001 in comparison to MC3T3-C24 EV cell cultures. 
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Figure 3.2. Establishing suitable exogenous phosphatase-substrate free 
conditions for the mineralisation of WT and Phospho1-/- primary calvarial 
osteoblast cell cultures.  
(A) Representative images of alizarin red staining and (B) relative quantification of 
cetylpyridinium chloride leached bound dye from WT and Phospho1-/- primary 
calvarial osteoblast cell cultures at day 28. Data are represented as mean ± S.E.M. 
(N=3 replicates). ** P<0.01 and *** P<0.001 in comparison to WT cultures. 
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in experiments utilising this model. Metatarsals where cultured in metatarsal medium 
containing 1 mM βGP for 7 days, and the growth and appearance of mineral was 
monitored. E15 metatarsals displayed no evidence of diaphyseal mineral upon 
dissection (day 0). Metatarsals from all groups exhibited increased linear growth 
through the course of the 7 day culture. No statistical differences in growth between 
the 2nd, 3rd and 4th metatarsals were observed at any point in the culture period. By day 
7 in culture the length of the 2nd, 3rd and 4th metatarsals had increased 93.6±2.84%, 
73.5±3.09% and 81.3±7.13% from day 0 respectively. Mineralisation of E15 
metatarsals was first observed on day 2 of culture and the length of mineralised region 
increased daily in all groups. At day 6 of culture the mineralised zone of cartilage was 
28.14±2.10%, 28.40±1.62%, and 25.36±1.19% of the total length of the metatarsal 
respectively. No significant differences in the extent of mineral were observed between 
metatarsals at any of the time points. The central three metatarsals from WT E15 
embryos were cultured in metatarsal media containing various additives for 7 days 
with the length of the rudiment and any diaphyseal mineral recorded each day. As no 
differences were observed in the growth or mineralisation capacity of the central three 
metatarsals (Fig. 3.3.), metatarsals were pooled upon dissection. E15 metatarsals did 
not possess mineralisation upon dissection (day 0). 
3.5.4. Mineralisation of E15 metatarsals in exogenous phosphatase-substrate free 
conditions 
In all of the conditions tested, metatarsals exhibited increased linear growth during the 
culture period. There were no significant differences in the percentage increase in 
length from day 0 between the different media additives. Metatarsals supplemented 
with 1 mM βGP displayed evidence of diaphyseal mineral by day 2 in culture. There  
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(Previous page) Figure 3.3. Comparison of the growth and mineralisation 
capacity of anatomically distinct WT E15 metatarsals in culture.  
(A) Representative images of the 2nd, 3rd and 4th metatarsals during culture. (B) 
Analysis of the growth rate and (C) percentage mineral of the 2nd, 3rd and 4th WT E15 
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was a complete absence of mineralisation observed in metatarsals supplemented with 
3 mM calcium chloride. Metatarsals cultured with 1.5 mM calcium chloride 
mineralised their ECM from day 3 onwards, but the extent of ECM mineralisation was 
noticeably less than that of non-calcium chloride treated rudiments. Metatarsals 
cultured with ascorbic acid only and 3 mM PCho supplemented media showed 
evidence of diaphyseal mineral at day 3, which increased daily. By day 7  in culture, 
metatarsals cultured in ascorbic acid only media and 1 mM βGP supplemented media 
displayed significantly increased percentage mineral compared to 3 mM PCho and 1.5 
mM calcium chloride supplemented metatarsals (P<0.01, Fig. 3.4.C).  
3.5.5. Assessment of the temporal ECM mineralisation of MC3T3-C14 and 
MC3T3-C24 cultures. 
Based on the data shown in Fig. 3.1.C & D, MC3T3-C14 and MC3T3-C24 cells were 
cultured in 1.5 mM calcium chloride supplemented mineralisation media (MC3T3 
mineralisation media) and matrix mineralisation was assessed by alizarin red staining 
and quantified as described in section 3.4.4. MC3T3-C14 cells mineralised their matrix 
by day 10 in culture (P<0.001 compared to day 0, Fig.3.5.). Alizarin red staining was 
not observed in MC3T3-C24 cultures. Quantification of the alizarin red staining 
confirmed the enhanced ECM mineralisation in MC3T3-C14 cell cultures compared 
to MC3T3-C24 cell cultures (P<0.001) which is in agreement with previously 
published data.  
3.5.6. Analysis of the temporal gene and protein expression during MC3T3-C14 
and MC3T3-C24 matrix mineralisation 
The temporal expression of key mineralisation-dependent enzymes was investigated 
in MC3T3-C14 and MC3T3-C24 cell cultures by RT-qPCR and western blotting.  
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(Previous page) Figure 3.4. Establishing suitable exogenous phosphatase-
substrate free conditions for the mineralisation of cultured WT E15 metatarsals.  
(A) Representative images during culture. (B) Comparison of the growth rate of WT 
E15 metatarsals cultured with the various additives for 7 days. (C) Comparison of the 
percentage mineral of WT E15 metatarsals cultured with the various additive for 7 
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Phospho1 mRNA expression markedly increased in a temporal manner in MC3T3-
C14 cell cultures and by day 10, mRNA levels were ~150-fold higher (P<0.001) 
compared to day 0 (Fig. 3.6.A). Furthermore Phospho1 mRNA expression was 
significantly higher in MC3T3-C14 cultures compared to MC3T3-C24 cultures at day 
3, 5, 7 and 10 in culture. A similar temporal increase in Alpl and Smpd3 was also noted 
and by day 10 in culture the expression of both genes in MC3T3-C14 cell cultures was 
increased by >60-fold (P<0.001) compared to day 0 (Fig. 3.6.B & C). Smpd3 mRNA 
expression was significantly higher in MC3T3-C14 cultures compared to MC3T3-C24 
cultures at day 3, 5, 7 and 10 in culture. Alpl mRNA expression, on the other hand, 
was similarly expressed throughout the culture period by both cell lines. Enpp1 mRNA 
displayed a steady state expression between days 0 and 7 in culture which was 
comparable in MC3T3-C14 and MC3T3-C24 cultures. By day 10 of culture, Enpp1 
mRNA expression was markedly increased in MC3T3-C14 cell cultures (P<0.001 
compared to day 0, P<0.001 compared to MC3T3-C24 cell cultures). The mRNA 
expression of Chkβ was comparable between MC3T3-C14 and MC3T3-C24 cell 
cultures until day 10 of culture when its expression was enhanced in MC3T3-C14 
cultures (P<0.001, Fig. 3.6.F). The mRNA expression of Chkα on the other hand, was 
significantly greater in MC3T3-C24 cell cultures at days 5, 7 and 10 of culture 
(P<0.01). The changes in Phospho1, Alpl and Smpd3 gene expression were similarly 
noted at the protein level by western blotting (Fig. 3.6.G & H). 
3.5.7. Assessment of the temporal mineralisation of WT and Phospho1-/- primary 
calvarial osteoblast cell cultures. 
Based on the data presented in Fig. 3.2.A & B, WT and Phospho1-/- primary calvarial 
osteoblasts were cultured in 6 mM calcium chloride supplemented mineralisation 
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media (primary osteoblast mineralisation media) for 28 days. Matrix mineralisation 
was assessed at days 0 (confluency), 7, 14, 21 and 28 of culture by alizarin red staining 
and quantification as described in 3.4.4. The first evidence of ECM mineralisation was 
observed at day 21 of culture in both WT and Phospho1-/- cultures (P<0.001 for both 
genotypes compared to day 0). By day 28 in culture, WT osteoblast cultures displayed 
extensive ECM mineralisation which was significantly greater than that of     
Phospho1-/- osteoblast cultures (P<0.001, Fig. 3.7.).  
3.5.8. Analysis of the temporal gene and protein expression during WT and 
Phospho1-/- primary calvarial osteoblast matrix mineralisation. 
RT-qPCR and western blotting were used to investigate the mineralisation-dependent 
gene and protein expression respectively throughout the culture of WT and     
Phospho1 -/- primary calvarial osteoblast matrix mineralisation. In WT osteoblast 
cultures, Phospho1 mRNA expression showed a marked and temporal up-regulation, 
peaking at day 21 of culture (P<0.001 compared to day 0, Fig. 3.8.A) prior to returning 
to basal levels at day 28 of culture. Smpd3 mRNA expression in WT osteoblast cultures 
displayed similar increases to day 21 (P<0.001 compared to day 0, Fig. 3.8.C). 
Furthermore, Smpd3 mRNA expression was significantly greater in WT cell cultures 
compared to Phospho1-/- osteoblast cultures at days 14 and 21 of culture (P<0.001). 
By day 28, Phospho1-/- cultures displayed comparable expression of Smpd3 to WT 
cultures. Alpl mRNA expression was found to temporally increase during the ECM 
mineralisation of WT and Phospho1-/- osteoblast cultures. In WT osteoblast cultures, 
Alpl mRNA expression peaked at day 21 of culture (P<0.001 compared to day 0, 
Fig. 3.8.B) where it was likewise significantly greater than Phospho1-/- cultures. By 
day 28 of culture, the expression of Alpl mRNA had fallen from day 21 levels and was 
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Figure 3.5. Temporal mineralisation of MC3T3-C14 and MC3T3-C24 cell 
cultures in 1.5 mM calcium chloride supplemented media.  
(A) Representative images of alizarin red staining of cell monolayers at day 0 
(confluency), 3, 5, 7 and 10 of culture. (B) Relative quantification of cetylpyridinium 
chloride leached bound dye from MC3T3-C14 and MC3T3-C24 cell cultures at each 
time point in culture. Data are represented as mean ± S.E.M. (N=3 replicates), Two-
way ANOVA, CP<0.001 in comparison to day 0, *** P<0.001 in comparison to 
MC3T3-C24 cultures. 
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(Previous page) Figure 3.6. Analysis of the temporal gene and protein expression 
during MC3T3-C14 and MC3T3-C24 matrix mineralisation. 
RT-qPCR analysis of (A) Phospho1, (B) Alpl, (C) Smpd3, (D) Enpp1, (E) Chkα and 
(F) Chkβ mRNA expression in MC3T3-C14 and MC3T3-C24 cell cultures  at day 0  
(confluency), 3, 5, 7 and 10 of culture. (G) Western blotting of PHOSPHO1, TNAP, 
nSMase2 and the loading control, β-actin, at day 0, 3, 5, 7 and 10 of MC3T3-C14 cell 
culture. (H) Western blotting of PHOSPHO1, TNAP, nSMase2 and the loading 
control, β-actin, at day 0, 3, 5, 7 and 10 of MC3T3-C24 cell culture. Data are 
represented as mean ± S.E.M. (N=3 replicates), Two-way ANOVA, aP<0.05, bP<0.01 
and cP<0.001 in comparison to day 0, **P<0.01 and *** P<0.001 in comparison to 




Chapter 3               Development and characterisation of novel in vitro models of ECM mineralisation 
 
~ 85 ~ 
 
 
Figure 3.7. Temporal mineralisation of WT and Phospho1-/- primary calvarial 
osteoblast cell cultures in 1.5 mM calcium chloride supplemented media. 
(A) Representative images of alizarin red staining of cell monolayers at day 0 
(confluency), 7, 14, 21 and 28 of culture. (B) Relative quantification of 
cetylpyridinium chloride leached bound dye from WT and Phospho1-/- primary 
calvarial osteoblast cell cultures at each time point in culture. Data are represented as 
mean ± S.E.M. (N=3 replicates), Two-way ANOVA, CP<0.001 in comparison to day 
0, *** P<0.001 in comparison to Phospho1-/- cultures. 
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(Previous page) Figure 3.8. Analysis of the temporal gene and protein expression 
during WT and Phospho1-/- primary calvarial osteoblast matrix mineralisation.  
RT-qPCR analysis of (A) Phospho1, (B) Alpl, (C) Smpd3, (D) Enpp1, (E) Chkα and 
(F) Chkβ mRNA expression in WT and Phospho1-/- primary osteoblast cell cultures  at 
day 0 (confluency), 7, 14, 21 and 28 of culture. (G) Western blotting of PHOSPHO1, 
TNAP, nSMase2 and the loading control, β-actin, at day 0, 7, 14, 21 and 28 of WT 
primary osteoblast cell cultures. (H) Western blotting of PHOSPHO1, TNAP, 
nSMase2 and the loading control, β-actin, at day 0, 7, 14, 21 and 28 of Phospho1-/- 
primary osteoblast cell cultures. Data are represented as mean ± S.E.M. (N=3 
replicates), Two-way ANOVA, aP<0.05, bP<0.01 and cP<0.001 in comparison to day 
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comparable to the expression level of Phospho1-/- cultures. The changes in Phospho1, 
Alpl and Smpd3 gene expression were similarly noted at the protein level by western 
blotting (Fig. 3.8.G & H). Enpp1 expression levels were increased from day 7 onwards 
in both WT and Phospho1-/- osteoblast cultures (P<0.05 compared to day 0, 
Fig. 3.8.D). Phospho1-/- osteoblast cultures showed significantly enhanced Chkα 
mRNA expression at all time points in culture compared to WT cultures (P<0.001, 
Fig. 3.8.E). Chkβ mRNA expression in Phospho1-/- osteoblasts did not change 
throughout the 28-day culture. In WT cultures, Chkβ showed strong up-regulation at 
day 28 (P<0.001 compared to day 0) and indeed it expression was enhanced compared 
to Phospho1-/- cultures at days 21 and 28 of culture (P<0.001, Fig. 3.8.F).  
3.5.9. Comparison of the growth and mineralisation capacity of WT and 
Phospho1-/- E15 metatarsals in culture 
Based on the data described in section 3.5.4. the metatarsals from WT and        
Phospho1-/- E15 embryos were dissected and cultured for five days in AA only 
supplemented metatarsal media. Metatarsals from both genotypes progressively 
increased their length during the five day culture. WT metatarsals displayed increased 
longitudinal growth compared to Phospho1-/- counterparts from day three in culture 
onwards (P<0.001 compared to Phospho1-/- counterparts, Fig. 3.9.B). Cultured WT 
metatarsals displayed clear evidence of diaphyseal mineralisation initiating at day 
three, and increasing as previously shown in section 3.5.4. up to day five in culture 
(Fig. 3.9.C). Compared to WT metatarsals, cultured Phospho1-/- metatarsals displayed 
reduced mineralisation at both days four and five of culture (P<0.001). Qualitative 
assessment of the mineralisation zone during the culture period revealed a reduced 
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capacity of the mineralisation zone in Phospho1-/- metatarsals at all time points 
assessed.  
3.5.10. Analysis of the temporal gene and protein expression during WT and 
Phospho1-/- E15 metatarsal mineralisation in vitro. 
RT-qPCR and western blotting were used to investigate the mineralisation-dependent 
gene and protein expression respectively at days 1, 3 and 5 of the culture of WT and 
Phospho1-/- E15 metatarsals. In WT metatarsals, Phospho1 mRNA expression and 
PHOSPHO1 protein was found to be strongly up-regulated at days 3 and 5 of culture 
compared to day 1 (P<0.001, Fig. 3.10.A,G & H). Quantification of TNAP protein 
revealed a temporal increase during the culture period in both WT and Phospho1-/- 
metatarsals (Fig. 3.10.I). This was similarly shown through assessment of Alpl mRNA 
expression (Fig. 3.10.B). In contrast, the levels of nSMase2 protein were found to be 
significantly higher in WT compared to Phospho1-/- metatarsals at both days 3 and 5 
(Fig. 3.10.J). Indeed there was also a temporal rise in the expression of Smpd3 mRNA 
in WT metatarsals peaking at day 5 (P<0.001, Fig.3.10.C), where its expression was 
likewise significantly higher than in Phospho1-/- metatarsals (P<0.001). There were no 
significant differences in the mRNA expression of Enpp1 or Chkβ during the culture 
period or between genotypes. Chkα on the other hand, showed a strong enhancement 
of expression in Phospho1-/- metatarsals compared to WT metatarsals at all time points 
in culture (P<0.001, Fig. 3.10.E).  
3.6. Discussion 
ECM mineralisation has to date been studied extensively in vitro through the use of 
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Figure 3.9. Comparison of the growth and mineralisation capacity of WT and 
Phospho1-/- E15 metatarsals in culture.  
(A) Representative images WT and Phospho1-/- E15 metatarsals during culture. (B) 
Comparison of the growth rate of WT and Phospho1-/- E15 metatarsals cultured in 
ascorbic acid only media for 5 days. (C) Comparison of the percentage mineral of WT 
and Phospho1-/- E15 metatarsals cultured in ascorbic acid only media for 5 days. Data 
are represented as mean ± S.E.M. (N=6 replicates), Two-way ANOVA, *P<0.05, 
**P<0.01 and ***P<0.001 compared to Phospho1-/- metatarsals at each time point in 
culture. 
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(Previous page) Figure 3.10. Analysis of the temporal gene and protein expression 
during WT and Phospho1-/- E15 metatarsal mineralisation in vitro.  
RT-qPCR analysis of (A) Phospho1, (B) Alpl, (C) Smpd3, (D) Enpp1, (E) Chkα and 
(F) Chkβ mRNA expression in WT and Phospho1-/- E15 metatarsals  at day 1, 3 and 5 
of culture. (G) Western blotting of PHOSPHO1, TNAP, nSMase2 and the loading 
control, β-actin, at day 0, 7, 14, 21 and 28 of WT and Phospho1-/- E15 metatarsals  at 
day 1, 3 and 5 of culture. Relative quantification of (H) PHOSPHO1, (I) TNAP and 
(J) nSMase2 protein levels during the culture of WT and Phospho1-/- E15 metatarsals. 
Data are represented as mean ± S.E.M. (n=3 replicates, with 5 metatarsals per 
replicate), Two-way ANOVA, aP<0.05, bP<0.01 and cP<0.001 in comparison to day 
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immortalised cell lines, primary cell cultures and organ cultures. Despite this, the use 
of βGP in these cultures as an inducer of mineralisation has limited the ability to 
understand the physiological mechanisms surrounding the initiation of mineralisation. 
The data presented in this Chapter has led to the establishment of phosphatase-
substrate free conditions for the culture of three distinct models of in vitro ECM 
mineralisation. Furthermore, these models systems have been employed to begin to 
understand the temporal expression of key regulators of ECM mineralisation.  
This study initially utilised the murine osteoblast-like cell line, MC3T3-E1, originally 
isolated by (Sudo et al., 1983). In particular, sub-clones 14 and 24 of the MC3T3-E1 
cell lines, characterised previously as having respectively low and high basal 
expression levels of Alpl (Wang et al., 1999) were used. Clone 14 cells express high 
levels of Runx2, Bglap (osteocalcin) and Ibsp (bone sialoprotein) compared with clone 
24 cells (Wang et al., 1999). My observation here that clone 14 cells express 
significantly higher levels of Phospho1 than clone 24 cells may explain the inability 
of clone 24 cells to induce in vivo osteogenesis or in vitro ECM mineralisation despite 
high levels of TNAP (Wang et al., 1999, Huesa et al., 2015). The presence of 
PHOSPHO1 may be essential to drive the initiation of MV mineralisation, a process 
that is not thought to involve TNAP (Millán, 2012, Yadav et al., 2016). The suitability 
of MC3T3 cell cultures as models of in vivo mineralisation have been further 
strengthened through the identification that the organisation, orientation and 
composition of the mineral phase formed within these cultures is remarkably similar 
to that of bone (Addison et al., 2015). The observation that MC3T3-C14 cells show 
evidence of ECM mineralisation within 10 days highlights their use as a rapid and 
reproducible model of ECM mineralisation. The mineralisation of the cartilaginous 
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ECM of hypertrophic chondrocytes is an essential precursor for subsequent functional 
bone formation (Heilig et al., 2016). The study of isolated chondrocytes in vitro 
however, has limitations, for example, the dedifferentiation and loss of key markers 
such as Col2a1 (Ma et al., 2013). The mouse metatarsal explant culture provides a 
highly physiological ex vivo model for studying endochondral ossification (Haaijman 
et al., 1999, Marino et al., 2016). In particular, the absence of HA mineral in E15 
metatarsal bones means that they provide an unrivalled model to investigate the 
initiation of skeletal mineralisation. The maintenance of the discrete chondrocyte 
zones, cell-cell and cell-matrix interaction offers conditions closer to the in vivo 
situation than cells in culture (Scheven and Hamilton, 1991, Coxam et al., 1996, 
Andrade et al., 2011). Furthermore, the absence of foetal calf serum from these 
cultures allows for a more defined media and eliminates the variability in ECM 
mineralisation which is often associated with the use of animal sera (Boskey and Roy, 
2008).  
Unfortunately, with the purpose of the current study in mind, i.e. to understand the 
temporal expression of key regulators of MV phosphate generation, the currently 
accepted methods of inducing ECM mineralisation in the models described, limit their 
use. It is vital that the ECM mineralisation observed in these models is cell mediated. 
The addition of βGP to the aforementioned model systems, a substrate of TNAP 
(Roberts et al., 2004), was a major concern for the current study. In the presence of 
recombinant TNAP, mineral deposition has been observed in human fibroblast 
cultures and cell-free, media only cultures supplemented with 10 mM βGP (Khouja et 
al., 1990, Chung et al., 1992). Greater than 80% hydrolysis of βGP occurs in the 
presence of TNAP (Bellows et al., 1992). The generation of supra-physiological levels 
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of Pi alongside calcium (~1 mM in most basal media) results in the precipitation of 
amorphous calcium phosphate (Boskey and Roy, 2008). Gronowicz et al. (1989) 
showed this non-physiological mineralisation, characterised by ectopic mineralisation 
(i.e. out-with the collagenous matrix), in rat parietal bone cultures in the presence of 
1-10 mM βGP. The effects of other exogenous phosphate sources on the induction of 
TNAP and other essential phosphate generating enzymes has not been studied as 
thoroughly. Regardless, this study sought to understand the expression of enzymes 
involved in the endogenous production of Pi, and as such it was the aim of this study 
to eliminate the use of βGP from in vitro models of ECM mineralisation.  
Experimentation carried out in this Chapter identified calcium chloride 
supplementation as a suitable inducer of ECM mineralisation in cell culture 
experiments. ECM mineralisation of around 70% of that observed in βGP treated 
cultures, was achieved in the presence of calcium chloride in both MC3T3 and primary 
calvarial osteoblasts cultures. This study expands on previous studies which observed 
ECM mineralisation in the presence of calcium chloride, albeit with concomitant Pi 
supplementation, in rat osteoblast-like cell cultures and vascular smooth muscle cell 
calcification studies (Chang et al., 2000, Kapustin et al., 2011). Chang et al. (2008) 
achieved osteoblast ECM mineralisation with 14 mM calcium chloride supplemented 
media. Previous reports however, highlight that TNAP activity may be enhanced in 
osteoblastic ROS17/2.8 cells cultured with calcium chloride concentration exceeding 
6 mM (Rashid et al., 2003), hence in this study only calcium chloride concentrations 
of less than 6 mM were assessed. The present study would have benefited from 
analysis of cell-free cultures in the presence of the calcium containing media assessed, 
so as to rule out any non-cell mediated precipitation of calcium phosphate. 
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Intriguingly, E15 metatarsals failed to initiate diaphyseal mineralisation when cultured 
in 3 mM calcium chloride supplemented media despite exhibiting typical longitudinal 
growth. The presence of sodium bicarbonate in the culture medium (a standard 
buffering agent in αMEM) alongside calcium chloride may lead to the formation of 
calcium carbonate, and thus reduction of free calcium levels (Amin et al., 2009). This 
may provide some explanation to the observed inhibition of mineral formation. The 
mineralisation of cultured metatarsals was however achieved in ascorbic acid only 
supplemented metatarsal media. The addition of ascorbic acid only, provides the 
optimum conditions to investigate the role of phosphatases in the initiation of 
mineralisation.  
Having established suitable, phosphatase-substrate free conditions for the culture of 
osteoblasts and embryonic metatarsals, the temporal expression of key regulators of 
ECM mineralisation was assessed in these in vitro models. In all of the models 
assessed in this study, PHOSPHO1, nSMase2 and TNAP displayed coordinated and 
significant increases in the levels of transcript and protein prior to the onset of ECM 
mineralisation. In particular, the similarities in the temporal rise of PHOSPHO1 and 
nSMase2 protein bolsters the idea that these phosphatases work in tandem to generate 
Pi within MV during the initiation of mineralisation. Furthermore, PHOSPHO1 has 
recently been implicated in the biogenesis of MV (Yadav et al., 2016) and as such its 
expression prior to the onset of mineralisation may be crucial for the formation of MV 
that ultimately contain a precipitated carbonate-substituted hydroxyapatitic mineral 
phase (Anderson, 1969, Register et al., 1986). Perhaps unsurprising, the function of 
nSMase2 has similarly been linked with MV biogenesis, whereby siRNA and 
pharmacological inhibition of nSMase2 activity results in reduced MV production, 
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albeit in macrophages and vascular smooth muscle cell cultures (Kapustin et al., 2015, 
Chen et al., 2016, Thouverey et al., 2011). The higher expression of TNAP late on 
(day 10) in MC3T3-C14 cell cultures is indicative of its role in the later stages of 
mineralisation where it allows the propagation of HA within the ECM beyond the 
confines of the MV membrane (Huesa et al., 2011, Millán, 2012). In contrast, TNAP 
was strongly expressed early on (day 7) in WT primary osteoblast cultures and in E15 
metatarsals, suggesting that it may be necessary to modulate the ECM Pi/PPi ratio in 
advance of the mineral propagation stage. Alternatively, recent studies have 
highlighted the importance of extravesicular to intravesicular Pi transport through the 
type III Na/Pi co-transporter, Pit1 (Yadav et al., 2016). The production of Pi through 
TNAP hydrolysis of PPi in the extravesicular environment and its transport into MV 
may provide an additional and necessary source of Pi for the nucleation of calcium 
phosphate within MV and may explain why MV mineralisation is not completely 
absent in Phospho1 deficient mice (Yadav et al. 2016). These findings also highlight 
the similar expression patterns of PHOSPHO1 and nSMase2 during osteoblast and 
hypertrophic chondrocyte ECM mineralisation. However, it is essential to take into 
account that this study did not assess the activity of the proteins investigated. Changes 
in mRNA or protein abundance are not directly related to enzyme activity or the 
concentrations of the generated or utilised intravesicular metabolites (Glanemann et 
al., 2003).  
Alpl expression and TNAP activity have previously been shown to be reduced in the 
Phospho1-/- mouse (Yadav et al., 2011). In the current study, Alpl expression was 
similarly decreased in mineralising osteoblast cultures with either diminished or absent 
Phospho1 expression. Expanding on this, nSMase2 expression was markedly reduced 
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in MC3T3-C24 cell cultures and Phospho1-/- calvarial osteoblast and metatarsal 
cultures. One might hypothesise, that in the absence of PCho utilisation by 
PHOSPHO1, there is a reduced requirement to generate PCho through the hydrolysis 
of sphingomyelin by nSMase2. In Chkβ-/- chondrocyte cultures, the reduced substrate 
(PCho) generation, results in an enhancement of PHOSPHO1 expression, perhaps as 
a compensatory rescue mechanism to ensure sufficient Pi generation for calcium 
phosphate precipitation (Li et al., 2014a). In this study, Chkα expression was notably 
higher in Phospho1-/- osteoblast and metatarsal cultures. These data are in 
disagreement with the hypothesis that in the absence of PHOSPHO1 there would a 
reduced demand for PCho generation. Importantly, despite both isoforms (Chkα and 
Chkβ) being involved in the generation of PCho and PEth, recent studies have shown 
that these enzymes have divergent roles in cancer pathogenesis (Gallego-Ortega et al., 
2009). It is possible therefore, that these enzymes also play differential roles in skeletal 
mineralisation. 
The expression of Enpp1 which generates extravesicular PPi through its 
phosphodiesterase and pyrophosphatase activity (Mackenzie et al., 2012b, Kato et al., 
2012), was the only negative regulator of mineralisation examined in this study. Enpp1 
expression was moderately upregulated during the mineralisation of primary calvarial 
osteoblast and embryonic metatarsals cultures. In MC3T3-C14 cell cultures, Enpp1 
expression displayed a marked upregulation at day 10 of culture, when mineral could 
first be observed by alizarin red staining. It is plausible that the expression of Enpp1 
is suppressed during the initiation of mineralisation and induced by the presence of 
HA so as to provide some form of negative regulation to the extravesicular propagation 
of mineral. In future experiments, it would be worthwhile examining the expression of 
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other proteins know to modulate local PPi levels, for example ANK and ABCC6 an 
ATP-binding cassette, which, by an as yet unidentified mechanism, raises extracellular 
levels of PPi (Jansen et al., 2013).  
Data from this Chapter provides a comprehensive understanding of the temporal 
expression of phosphate manipulating enzymes during ECM mineralisation. Indeed, it 
is the first in vitro evidence which bolsters the hypothesis that nSMase2 and 
PHOSPHO1 function in tandem for the generation and processing of PCho 
respectively, during the initiation of MV-mediated mineralisation. Furthermore, the 
reduced expression of nSMase2 in the absence of PHOSPHO1, highlights a potential 
negative feedback mechanism. In addition, the exogenous phosphatase-substrate free 
culture conditions developed in this Chapter will allow the further investigation of the 
interplay and regulation of these enzymes to be carried out.  
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4.1. Introduction 
In the previous Chapter, the paucity of information surrounding the expression patterns 
and regulation of the key regulators of MV mediated mineralisation, PHOSPHO1 and 
nSMase2 was emphasised. Chapter 3 addressed this in part, by providing data on the 
temporal expression of these enzymes during ECM mineralisation in vitro. With such 
an essential role in the initiation of mineralisation, targeting the regulation of 
PHOSPHO1 and nSMase2 could provide a novel target for therapeutic interventions 
seeking to modulate the mineralisation process. This Chapter sought to uncover if 
these mineralisation-dependent enzymes were under endocrine regulation.  
Shortly after the original identification of Phospho1 as a novel phosphatase, expressed 
exclusively in mineralising bone and cartilage (Houston et al., 1999), researchers 
sought to uncover the regulation of the enzyme in vitro. These original studies, 
focussed their attention to the human osteosarcoma cell line SaOS-2, where they 
showed that neither dexamethasone, estradiol, Vitamin D3, PTH nor parathyroid 
hormone related peptide (PTHrP) elicited any effect on the expression of Phospho1 
(Houston et al., 2004). Although limited in the extent of data provided, there exists 
additional data regarding the regulation of Phospho1 (described as 4G8 by the authors) 
expression by TGFβ, however this work only appeared in a meeting abstract (Aukhil 
et al., 2000). Knowledge surrounding the regulation of Smpd3 expression is more 
comprehensive. To date, tumour necrosis factor α, BMP-2, PTHrP and the master 
regulator of chondrogenesis, SOX9, have all been shown to modulate the expression 
of Smpd3 in vitro (Chae et al., 2009, Clarke et al., 2011, Kakoi et al., 2014, Li et al., 
2016). 
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A recent RNA-seq analysis by St John et al., 2015, revealed that Phospho1 and Smpd3 
expression are negatively regulated by PTH treatment in IDG-SW3 cells (an osteocyte-
like cell line). This study extends a growing body of evidence revealing that PTH can 
regulate a plethora of genes involved in bone formation and osteoblast function (Silva 
and Bilezikian, 2015). Indeed, a microarray study of PTH treated UMR-106-01 cells, 
a rat osteosarcoma cell line, revealed >100 differentially regulated genes, with the gene 
expression profile closely mimicking the gene expression pattern observed during 
osteoblast differentiation (Qin et al., 2003). The transcription and post-translational 
modification (phosphorylation) of Runx2, the transcription factor and master regulator 
of osteoblast differentiation, are also strongly enhanced by PTH (Krishnan et al., 
2003). Interestingly, the overexpression of Runx2 in mouse limb bud cultures 
simultaneously enhances the expression of both Phospho1 and Smpd3 (Nishimura et 
al., 2012). These alterations in osteoblast gene expression may underscore the ability 
of PTH to elicit both anabolic and catabolic effects on the skeleton depending on the 
duration of the exposure. For example daily injections of low dose PTH are anabolic 
to the skeleton whereas continuous exposure to PTH, the likes observed in 
hyperparathyroidism, results in bone loss and increased porosity especially in the 
cortical compartment (Locklin et al., 2003). Indeed, despite an overall increase in bone 
remodelling (Eriksen, 2002), the enhancement of RANKL expression and thus 
osteoclastogenesis, and the suppression of OPG (Ma et al., 2001), ensures that any 
increases in bone formation are outweighed by a prevailing bone resorption response. 
Furthermore, the bone formation response that occurs is predominated by osteoid 
production rather than a true mineralised bone matrix (Dempster et al., 1999). The 
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reduction in bone mineral density (BMD) associated with hyperparathyroidism (Iida-
Klein et al., 2005) may be a direct effect of PTH on key regulators of mineralisation. 
This study therefore, sought to examine the effect of PTH exposure on PHOSPHO1, 
TNAP and nSMase2 expression in osteoblast-like cells and calvariae explants as well 
as to identify the PTH signal transduction pathways involved. 
4.2. Hypothesis 
Phospho1 is potently regulated by PTH in osteoblasts in a cAMP/PKA dependent 
manner.   
4.3. Aims 
I) Confirm the down-regulation of Phospho1 expression in IDG-SW3 cells  
II) Detail the temporal PTH regulation of Phospho1, Smdp3 and Alpl in osteoblasts. 
III) Determine whether the regulation of these genes by PTH is dependent on protein 
synthesis 
IV) Investigate the PTH signalling pathways in osteoblasts that mediate the changes 
in Phospho1, Alpl and Smpd3 gene expression 
4.4. Materials and Methods 
4.4.1. IDG-SW3 cell culture 
IDG-SW3 cells were seeded in 6-well plates at 4 x 104 cells/cm2 with IDG-SW3 
proliferation medium as described in section 2.2.4. Upon confluency, proliferation 
media was replaced with differentiation media and cultures were maintained for up to 
28 days with media changes every 2-3 days. IDG-SW3 cultures were exposed to PTH 
(50 nM) for 24 h prior to each of the time points investigated.  
Chapter 4                                Investigating the effects of parathyroid hormone on PHOSPHO1 in vitro 
 
~ 104 ~ 
 
4.4.2. MC3T3-C14 cell culture 
MC3T3-C14 cells were plated at 1 x 104 cells/cm2 in 6-well plates and cultured in 
maintenance medium as described in section 2.2.3. Upon confluency, maintenance 
media was replaced with MC3T3 mineralisation media and cultures were maintained 
for up to 14 days with media changes every 2-3 days. 
To examine the effects of continuous PTH on MC3T3-C14 gene and protein 
expression, the culture media was replaced with fresh mineralisation media containing 
either bPTH (1-34) (Sigma-Aldrich) (referred to as PTH) at various concentrations 
(0.5 -50 nM) or vehicle (PBS) and for various lengths of time (15 min - 72 h). Unless 
otherwise stated, cells were cultured for six days (from confluency) under osteogenic 
conditions prior to the addition of PTH in order to avoid suppression of osteoblast 
differentiation (Bellows et al., 1990, Isogai et al., 1996). To investigate the signalling 
pathways mediating the effects of PTH, cells were also treated with forskolin (25 µM, 
Sigma-Aldrich), phorbol 12-myristate 13-acetate (PMA, 100 nM, Sigma-Aldrich), 
PKI (5-24) (100 nM, Santa Cruz Biotechnology, Texas, USA) and napthol-AS E-
phosphate (20 µM, Sigma-Aldrich) or appropriate vehicle controls for the time 
indicated. To assess the requirement of protein synthesis in the PTH regulation of 
Phospho1, Alpl and Smpd3, cells were pre-incubated for 2 h with cycloheximide 
(25 µM, Sigma-Aldrich) or DMSO control prior to stimulation with either 50 nM PTH 
or PBS for 6 h.  
To examine the effects of intermittent PTH, MC3T3-C14 cell cultures were exposed 
to 50 nM PTH for either 1 h or 6 h in every 24 h period. After the PTH exposure period 
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was finished, cell monolayers were rinsed in MC3T3 mineralisation media, before 
culturing cells in this media for the remainder of the 24 h.  
4.4.3. Murine calvariae culture  
Calvariae from 4-5 day old wild-type (WT) pups were dissected under sterile 
conditions. Hemi-calvariae were cultured in 24-well plates in 350 µL of calvaria 
culture medium as described in section 2.3.2. After 24 h hemi-calvariae were treated 
with 50 nM PTH, forskolin (25 µM), PMA (100 nM), and PKI (5-24) (100 nM) or 
appropriate vehicle controls for the times indicated.  
4.4.4. Murine primary calvarial osteoblast culture 
Primary osteoblasts from the calvaria of new born WT and Phospho1-/- mice were 
extracted and seeded in 6-well plates at 1 x 104 cells/cm2 with maintenance medium 
as described in section 2.2.5. Upon confluency, maintenance media was replaced with 
primary osteoblast mineralisation media and cultures were maintained for up to 28 
days with media changes every 2-3 days. Primary osteoblast cultures were exposed to 
PTH (50 nM) for 24 h prior to each of the time points investigated.  
4.4.5. Human subchondral bone osteoblast culture 
Subchondral bone osteoblasts were extracted from excised human knee replacement 
samples as described in section 2.2.6. Osteoblasts were seeded in 6-well plates at 3 x 
104 cells/cm2 in human osteoblast maintenance media. Upon confluency, cell cultures 
were exposed to PTH (50 nM) for 24 h.  
4.5.6. Embryonic metatarsal culture 
The central three metatarsals from WT embryonic day 15 (E15) mice were dissected 
under sterile conditions and cultured in 24-well plates containing 350 µL metatarsal 
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medium as described in section 2.3.1. Metatarsals were cultured for 4 days, at which 
point they were exposed to PTH (50 nM) for 24 h.  
4.4.7. Gene expression analysis 
Cell monolayers and tissue from organ cultures were harvested at the specific time 
point in culture.  RNA was extracted and reverse transcribed as described in sections 
2.4.1. 2.4.2. and 2.4.3. respectively. RT-qPCR was performed on three technical 
replicates per sample and the results for each gene of interest were normalised to the 
appropriate housekeeping gene for the sample: Atp5b was used for MC3T3-C14; 
murine primary osteoblasts and murine calvarial organ cultures; Gapdh was used for 
IDG-SW3 and murine E15 metatarsal cultures; GAPDH was used for human 
subchondral bone osteoblast cultures. Relative gene expression was calculated using 
the ΔΔCt method (section 2.4.4.) and expressed as a fold change against control 
cultures. 
4.4.8. Protein analysis 
Protein was extracted from MC3T3-C14 cell monolayers at the specified time point of 
culture as described in section 2.5.1. The concentration of the protein lysate was 
determined by DC assay as described in section 2.5.3. and protein (15 µg) was 
electrophoresed in 10% Bis-Tris polyacrylamide gels. The resultant nitrocellulose 
membrane was probed by western blotting for PHOSPHO1, nSMase2, TNAP and β-
actin as described in section 2.5.4.  
4.4.9. Assessment of ECM mineralisation 
The ECM mineralisation of MC3T3-C14 cell cultures continuously exposed to PTH 
for 10 days was assessed by alizarin red staining. Cell monolayers were fixed in 4% 
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PFA on the specified day of culture and alizarin red staining and quantification was 
carried out as described in section 2.8.1. 
4.5. Results 
4.5.1 The effects of PTH on the expression of Phospho1 in IDG-SW3 cells. 
To validate and expand on the findings of St John et al., 2015, IDG-SW3 cells were 
treated with 50 nM PTH for 24 h at different time points during the 28 day culture 
period. A downregulation of Phospho1 expression was noted at all time points 
assessed (P<0.05, Fig. 4.1.).    
4.5.2. The effects of PTH on gene and protein expression in MC3T3 cells  
Initial experiments assessed the ability of varying concentrations of PTH to regulate 
Phospho1, Alpl and Smpd3 expression in MC3T3-C14 cells. MC3T3-C14 cells were 
treated with 0.05 – 50 nM PTH for 24 h on day 6 of culture, when initial mineral 
formation could be observed with light microscopy. At concentrations of 0.5 nM and 
above, PTH significantly down-regulated Phospho1 mRNA expression (P<0.001, 
Fig. 4.2.A). PTH increased Alpl expression at the two highest concentrations 
examined, 25 nM (P<0.05) and 50 nM (P<0.001), whereas it down regulated Smpd3 
expression at all concentrations examined (P<0.001, Fig. 4.2.B & C). Western blotting 
confirmed that the changes in gene expression were replicated at the protein level 
(Fig. 4.2.J).   
The temporal effects of PTH on Phospho1, Alpl and Smpd3 expression at day 7 of 
culture (matching the end point in experiments described in Fig. 4.2.A-C) were next 
examined. PTH rapidly down-regulated Phospho1 after 15 min which was further 
exacerbated after 1 h and 6 h exposures (P<0.001, Fig. 4.2.D). By 24 h, the down-  
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Figure 4.1. The effects of PTH on Phospho1 expression in IDG-SW3 cells. 
(A) Phospho1 mRNA expression in response to 24 h bPTH (1-34) (50 nM) exposure 
in IDG-SW3 cells at different stages of differentiation (confluency (day 0), days 7, 14, 
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regulation of Phospho1 by PTH was lessened (P<0.05) and after 48 h and 72 h 
exposures Phospho1 expression had returned to basal levels. Enhancement of Alpl 
expression by PTH was noted after 1 h (P<0.05), peaking at 6 h (P<0.001) before 
returning to control levels after 24 h and longer exposures (Fig. 4.2.E). The expression 
pattern of Smpd3 in response to PTH was similar to that of Phospho1 however the 
speed of reduced expression and its normalisation were slower (Fig. 4.2.F). Changes 
in protein levels of PHOSPHO1, TNAP and nSMase2 reflected their respective 
changes in gene expression (Fig. 4.2.K). Notably, the expression levels of PHOSPHO1 
and nSMase2 were less and TNAP was greater after 24 h and 48 h PTH exposure. 
After a 72 h exposure all proteins were expressed at a comparable level to the control 
treated cultures.   
Finally, the effect of PTH (50 nM, 24 h) on the expression of Phospho1, Alp1 and 
Smpd3 was assessed in MC3T3-C14 cells at different stages of differentiation. 
Phospho1 and Smpd3 regulation by PTH was not dependent on the differentiation 
status of the cell cultures, with both genes being significantly down-regulated 
(P<0.001) at 0, 7 and 10 days in culture (Fig. 4.2.G & I).  In contrast, PTH induced 
expression of Alpl was more restricted and only reached significance at day 0 
(P<0.01, Fig. 4.2.H). Little or no PHOSPHO1, nSMase2 or TNAP protein was 
expressed at day 0 in culture and this was not obviously altered by PTH treatment 
(Fig. 4.2.L). At days 7 and 10 however, PTH decreased PHOSPHO1 and nSMase2 
expression whilst increasing TNAP expression, consistent with the gene expression 
data. 
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(Previous page) Figure 4.2. Regulation of key mineralisation genes by PTH in 
MC3T3-C14 cells.  
RT-qPCR analysis of (A) Phospho1, (B) Alpl and (C) Smpd3 mRNA expression in 
response to a 24 h exposure of various doses of bPTH (1-34) on day 6 of culture. RT-
qPCR analysis of (D) Phospho1, (E) Alpl and (F) Smpd3 mRNA expression in 
response to various exposure times of bPTH (1-34) (50 nM). The timing of PTH 
addition was adjusted to ensure all experiments finished on day 7 of culture. RT-qPCR 
analysis of (G) Phospho1, (H) Alpl and (I) Smpd3 mRNA expression in response to 
24 h exposure PTH (50 nM) in MC3T3-C14 cells at different stages of differentiation 
(confluency (day 0), days 7 and 10 post confluency). (J) Western blotting analysis of 
PHOSPHO1, TNAP, nSMase2 in response to a 24 h exposure of various doses of PTH. 
The fold change in fluorescence intensity against control treated cultures (normalised 
against beta-actin) is shown below each protein of interest. (K) Western blotting 
analysis of PHOSPHO1, TNAP, nSMase2 in response to various exposure times of 
PTH (50 nM). The fold change in fluorescence intensity against control treated 
cultures (normalised against beta-actin) is shown below each protein of interest. (L) 
Western blotting analysis of PHOSPHO1, TNAP, nSMase2 in response a 24 h PTH 
(50 nM) exposure in MC3T3-C14 cells at different stages of differentiation. The fold 
change in fluorescence intensity against day 0 control treated cultures (normalised 
against beta-actin) is shown below each protein of interest.  N=3, P<0.05*, P<0.01** 
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4.5.3. The effects of continuous PTH on the ECM mineralisation of MC3T3-C14 
cell cultures 
The addition of 50 nM PTH every 48 h to MC3T3-C14 cell cultures for 10 days caused 
a reduction in the extent of matrix mineralisation compared to control cultures as 
assessed by the quantitative alizarin red assay (0.141±0.005 vs. 0.083±0.018, P< 0.05, 
data no shown). 
4.5.4. The effects of PTH on gene expression in murine calvariae.  
Murine hemi-calvariae were treated with 50 nM PTH for 2, 6 and 24 h. A significant 
downregulation of both Phospho1 and Smpd3 expression in response to PTH was 
observed at 2 h (P<0.05), 6 h and 24 h (P<0.001, Fig. 4.3.A & C). Likewise, PTH 
exposure induced a down-regulation of Alpl expression, albeit only with 24 h exposure 
(P<0.01, Fig. 4.3.B). 
4.5.5. The effects of cycloheximide on Phospho1, Alpl and Smpd3 gene regulation 
by PTH. 
To determine whether PTH directly regulates Phospho1, Alpl and Smpd3 gene 
expression, MC3T3-C14 cells were pre-treated for 1 h with the protein synthesis 
inhibitor cycloheximide (25 µM), followed by treatment with 50 nM PTH for 6 h. 
Cycloheximide treatment alone did not affect basal levels of Phospho1, Alpl or Smpd3. 
In the presence of cycloheximide, PTH reduced the expression of Phospho1 (44.1%, 
P<0.01) but this was not to the same extent observed in the absence of cycloheximide 
(93.9%, P<0.001, Fig. 4.4.A). Cycloheximide treatment did not affect the potent 
regulation of Alpl and Smpd3 expression by PTH (Fig. 4.4.B & C). 
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Figure 4.3. Regulation of key mineralisation genes by PTH in cultured calvariae.  
RT-qPCR analysis of (A) Phospho1, (B) Alpl and (C) Smpd3 mRNA expression in 
response to various exposure times of PTH (50 nM). N>3 per time point, P<0.05* and 
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Figure 4.4. The effects of bPTH (1-34) on Phospho1, Alpl and Smpd3 in MC3T3-
C14 cells does not require protein synthesis.  
MC3T3-C14 cells were treated for 6 h with 50 nM PTH or vehicle control after a 2 h 
pre-treatment with 25 μM cycloheximide (CHX) or solvent control on day 7 in culture. 
(A) Phospho1, (B) Alpl and (C) Smpd3 mRNA expression was assessed by RT-qPCR. 
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4.5.6. Identification of the intracellular signalling pathways responsible for PTH 
regulation of Phospho1, Alpl and Smpd3 expression. 
Binding of PTH to the G-protein coupled receptor parathyroid hormone 1 receptor 
(PTH1R) primarily activates cAMP/PKA and PKC signalling pathways (Qin et al., 
2004). To determine which of these pathways was utilised by PTH to regulate 
Phospho1, Alpl and Smpd3 expression, MC3T3-C14 cells and murine hemi-calvariae 
were treated with the cAMP inducer forskolin (10 µM) or the PKC activator, PMA 
(100 nM) for 24 h. In MC3T3-C14 cells, forskolin replicated the effects of 50 nM PTH 
by inducing significant decreases in Phospho1 (P<0.001) and Smpd3 expression 
(P<0.001) whilst significantly increasing the expression of Alpl (P<0.001). PMA 
treated cells displayed no differences in Phospho1, Alpl or Smpd3 expression 
compared to control cultures (Fig. 4.5.A-C). The gene expression results in MC3T3-
C14 cells were confirmed at the protein level by western blotting (Fig. 4.5.D). In hemi-
calvariae, forskolin similarly replicated the effects of 50 nM PTH by inducing a 
significant decrease in Phospho1 (P<0.05), Smpd3 (P<0.001) and Alpl (P<0.001) 
expression (Fig. 4.5.E-G). PMA treated hemi-calvariae displayed no differences in 
Phospho1 expression, however the expression of Alpl and Smpd3 was strongly down-
regulated by exposure to PMA (P<0.001) (Fig. 4.5.E-G). To confirm the role of the 
cAMP/PKA signalling pathway as the mediator of the effects of PTH in MC3T3-C14 
cells, cell cultures were treated with the PKA inhibitor PKI (5-24) (100 nM) alone or 
in the presence of PTH for 6 h. The addition of PKI (5-24) alone did not alter the basal 
expression of Phospho1, Alpl or Smpd3. The addition of the PKA inhibitor reduced 
the ability of 50 nM PTH to significantly inhibit the expression of Phospho1 and  
 
Chapter 4                                Investigating the effects of parathyroid hormone on PHOSPHO1 in vitro 
 




Figure 4.5. Investigation of signalling pathways regulating the effects of PTH.  
MC3T3-C14 cells were treated with 50 nM PTH, 25 µM forskolin, 100 nM PMA or 
vehicle control for 24 h on day 6 in culture. (A) Phospho1, (B) Alpl and (C) Smpd3 
mRNA expression was assessed by RT-qPCR. (D) Western Blotting analysis of 
MC3T3-C14 cells treated as described above. Hemi-calvariae were treated with 50 nM 
PTH, 25 µM forskolin, 100 nM PMA or vehicle control for 24 h. (E) Phospho1, (F) 
Alpl and (G) Smpd3 mRNA expression was assessed by RT-qPCR. N=3, P<0.05*, 
P<0.01** and P<0.001*** in comparison vehicle control. 
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Figure 4.6. Inhibition of PKA signalling pathway abolishes the effects of PTH. 
MC3T3-C14 cells and hemi-calvariae were treated with 50 nM PTH or vehicle control 
for 6 h following a 1 h pre-treatment with 100 nM PKI (5-24) on day 6 of culture. (A) 
Phospho1, (B) Alpl and (C) Smpd3 mRNA expression in MC3T3-C14 and (D) 
Phospho1, (E) Alpl and (F) Smpd3 mRNA expression in hemi-calvariae, all assessed 
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Smpd3 (Fig. 4.6.A & C). Similarly, the induction of Alpl expression by PTH was 
abrogated by the co-incubation of PKI (5-24) (Fig. 4.6.B). In cultured hemi-calvariae, 
PKI (5-24) inhibited the down regulation of Phospho1 by PTH (Fig 4.6.D), whereas 
the down-regulation of Smpd3 by PTH was not affected by PKI (5-24) (P<0.001, Fig. 
4.6.F). In light of the previous data (Fig. 4.3.B) where PTH did not alter Alpl 
expression after 6 h (cf. 24 h) it was not surprising that PTH or the co-incubation of 
PKI and PTH had no effect on Alpl expression (Fig. 4.6.E). 
4.5.7. Investigation of transcription factors which may mediate the effects of PTH 
in cultured MC3T3 cells and murine calvariae. 
To investigate the role of the transcription factor CREB (cAMP response element-
binding protein) in mediating the effects of PTH on Phospho1 expression, napthol AS-
E phosphate (20 µM, a CREB, CREB binding protein (CBP) interaction inhibitor) was 
pre-incubated with MC3T3-C14 cells for 1 h prior to the addition of PTH (50 nM) for 
6 h. Napthol AS-E phosphate exposure did not modulate the downregulation of 
Phospho1 observed in the presence of PTH (Fig. 4.7.A). To understand the expression 
profile of other known osteoblast regulating transcription factors, MC3T3-C14 cells 
and murine calvariae were exposed to PTH for up to 6 h and the expression of the 
transcription factors Runx2, Sp7, Atf4 and Trps1 was assessed by RT-qPCR. The 
effects on expression were modest, in brief, the expression of Runx2 and Trps1 did not 
change in response to PTH exposure (Fig. 4.7.B & E) where as Sp7 expression was 
reduced after a 6 h PTH exposure (P<0.01, Fig. 4.7.C) and Atf4 was enhanced after 15 
min PTH exposure (P<0.01, Fig. 4.7.D). In cultured murine calvariae, the expression 
of Runx2, Atf4 and Trps1 was not altered in response to PTH (Fig. 4.7.F, H & I). In 
contrast, Sp7 expression was significantly down regulated  (P<0.05, Fig. 4.7.G). 
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Figure 4.7. Understanding the involvement of transcription factors in mediating 
the effects of PTH.  
MC3T3-C14 cells were treated with 50 nM PTH or vehicle control for 6 h following 
a 1 h pre-treatment with 20 µM napthol AS-E phosphate on day 6 of culture. (A) 
Phospho1 mRNA expression was assessed by RT-qPCR. (B) Runx2, (C) Sp7, (D) Atf4 
and (E) Trps1 mRNA expression was assessed by RT-qPCR in MC3T3-C14 cell 
cultures in response to a short-term exposure to 50 nM PTH on day 7 of culture. (F) 
Runx2, (G) Sp7, (H) Atf4 and (I) Trps1 mRNA expression was assessed by RT-qPCR 
in cultured murine calvariae in response to a short-term exposure to 50 nM PTH. N=3, 
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Figure 4.8. Combined effects of continuous PTH and BMP-2 exposure 
on Phospho1, Alpl and Smpd3 expression in MC3T3-C14 cells.  
(A) Phospho1, (B) Alpl and (C) Smpd3 mRNA expression was assessed by RT-qPCR 
in MC3T3-C14 cell cultures in response to a 24 h exposure to 50 nM PTH, 300 ng/mL 
BMP-2 or both on day 6 of culture. N = 3, *P<0.05, ***P<0.001 in comparison to 
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4.5.8. Investigating the combined effects of continuous PTH and BMP-2 exposure 
on gene expression in MC3T3 cells 
 
To investigate the effects of PTH exposure in MC3T3 cells treated with BMP-2, cells 
were cultured with either 50 nM PTH, 300 ng/mL BMP-2 or both for 24 h on day 6 of 
culture, and the expression of Phospho1, Alpl and Smpd3 was assessed by RT-qPCR. 
BMP-2 exposure significantly induced the expression of Phospho1, Alpl and Smpd3 
(P<0.001, Fig. 4.8.A–C). The stimulatory effect of BMP-2 on Phospho1 expression 
was nullified by the dual exposure of PTH, which caused Phospho1 expression to 
return to unstimulated control levels (Fig. 4.8.A). In contrast, the Smpd3 expression in 
cells treated with PTH or PTH and BMP-2 was similar (P<0.001, Fig. 4.8.C), 
suggesting that Smpd3 expression was highly sensitive to PTH exposure. The 
increased expression of Alpl by BMP-2 was not affected by the co-incubation of PTH. 
4.5.9. Alternate regulation of Phospho1 by PTH in primary osteoblast and 
embryonic metatarsal cultures.  
 
The effects of PTH on the regulation of Phospho1 expression was further assessed in 
murine primary calvarial osteoblasts, human subchondral bone osteoblasts and murine 
E15 metatarsals. Surprisingly, Phospho1 expression was enhanced in response to 24 h 
exposure to PTH in all three model systems. In murine primary calvarial osteoblasts, 
PTH enhancement of Phospho1 expression was observed at day 0, 7, 14, 21 and 28 of 
culture (P<0.001, Fig. 4.9.A). In human subchondral bone osteoblasts (derived from 
three different patients), 24 h PTH exposure resulted in a 5.7-fold increase compared 
to control cultures (P<0.001, Fig. 4.9.B). Finally, murine E15 metatarsals cultured for 
4 days in mineralising conditions, exhibited an upregulation of Phospho1 expression 
in response to 24 h PTH treatment (P<0.001, Fig. 4.9.C). 
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Figure 4.9. Alternate regulation of Phospho1 by PTH in primary osteoblast and 
embryonic metatarsal cultures. 
(A) Phospho1 mRNA expression in response to 24 h bPTH (1-34) (50 nM) exposure 
in murine primary osteoblast cells at different stages of differentiation (confluency 
(day 0), days 7, 14, 21 and 28 post confluency) (N=3). (B) Phospho1 mRNA 
expression in response to 24 h bPTH (1-34) (50 nM) exposure in human subchondral 
bone osteoblast cells. (N=3) (C) Phospho1 mRNA expression in response to 24 h 
bPTH (1-34) (50 nM) exposure on day 4 of culture in murine E15 metatarsals. N=3, 5 
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Figure 4.10. The effects of intermittent PTH exposure on the expression of 
Phospho1, Alpl and Smpd3 in MC3T3-C14 cells.  
MC3T3-C14 cells were cultured in mineralising conditions for 10 days. For either 1h 
or 6 h every day, cells were exposed to PTH before returning to standard mineralisation 
media. The mRNA expression of (A) Phospho1, (B) Alpl and (C) Smpd3 was assessed 
by RT-qPCR on day 10 of culture. N = 3, **P<0.05, ***P<0.001 in comparison to 






Chapter 4                                Investigating the effects of parathyroid hormone on PHOSPHO1 in vitro 
 
~ 124 ~ 
 
4.5.10. The effects of intermittent PTH on the expression of Phospho1, Alpl and 
Smpd3 in vitro. 
To assess the effect of intermittent PTH on mineralisation gene expression in MC3T3-
C14 cell cultures, cells were exposed to 50nM PTH for either 1 h or 6 h in every 24 h 
period for 10 days. Surprisingly, the expression of Phospho1, Alpl and Smpd3 were all 
significantly downregulated with both 1 h and 6 h intermittent PTH exposure 
(P<0.001, Fig. 4.10.A-C). 
4.6. Discussion 
The crucial role of both Phospho1 and Smpd3 in the mineralisation of the skeleton and 
dentition are well established (Yadav et al., 2011, Khavandgar et al., 2011, McKee et 
al., 2013, Khavandgar et al., 2013). Despite this understanding of their function, there 
exists a hiatus in the knowledge surrounding their regulation. A recent transcriptome 
sequencing investigation however, has revealed that Phospho1 is regulated by PTH in 
osteocytes (St John et al., 2015). This study provided the impetus for this research, 
which sought to determine the effects of PTH on the regulation of PHOSPHO1, 
nSMase2 and TNAP expression in osteoblasts.  
 
This study initially expanded the analysis of St John et al. (2015) (who had treated 
IDG-SW3 cells after 35 days in culture with PTH) by assessing the effects of PTH at 
different differentiation stages of these cells. Confirming and extending the results of 
this study, Phospho1 downregulation by PTH was observed at every time point 
investigated. IDG-SW3 cells recapitulate the late osteoblast to late osteocyte 
progression, initially expressing high levels of Alpl before showing significant 
increases in Sost expression by day 21 of culture (Woo et al., 2011). These initial 
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results suggest that the PTH regulation of Phospho1 is not limited to osteocytes as 
originally suggested by St John et al. (2015). The effect of PTH on osteoblasts was 
therefore investigated more thoroughly in the experiments described herein. This study 
provides the first evidence for the potent regulation of Phospho1 and Smpd3 by PTH 
in osteoblast-like cells and cultured calvariae. Data presented here builds on previous 
investigations that sought to uncover the regulation of mineralisation-dependent genes 
by growth factors and hormones. The enhancement of nSMase2 expression by BMP 
signalling was recently elucidated in chondrocytes and C2C12 cells (Kakoi et al., 
2014, Chae et al., 2009). These findings have been confirmed and expanded, by 
revealing that PTH exposure is able to significantly down-regulate Smpd3 expression 
even in the presence of BMP-2. Phospho1 expression was similarly enhanced by 
BMP-2 exposure, with concomitant PTH exposure restoring expression levels to those 
of control cultures. The effects of BMP signalling on PHOSPHO1 regulation and the 
interaction between BMP and PTH signalling are intriguing and worthy of further 
investigation. Whilst no interaction between PTH and BMP- 2 in the regulation of Alpl 
expression was found, the effects of PTH alone on Alpl expression have been well 
documented. For example, intermittent exposure to PTH has been shown to stimulate 
ALP activity and bone nodule formation (Terakado et al., 1995). However, it should 
be noted that the inhibition of osteoblast differentiation by PTH has been reported in 
other studies (Zerega et al., 1999, van der Horst et al., 2005) and this variation in 
response may be explained by differences in osteoblast differentiation stage and PTH 
exposure time and dosage. 
PTH can exert entirely opposing effects on bone, which depend upon the length of 
exposure. Intermittent exposure to PTH is anabolic to the skeleton, with reactivation 
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of bone lining cells (Dobnig and Turner, 1995), inhibition of osteoblast apoptosis (Jilka 
et al., 1999), and down-regulation of sclerostin, the potent negative regulator of Wnt 
signalling and bone formation (Kramer et al., 2010). Currently, rhPTH (1-34) 
(Teriparatide) is the only anabolic therapy for osteoporosis aimed at preventing both 
vertebral and non-vertebral fractures in post-menopausal women (Poole and Reeve, 
2005). Contrastingly, continuous exposure to PTH, as observed in 
hyperparathyroidism, is catabolic to bone, increasing osteoclastogenesis through 
upregulation of  RANKL and inhibition of OPG expression (Ma et al., 2001). 
Knowledge of the effects of continuous exposure to PTH are however limited with 
regards to the regulation of mineralisation promoting enzymes despite an overall 
increase in the remodelling rate observed in hyperparathyroidism (Eriksen, 2002).  
 
The nature of the PTH administration described in this study, whereby PTH is added 
to the culture medium and the medium is not changed before the experiments are 
stopped for collection of RNA/protein, most closely resembles a continuous exposure 
to PTH. Indeed a number of investigations to date have demonstrated this method of 
PTH exposure to better model the catabolic effects of PTH (Ishizuya et al., 1997, Liu 
et al., 2012).  With bovine PTH (1-34) having a reported half-life of 10-12 h in vitro a 
biologically effective dose of ~3 nM should have remained in the cultures after 48 h.  
However, as the time exposure studies show (Fig. 4.2.D-E), Phospho1 and Alpl gene 
expression levels were normalised by 48 h. This suggests the lack of a biologically 
effective dose of PTH at this time point. In contrast, Smpd3 expression remained 
significantly down regulated at 48 h possibly reflecting the increased sensitivity of this 
gene to PTH challenge (Fig. 4.2.F).  These data bring into question the levels of 
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biologically active PTH remaining in the experimental cultures and highlight the 
limitations of this approach. However, this method of PTH exposure is in contrast to 
in vitro studies which seek to model the effects of intermittent PTH, whereby PTH is 
added to cell cultures for 1-6 h per 24 or 48 h incubation cycle (Ishizuya et al., 1997, 
Lotinun et al., 2002). These in vitro intermittent exposure methods were replicated in 
this study and showed comparable inhibition of Phospho1 and Smpd3 expression as 
achieved with continuous exposure. The findings presented here therefore, show for 
the first time that PTH administration to MC3T3-C14 cell cultures inhibits the 
expression of Phospho1 and Smpd3.  
 
The reduction of PHOSPHO1 and nSMase2 may provide a novel mechanism by which 
continuous PTH exposure results in decreased bone mineral density. Continuous 
exposure to PTH reduced the extent of matrix mineralisation in MC3T3-C14, which 
has similarly been observed in rat calvarial osteoblast cultures (Ishizuya et al., 1997). 
Intriguingly, recent studies have also provided data which highlight a role for 
PHOSPHO1 and nSMase2 in the biogenesis of matrix vesicles (Thouverey et al., 2011, 
Kapustin et al., 2015, Yadav et al., 2016). It is possible therefore, that the reduced 
mineralisation of MC3T3-C14 cell cultures observed in response to continuous 
exposure to PTH is due to both a decreased number of MVs being released and a 
decrease in their ability to initiate amorphous hydroxyapatite formation. Despite this, 
Alpl expression was induced in response to PTH in MC3T3-C14 cell cultures. An 
enhancement of Alpl expression and TNAP activity in response to a continuous 
exposure to PTH has previously been shown in periodontal ligament cells (Wolf et al., 
2013) and in the UMR-106 cell line (Kano et al., 1994) respectively. Even with this 
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body of evidence in mind, the differential regulation of Phospho1 and Alpl by PTH is 
perhaps surprising. The genetic ablation of Phospho1 in the mouse, leads to reduced 
serum TNAP activity and reduced Alpl expression in cultured chondrocytes derived 
from these mice (Yadav et al., 2011). Importantly, cultured hemi-calvariae exposed to 
continuous PTH exposure for 24 h displayed a downregulation of Alpl expression 
(Fig. 4.3.B). The ex vivo culture of calvariae may provide a more physiologically 
relevant model of osteoblast behaviour due to the maintenance of both cell-cell and 
cell-matrix interactions in three-dimensional space. 
 
To enact its effects, PTH binds to the PTH1R , a G-protein coupled receptor, through 
a receptor binding domain between amino acids 15-24 (Mannstadt et al., 1999). Both 
PKA and PKC signal transduction pathways may be activated by binding of PTH to 
PTH1R. The effects of PTH are primarily elicited through the PKA pathway whereby, 
stimulatory Gαs proteins activate adenylyl cyclase, with subsequent production of 
cAMP and phosphorylation of PKA (Silva and Bilezikian, 2015). A limited number of 
genes, for example those encoding the insulin like growth factor binding protein 5 and 
TGF-β1, have been found to be regulated by Gαq activation which results in PKC 
activation, 1,4,5-inositol triphosphate production and a rise in intracellular Ca2+ (Qin 
et al., 2004). A critical role for the cAMP-PKA pathway in mediating the effects of 
PTH on PHOSPHO1, nSMase2 and TNAP expression in osteoblast cell culture models 
has been revealed in this study. Firstly, the adenylyl cyclase agonist, forskolin, 
replicated the effects of PTH whereas exposure to the PKC agonist, PMA, caused no 
effects. Furthermore, specific inhibition of the cAMP activation of PKA by the 
synthetic peptide PKI (5-24) abrogated the effects of PTH on Phospho1, Alpl and 
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Smpd3 expression (these results of these investigatory experiments are summarised in 
Table 2). In support of a role for PKA signalling in the downregulation of the 
mineralisation-dependent enzymes, PHOSPHO1 and nSMase2, studies to date have 
shown the inhibition of both MC3T3-E1 matrix mineralisation and bone nodule 
formation by cultured rat calvarial cells with long term exposure to forskolin (Kaneki 
et al., 1999, Tintut et al., 1999). Experiments utilising cycloheximide, revealed that 
this genetic regulation did not appear to be solely dependent on protein synthesis. It 
was noted that cycloheximide appeared to partially affect the downregulation of 
Phospho1 by PTH exposure (inducing a 49.5% decrease as opposed to a 93.9% 
decrease by PTH alone). Despite this, it is well accepted that cycloheximide can exert 
off-target effects (McMahon, 1975) and these may account for this difference.  
As the archetypal target of the cAMP/PKA signalling pathway, the role of the 
transcription factor CREB was investigated as a potential facilitator of the effects of 
PTH on Phospho1 mRNA expression. Napthol AS-E phosphate has previously been 
shown to inhibit the interaction between phosphorylated CREB and the histone 
acetyltransferase, CBP, thus mitigating the gene expression modulating potential of 
this interaction (Best et al., 2004). Napthol AS-E phosphate did not affect the PTH 
mediated downregulation of Phospho1 in MC3T3-C14 cells. A more comprehensive 
investigation of the transcription factor binding sites of the Phospho1 promoter will be 
required to identify other potential PKA targets. The expression of the osteogenic 
transcription factors Runx2, Sp7 and Atf4 and Trps1, of which the latter has recently 
been implicated in the regulation of Phospho1 in a preodontoblastic cell line (Kuzynski 
et al., 2014), were additionally assessed. In both cultured murine calvariae and 
MC3T3-C14 cells, Sp7 expression was reduced in response to PTH. This suggests that 
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osterix (encoded by the Sp7 gene), one of the master transcription factors regulating 
osteogenic differentiation, may be an important transcription factor in the regulation 
of both Phospho1 and/or Smpd3 expression (Nishimura et al., 2012). Again, the 
transcriptional and epigenetic regulation of these mineralisation-dependent genes 
requires further study.  
These data are novel for the PTH control of Phospho1 and Smpd3 expression but 
previous reports have demonstrated the involvement of the cAMP-PKA pathway in 
the regulation (both positive and negative) of  TNAP activity in a variety of cell culture 
models of mineralisation (Ishizuya et al., 1997, Wolf et al., 2013, Kano et al., 1994, 
Terakado et al., 1995). The PTH-dependent enhancement of TNAP activity has been 
shown to be enacted through cAMP-PKA mediated activation of p38 MAP kinase 
(Rey et al., 2007). In the cultured calvariae experiments, cAMP stimulation by 
forskolin simulated the effects of PTH by inducing a downregulation of Phospho1, 
Alpl and Smpd3. In contrast to MC3T3-C14 cell cultures however, PMA similarly 
induced the downregulation of Alpl and Smpd3 and blockade of PKA activation by 
PKI (5-24) did not affect the PTH induced downregulation of Smpd3. To date, 
Phospho1 has been shown to be exclusively expressed by osteoblasts, hypertrophic 
chondrocytes, odontoblasts and calcifying vascular smooth muscle cells (Houston et 
al., 2004, McKee et al., 2013, Kiffer-Moreira et al., 2013). Smpd3 and Alpl on the other 
hand are more broadly expressed amongst different tissues and cell types. Although 
providing a more physiological environment, the presence of osteocytes, osteoclasts 
and stromal cells, as well as osteoblasts at differing stages of development in the 
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Table 2. Summary of the effects of the activator and inhibitor experiments 
performed in MC3T3-C14 cell cultures. 
 
ex vivo calvariae model, may be confounding our investigation of the signalling 
pathways in this model.  
Further complexity regarding the PTH-mediated regulation of Phospho1 arose through 
experimentation in additional in vitro models. In contrast to MC3T3-C14 and calvarial 
Activator / 
Inhibitor 
Action Rationale Effects on 
Phospho1 
expression 
Cycloheximide Protein synthesis 
inhibitor  
Assess the role of 
protein synthesis 




Forskolin  Adenylyl cyclase 
activator 





effects of PTH on 
Phospho1 
Replicated the 
effects of PTH 
(i.e. inhibition of 
Phospho1 
expression) 





effects of PTH on 
Phospho1 
No effect 
PKI (5-24) Competitive PKA 
inhibitor 
Confirm the role 
of PKA in 
mediating the 
effects of PTH on 
Phospho1 
No reduction in 
Phospho1 
expression in the 





CREB and CREB 
binding protein 
Assess the role of 
the transcription 
factor CREB in 
mediating the 
effects of PTH on 
Phospho1 
No effect 
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organ cultures, E15 metatarsal cultures alongside primary osteoblasts derived from 
both murine calvaria and human subchondral bone, all displayed increased Phospho1 
expression in response to 24 h PTH treatment (see Table 3 for summary of the effects 
of PTH on the different cell/organ culture models assessed). Of course, one must be 
cautious when interpreting the results from clonal cell lines, such as MC3T3-C14, 
whose responsiveness to PTH may be distinct from heterogeneous cell populations 
observed in primary cell cultures or indeed in vivo. More stringent analysis of the 
effects of continuous and intermittent PTH exposure in vivo will be needed to assess 
the endocrine regulation of Phospho1 expression within bone.  
In summary, the data presented here provide evidence for a potent negative regulation 
of Phospho1 and Smpd3 by continuous exposure to PTH in MC3T3-C14 and calvarial 
organ cultures. This downregulation of essential mediators of skeletal mineralisation 
may provide a novel mechanism which explains the poor bone quality observed in 
response to sustained and elevated exposures to PTH. Additional studies in vivo will 
be indispensable to confirm the regulation of Phospho1 and Smpd3 in bone. 
Table 3. Summary of the effects of PTH on various cell/organ culture models.  
Model System Effect of PTH (50 nM; 24 h) 
Phospho1 Smpd3 Alpl 
IDG-SW3 ↓ n/a n/a 
MC3T3-C14 ↓ ↓ ↑ 
Primary murine calvarial osteoblast ↑ n/a n/a 
Murine calvarial culture ↓ ↓ ↓ 
Embryonic metatarsals ↑ n/a n/a 
Primary human subchondral 
osteoblasts 
↑ n/a n/a 
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5.1. Introduction  
The potent regulation of Phospho1 and Smpd3 by PTH, as observed in Chapter 4, may 
provide an additional mechanism which goes some way to explain the disparate effects 
of intermittent and continuous PTH exposure. The previous Chapter highlighted, 
through examination of the literature surrounding TNAP’s regulation by PTH, that 
understanding the effects of PTH in vitro is challenging and has produced conflicting 
results (Yee, 1985, Kato et al., 1990). This is at least in part due to the variety of cell 
lines and culture model systems utilised, the difficulty in replicating intermittent and 
continuous exposure in vitro and the complexity of PTH’s role in vivo. With this in 
mind, and to get a more physiological comprehension of the biological effects of PTH 
on mineralisation-dependent gene expression, the overarching aim of this Chapter was 
to investigate the effects of PTH on these genes in vivo. 
PTH has long been known as one of the major regulators of calcium, and to a lesser 
extent, phosphate homeostasis in mammals. Binding of PTH to the PTH1R within the 
primary target tissues of the kidney and bone elicits a range of molecular and cellular 
events which ultimately results in an increase in serum calcium concentration 
(Schluter, 1999, Hewison et al., 2000, Silva and Bilezikian, 2015). This present study 
however, is primarily concerned with the anabolic effects of exogenously administered 
PTH on bone. These anabolic effects have similarly been known for some time. 
Indeed, pioneering studies by Reeve and colleagues in the seventies revealed an 
increased bone formation rate in osteoporotic women in response to daily exposure to 
low dose PTH 1-34 (Reeve et al., 1976a, Reeve et al., 1976b). The large, multicentre 
trial of Neer et al. (2001) highlighted the efficacy of daily injection of PTH 1-34 in 
reducing vertebral and non-vertebral fractures, alongside increasing BMD in post-
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menopausal osteoporotic women. As the only approved osteoanabolic agent (although 
PTH 1-34 is likely to lose this exclusivity with the impending approval of anti-
sclerostin antibodies in 2017 (MacNabb et al., 2016)), the molecular events 
underpinning this anabolism are beginning to be more thoroughly understood.  
Cells of the osteoblast lineage are the primary effectors of the osteoanabolic effects of 
PTH. Indeed, intermittent PTH (iPTH) exposure significantly increases osteoblast 
number (Silva and Bilezikian, 2015). Through the induction of Runx2, Sp7 and c-Fos 
transcription, PTH promotes the commitment and differentiation of mesenchymal cells 
and osteoblast precursors to progress through the osteoblast lineage (Aslan et al., 
2012). In addition, PTH modulates the expression and post-transcriptional regulation 
of apoptotic signalling molecules to reduce osteoblast apoptosis (Jilka et al., 1999, 
Bellido et al., 2003). Interestingly, osteoblast number increases, whilst the pool of 
quiescent bone lining cells shrinks in response to PTH exposure (Dobnig and Turner, 
1995). Lineage tracing experiments confirmed that PTH exposure induces the 
reactivation of bone lining cells to functional osteoblasts (Kim et al., 2012). More 
recently, utilising the same lineage tracing technique, Jang et al. (2015) revealed that 
PTH also delays the transition of mature osteoblasts to bone lining cells. Osteocytes 
(terminally differentiated osteoblasts) express the PTH1R and are therefore also 
targets of PTH. The secreted glycoprotein, and potent negative regulator of the 
osteogenic WNT/β-catenin signalling pathway, SOST, is an important target of PTH 
signalling. PTH strongly inhibits Sost mRNA expression (Keller and Kneissel, 2005, 
Kramer et al., 2010), thereby offering an explanation for the bone anabolic actions of 
PTH. In vitro studies identified the cAMP/PKA signalling pathway as the mediator of 
the effect and more recent in vivo studies have highlighted the importance of the LRP 
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5/6 in mediating bone mass accrual in the absence of SOST (Li et al., 2005, Wan et 
al., 2008). As PHOSPHO1 activity is essential for successful ECM mineralisation, and 
is potently regulated by PTH (Houston et al., 2016), I hypothesised that its modulation 
in vivo could provide a novel unrecognised mechanism explaining the anabolic effects 
of PTH on bone.  
In the discussion of Chapter 4, the effects of continuous PTH (cPTH) exposure, in 
terms of the upregulation of the RANKL/OPG ratio and unrestrained 
osteoclastogenesis, were described. It is probable however, that these effects represent 
only a small portion of the mechanisms contributing to the catabolic effects of cPTH. 
Indeed, Onyia et al. (2005) revealed 173 genes uniquely regulated by cPTH in the 
distal femur of rats. The negative regulation of PHOSPHO1 and nSMase2 expression 
in MC3T3-C14 cell cultures in response to cPTH exposure (Houston et al., 2016), 
draws attention to the modulation of key mineralisation-effector proteins as a means 
of explaining the osteocatabolic effects of cPTH in vivo. 
This thesis has previously highlighted the importance of PHOSPHO1 in the initiation 
of skeletal mineralisation. This Chapter sought to investigate the regulation of 
Phospho1 and other key regulators of skeletal mineralisation by iPTH and cPTH 
exposure in mouse bone. Additionally, the availability of the Phospho1-/- mouse 
allowed me to investigate the hypothesis that PHOSPHO1 is required for the full 
repertoire of osteoanabolic effects of iPTH in vivo. 
5.2. Hypothesis 
The anabolic effects of iPTH on bone are mediated, in part, through the upregulation 
of Phospho1 and Smpd3. Conversely, the poor bone quality observed with continuous 
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exposure to PTH is mediated, in part, through the downregulation of Phospho1 and 
Smpd3. The genetic ablation of Phospho1 will diminish the anabolic and catabolic 
effects of iPTH and cPTH respectively.   
5.3. Aims 
I) Investigate the effects of a short-term PTH exposure on the expression of key 
mineralisation-dependent genes in vivo. 
II) Determine the effects of long term iPTH on mineralisation-dependent gene 
expression and bone microarchitecture in both WT and Phospho1-/- mice. 
III) Examine the effects of a 28-day continuous infusion of PTH on mineralisation-
dependent gene expression and bone microarchitecture in both WT and Phospho1-/- 
mice. 
IV) Investigate the PTH target genes within the kidney of iPTH treated mice as a 
possible mechanism to explain the differences between the WT and Phospho1-/- 
response to this therapy. 
5.4. Materials and methods 
5.4.1. PTH preparation 
Recombinant human parathyroid fragment 1-34 (from here on referred to as PTH) was 
reconstituted in PBS, aliquoted and stored at -20°C. Prior to injection or filling of 
micro osmotic pumps, PTH was diluted to the appropriate concentration in 0.9% saline 
containing 0.2% w/v BSA.   
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5.4.2. PTH administration 
5.4.2.1. Single dose PTH administration 
Male, WT mice at 28-days of age received a single subcutaneous injection of PTH 
(80 µg/kg) or vehicle control (0.9% w/v saline containing 0.2% w/v BSA) before 
culling by cardiac puncture under terminal anaesthesia 6 h later. The left femur was 
dissected, the epiphyses removed and marrow eliminated by centrifugation prior to 
snap freezing in LN2 and storage at -70°C for subsequent gene expression analyses.  
5.4.2.2. Intermittent administration of PTH  
Male, WT and Phospho1-/- mice at 28-days of age received a subcutaneous injection 
of PTH (80 µg/kg) or vehicle control once daily for 14 or 28 days. Mice were weighed 
each day prior to the injection. Mice were culled 24 h after the final injection of PTH 
by cardiac puncture under terminal anaesthaesia. The left femur was dissected, the 
epiphyses removed and marrow eliminated by centrifugation prior to snap freezing in 
LN2 and storage at -80°C. The left kidney was dissected and freed from any 
surrounding adipose before snap freezing in LN2 and storage at -80°C. The distal half 
of the femur and the left kidneywas used to extract mRNA for gene expression analysis 
as described in section 5.4.3.  
5.4.2.3. Continuous delivery of PTH 
The continuous administration of PTH was carried out using subcutaneously 
implanted micro-osmotic pumps. Male, WT and Phospho1-/- mice underwent surgical 
implantation of the mini-osmotic pumps at 28-days of age. Mice were deemed suitable 
for the surgery if they were greater than 20 g in weight on the day of surgery. Micro-
osmotic pumps were filled with 100 µL of PTH (0.308 mg/mL) or vehicle control and 
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submerged in sterile 0.9% w/v saline and incubated at 37°C for 48 h prior to surgical 
implantation. This priming step ensured the pumps began releasing their contents at 
the indicated rate immediately upon implantation. Pumps were implanted 
subcutaneously, posterior to the scapula in accordance with manufacturer’s guidelines 
and released 0.11 µL/h for 28 days. This strategy delivered PTH up to a maximum of 
80 µg/day. Mice were culled on day 29 post-surgery by cardiac puncture under 
terminal anaesthesia.     
5.4.3. Gene expression analysis 
The distal femora and left kidney of all mice were homogenised in Qiazol reagent and 
total RNA was extracted using an RNeasy lipid mini kit as described in section 2.4.2.  
RT-qPCR was performed in triplicate on between 4-6 biological replicates and the 
results for each gene of interest were normalised to the appropriate housekeeping gene 
(Atp5b for bone samples and Gapdh for kidney samples). Relative gene expression 
was calculated using the ΔΔCt method (section 2.4.4.) and expressed as a fold change 
against the WT vehicle control treated samples. 
5.4.4. Immunohistochemistry 
The left tibiae from experimental mice were processed to paraffin wax and sectioned 
at a thickness of 5µm as described in section 2.7.4. Immunolocalisation of TNAP was 
carried out as described in section 2.7.6. TNAP antibody was diluted 1:200 in 
FBS/PBS, with HRP-conjugated Goat anti-Rat secondary antibodies (1:100) used to 
detect TNAP antibody binding. Incubation of tissues sections with DAB for 15 s 
allowed visualisation of antibody binding and TNAP localisation. Rat IgG control 
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experiments were similarly carried out to ensure there was no non-specific binding of 
the secondary antibodies.  
5.4.5. Micro computed topography 
The right tibiae from experimental mice was dissected immediately upon death, freed 
from any surrounding soft tissues and stored in dH2O at -20°C prior to µCT scanning. 
MicroCT scanning and reconstruction was carried out as described in section 2.7.7. 
Metaphyseal trabecular bone of the proximal tibia was assessed in a 250 slice stack, 
5% of the total bone length below the first appearance of a trabecular ‘bridge’ 
connecting the two primary spongiosa bone islands as described in section 2.2.7. 
Cortical bone was assessed in 100 slice stacks at 37% and 50% of the total bone length 
(proximal-middle) from the reference starting slice (first appearance of the medial 
tibial condyles). To assess BMD, BMD phantoms were used to calibrate the CTAn 
software. BMD phantoms of known calcium hydroxyapatite mineral densities of 0.25 
and 0.75 g/cm3 were scanned and reconstructed using the same parameters as used for 
bone samples.    
5.4.6. Biomechanical testing  
Biomechanical testing of the right tibiae from experimental mice was carried out by 
three-point bending using an LXR material testing machine as described in section 
2.7.8. 
5.4.7. Analysis of serum calcium 
Serum was prepared from the terminal blood sample of experimental mice as described 
in section 2.8.2. Total serum calcium was assessed by a colorimetric assay (Randox 
calcium assay) as described in section 2.8.2. 
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5.4.8. Analysis of bone turnover markers  
Serum was prepared from the terminal blood sample of experimental mice as described 
in section 2.8.2. Serum P1NP and CTX-1 were assay by enzyme immunoassay as 
described in section 2.8.3. 
5.5. Results 
5.5.1. PTH exerts rapid effects on mineralisation gene expression in vivo 
Gene expression within the femora of 4 week old, male WT mice was assessed after a 
6 h exposure to a single subcutaneous injection of PTH (80 µg/kg). Animals exposed 
to PTH displayed around a 60% increase in the mRNA expression of Phospho1 
compared with vehicle treated animals (P<0.01, Fig. 5.1.A). Alpl and Smpd3 mRNA 
expression were similarly increased in response to PTH treatment (29%, P<0.01 and 
45%, P<0.001 respectively, Fig. 5.1.B & C). Chkα and Chkβ expression was not 
affected by PTH. The expression of the PPi generating, Enpp1, was enhanced with 
PTH exposure (P<0.05). Sost expression displayed a trend towards inhibition by PTH 
exposure, but this did not reach statistical significance (Fig. 5.1.G). The osteoblast 
transcription factor, Runx2, showed a 50% increase in expression (P<0.05, Fig. 5.1.I) 
with PTH administration. Trps1 was similarly increased in PTH treated femora (51%, 
P<0.05, Fig. 5.1.J). 
5.5.2. The effects of 14-day iPTH exposure on mineralisation gene expression 
within the femora of WT and Phospho1-/- mice. 
Gene expression was investigated by RT-qPCR within the distal femur of WT and    
Phospho1-/- mice receiving daily injection of PTH (80 µg/kg/day) or vehicle control 
for 14-days. In WT animals, exposure to PTH induced a 3.1-fold increase in  
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Figure 5.1. The effects of a single dose of PTH on gene expression within the 
femora of WT mice. 
RT-qPCR analysis of the mRNA expression within the femora of WT mice, 6 h 
following a single dose of PTH (80 µg/kg). (A) Phospho1 (B) Alpl (C) Smpd3 (D) 
Chkα (E) Chkβ (F) Enpp1 (G) Sost (H) Pth1r (I) Runx2 and (J) Trps1. Data are 
represented as mean ± S.E.M. N=4, *P<0.05, **P<0.01, ***P<0.001 compared to 
control. 
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Figure 5.2. The differential effects of 14-days iPTH on gene expression within the 
femora of WT and Phospho1-/- mice. 
RT-qPCR analysis of the mRNA expression within the distal femora of WT and 
Phospho1-/- mice receiving iPTH (80 µg/kg/day) for 14-days. (A) Phospho1 (B) Alpl 
(C) Smpd3 (D) Chkα (E) Chkβ (F) Enpp1 (G) Sost (H) Pth1r (I) Runx2 and (J) Trps1. 
Data are represented as mean ± S.E.M. N=4, *P<0.05, **P<0.01, ***P<0.001. 
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Phospho1 expression compared to vehicle treated control animals (P<0.05, 
Fig. 5.2.A). Similarly Smpd3 and Alpl displayed increases in their expression in 
response to this experimental regimen in WT mice (P<0.01 and P<0.001 respectively 
compared to vehicle treated WT animals, Fig. 5.2.C & D). In contrast, Phospho1-/- 
mice displayed no increases in either Smpd3 or Alpl compared to non-treated (control) 
Phospho1-/- mice. In WT animals receiving PTH, Chka and Chkb showed a 2.4 and 
1.9-fold increase in expression respectively compared to control animals, although this 
was not significant (Fig. 5.2.D & E). As expected, WT mice receiving PTH injections 
exhibited a reduction in Sost expression compared to vehicle control counterparts 
(P<0.05). The basal expression of Sost mRNA in Phospho1-/- was significantly reduced 
compared to WT mice (P<0.05, Fig. 5.2.G). Despite this, Phospho1-/- mice treated with 
PTH showed no further decrease in Sost. Pth1r was induced with iPTH administration 
in WT animals (P<0.01 compared to vehicle control animals) but not in Phospho1-/- 
animals. The effects of PTH on Runx2 and Trps1 expression in WT mice observed in 
the single dose study were accentuated with 14 days intermittent treatment. Runx2 and 
Trps1 expression showed a 2.6 and 2.4-fold increase respectively (P<0.05, 
Fig. 5.2.I & J) in WT mice receiving iPTH. Phospho1-/- mice showed no change in the 
expression of these transcription factors in response to PTH. 
5.5.3. The effects of 14-day iPTH exposure on the bone microarchitecture and 
biomechanical properties in WT and Phospho1-/- mice. 
The effects of the 14-day iPTH exposure on bone microarchitecture within both WT 
and Phospho1-/- tibiae was determined by µCT scanning. Metaphyseal trabecular  
 
 
Chapter 5                                Examining the in vivo regulation of Phospho1 by parathyroid hormone  
 
~ 145 ~ 
 
 
Figure 5.3. Metaphyseal trabecular bone parameters in WT and Phospho1-/- 
mice receiving iPTH or vehicle control for 14-days. 
(A) Representative 3D µCT images of metaphyseal trabecular bone in WT and 
Phospho1-/- mice receiving iPTH (80 µg/kg/day) or vehicle control for 14-days. 
Analysis of the trabecular bone parameters (B) trabecular bone volume/ total volume 
(BV/TV) (C) trabecular bone mineral density (BMD) (D) trabecular pattern factor 
(Tb.Pf) (E) trabecular thickness (Tb.Th.) (F) trabecular number (Tb.N.) and (G) 




Chapter 5                                Examining the in vivo regulation of Phospho1 by parathyroid hormone  
 
~ 146 ~ 
 
 
Figure 5.4. Cortical bone parameters at 37% tibial length in WT and   
Phospho1-/- mice receiving iPTH or vehicle control for 14-days.  
(A) Representative 3D micro-CT images of tibial cortical bone at 37% tibial length 
(Proximal to middle) in WT and Phospho1-/- mice receiving iPTH (80 µg/kg/day) or 
vehicle control for 14-days. Analysis of the cortical bone parameters (B) cortical bone 
volume/ total volume (BV/TV) (C) cortical cross-sectional thickness (Ct.Th.) (D) 
cortical bone mineral density (BMD) (E) cortical tissue area (Tt.Ar.) (F) cortical bone 
area (Ct.Ar.) and (G) medullary area (Ma.Ar.). Data are represented as mean ± S.E.M. 
N≥4, *P<0.05. 
WT + iPTH 
iPTH 
WT  
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Figure 5.5. Cortical bone parameters at 50% tibial length in WT and   
Phospho1-/- mice receiving iPTH or vehicle control for 14-days.  
(A) Representative 3D micro-CT images of tibial cortical bone at 50% tibial length in 
WT and Phospho1-/- mice receiving iPTH (80 µg/kg/day) or vehicle control for 14-
days. Analysis of the cortical bone parameters; (B) cortical bone volume/ total volume 
(BV/TV) (C) cortical cross-sectional thickness (Ct.Th.) (D) cortical bone mineral 
density (BMD) (E) cortical tissue area (Tt.Ar.) (F) cortical bone area (Ct.Ar.) and (G) 




Chapter 5                                Examining the in vivo regulation of Phospho1 by parathyroid hormone  
 
~ 148 ~ 
 
bone was assessed in a 1.25 mm volume of interest beginning at 5% below the 
reference point as described in section 5.4.4. Modest increases in trabecular thickness 
and BMD were noted in response to PTH exposure in both genotypes (P<0.05, 
Fig. 5.3.). There were no further changes detected in response to PTH in the trabecular 
compartment. Cortical bone was assessed in 500 µm regions at 37% (proximal to 
middle) and 50% of the total tibia length as described in section 5.4.4. No differences 
at either location were observed in response to 14-days iPTH exposure in both WT and 
Phospho1-/- tibiae (Figs. 5.4. & 5.5.). Perhaps unsurprisingly, no differences were 
noted in the biomechanical properties of the tibia as assessed by 3-point bending in 
response to the 14-day intermittent PTH exposure (Fig. 5.6.)  
5.5.4. Body weight, serum calcium and bone formation and resorption markers 
of WT and Phospho1-/- mice exposed to iPTH for 28-days. 
PTH injections were well tolerated and there were no adverse effects during the 
experiment. Assessment of the body weights during the experiment revealed no 
differences between control mice and mice receiving iPTH. There was however a trend 
towards increased weight in WT mice receiving iPTH compared to control mice, 
although this was not significant (Fig. 5.7.A). There were no differences in serum 
calcium between genotypes or treatments as assessed by colorimetric assay 
(Fig. 5.7.B). Serum P1NP appeared increased in response to iPTH exposure in both 
genotypes but this was not significant (Fig. 5.7.C). The serum concentration of CTX-
1 was not affected by iPTH in either genotype (Fig. 5.7.D). 
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Figure 5.6. Three-point bending analysis of the tibia from WT and Phospho1-/- 
mice receiving iPTH or vehicle control for 14-days. 
Analysis of the biomechanical parameters (A) maximum load (B) work to maximum 
load (C) deflection at maximum load (D) load at rupture (E) work to rupture (F) 
deflection at rupture and (G) stiffness in the tibiae of WT and Phospho1-/- mice 
receiving iPTH (80 µg/kg/day) or vehicle control for 14-days. Data are represented as 
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Figure 5.7. Body weight, serum calcium and bone formation and resorption 
markers of WT and Phospho1-/- mice exposed to iPTH for 28-days. 
(A) Body weights (up to day 20) of WT and Phospho1-/- mice receiving iPTH or 
vehicle control. (B) Total calcium, (C) P1NP and (D) CTX-1 were assessed in the 
serum obtained from the terminal blood sample of WT and Phospho1-/- mice receiving 
iPTH or vehicle control for 28-days. Data are represented as mean ± S.E.M. (N>5). 
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Figure 5.8. The differential effects of 28-days iPTH on gene expression within the 
femora of WT and Phospho1-/- mice. 
RT-qPCR analysis of the mRNA expression within the distal femora of WT and 
Phospho1-/- mice receiving iPTH (80 µg/kg/day) for 28-days. (A) Phospho1 (B) Alpl 
(C) Smpd3 (D) Chkα (E) Chkβ (F) Enpp1 (G) Sost (H) Pth1r (I) Runx2 and (J) Trps1. 
Data are represented as mean ± S.E.M. N=4, *P<0.05, **P<0.01. 
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5.5.5. The effects of 28-day iPTH exposure on mineralisation gene expression 
within the femora of WT and Phospho1-/- mice. 
With 28-day iPTH, Phospho1 mRNA expression remained enhanced in the distal 
femur compared to vehicle control treated animals (P<0.05, Fig.5.8.A). Smpd3 
expression was similarly enhanced in response to iPTH in WT mice but this was not 
observed in Phospho1-/- treated mice (P<0.01, Fig.5.8.C). There was no significant 
enhancement of Alpl Chkα, Chkβ or Enpp1 mRNA expression in either genotype in 
response to 28-day iPTH. Sost expression was marginally down-regulated by 28-day 
iPTH exposure in WT femora (although this was found not to be statistically 
significant). The transcription factors, Trps1 and Runx2 no longer exhibited any 
enhancement in response to 28-day iPTH exposure in WT or indeed, in Phospho1-/- 
femora.  
5.5.6. The effects of 28-day iPTH exposure on the bone microarchitecture and 
biomechanical properties in WT and Phospho1-/- mice. 
Assessment of the trabecular compartment in 28-day intermittent PTH exposed WT 
and Phospho1-/- mouse tibiae, revealed increased trabecular thickness (P<0.05) and 
BMD (P<.0.01, Fig. 5.9.). These parameters were likewise enhanced in WT mice 
treated with PTH compared to PTH treated Phospho1-/- mice (P<.0.01 in both cases). 
The percentage bone volume (BV/TV) was enhanced in PTH treated WT mice (P<0.01 
compared to WT control), but not in Phospho1-/- animals. Trabecular pattern factor 
(Tb.Pf, a measurement of trabecular connectivity (Hahn et al., 1992)) was reduced in 
response to 28-day iPTH exposure in both genotypes (P<0.05, Fig. 5.9.D).  
With 28 daily injections of PTH, the anabolic response in cortical parameters was now 
evident in WT mice. Cortical BV/TV was increased in both 37% and 50%  
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Figure 5.9. Metaphyseal trabecular bone parameters in WT and Phospho1-/- 
mice receiving iPTH or vehicle control for 28-days. 
(A) Representative 3D µCT images of metaphyseal trabecular bone in WT and 
Phospho1-/- mice receiving iPTH (80µg/kg/day) or vehicle control for 28-days. 
Analysis of the trabecular bone parameters (B) trabecular bone volume/ total volume 
(BV/TV) (C) trabecular bone mineral density (BMD) (D) trabecular pattern factor 
(Tb.Pf) (E) trabecular thickness (Tb.Th.) (F) trabecular number (Tb.N.) and (G) 
trabecular separation (Tb.Sp.). Data are represented as mean ± S.E.M. N>4, *P<0.05, 
**P<0.01, ***P<0.001. 
WT + iPTH 
iPTH 
WT  
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Figure 5.10. Cortical bone parameters at 37% tibial length in WT and 
Phospho1-/- mice receiving iPTH or vehicle control for 28-days.  
(A) Representative 3D micro-CT images of tibial cortical bone at 37% tibial length 
(Proximal to middle) in WT and Phospho1-/- mice receiving iPTH (80 µg/kg/day) or 
vehicle control for 28-days. Analysis of the cortical bone parameters (B) cortical bone 
volume/ total volume (BV/TV) (C) cortical cross-sectional thickness (Ct.Th.) (D) 
cortical bone mineral density (BMD) (E) cortical tissue area (Tt.Ar.) (F) cortical bone 
area (Ct.Ar.) and (G) medullary area (Ma.Ar.). Data are represented as mean ± S.E.M. 
N≥4, *P<0.05, ***P<0.001. 
WT + iPTH 
iPTH 
WT  
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Figure 5.11. Cortical bone parameters at 50% tibial length in WT and 
Phospho1-/- mice receiving iPTH or vehicle control for 28-days.  
(A) Representative 3D micro-CT images of tibial cortical bone at 50% tibial length in 
WT and Phospho1-/- mice receiving iPTH (80 µg/kg/day) or vehicle control for 28-
days. Analysis of the cortical bone parameters, (B) cortical bone volume/ total volume 
(BV/TV) (C) cortical cross-sectional thickness (Ct.Th.) (D) cortical bone mineral 
density (BMD) (E) cortical tissue area (Tt.Ar.) (F) cortical bone area (Ct.Ar.) and (G) 
medullary area (Ma.Ar.). Data are represented as mean ± S.E.M. N≥4, *P<0.05, 
**P<0.01, ***P<0.001. 
WT + iPTH 
iPTH 
WT  
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Figure 5.12. Three-point bending analysis of the tibia from WT and Phospho1-/- 
mice receiving iPTH or vehicle control for 28-days. 
Analysis of the biomechanical parameters (A) maximum load (B) work to maximum 
load (C) deflection at maximum load (D) load at rupture (E) work to rupture (F) 
deflection at rupture and (G) stiffness in the tibiae of WT and Phospho1-/- mice 
receiving iPTH (80 µg/kg/day) or vehicle control for 28-days. Data are represented as 
mean ± S.E.M. N=4, **P<0.01. 
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compartments in PTH treated WT mice (P<0.05, Figs. 5.10. & 5.11. respectively). This 
was not observed in Phospho1-/- animals. In WT mice exposed to iPTH, cortical 
thickness and BMD were significantly greater than Phospho1-/- treated animals 
(P<0.01). No differences were observed in cortical bone area, medullary area or total 
cortical area in response to iPTH in either genoptype at either site (Figs. 5.10. & 5.11.). 
Biomechanical testing did not reveal any obvious effects of 28-day iPTH on the 
strength of the tibia from WT or Phospho1-/- mice (Fig. 5.12).  
5.5.7. TNAP immunohistochemistry within the tibiae of WT and Phospho1-/- mice 
exposed to iPTH for 28-days. 
TNAP was localised within the hypertrophic chondrocyte zone and bone forming 
surfaces of trabeculae. Additionally, TNAP staining was observed in the osteoblasts 
residing on the endosteum and periosteum. In iPTH treated WT tibiae, there appeared 
to be more TNAP staining in the trabecular region compared to vehicle treated WT 
tibiae (Fig. 5.13.A). Furthermore, there appeared to be a larger zone of TNAP 
immunoreactivity within the growth plate of iPTH treated WT mice compared to 
vehicle treated WT tibiae. Similar observations were noted in Phospho1-/- mice 
receiving iPTH. TNAP staining of cortical bone did not appear to be affected by iPTH 
treatment in either genotype (Fig. 5.13.B).  
5.5.8. The effects of 28-day cPTH exposure on mineralisation gene expression 
within the femora of WT and Phospho1-/- mice. 
The continuous exposure of WT and Phospho1-/- mice to PTH had profoundly 
contrasting effects on mineralisation gene expression compared to the iPTH exposure. 
Phospho1 mRNA expression was not changed in the distal femur in response to this 
exposure regime in WT mice (Fig. 5.14.A). The expression of both Alpl and Smpd3  
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Figure 5.13. Localisation of TNAP by immunohistochemistry 
Representative images of TNAP Localisation on (A) trabecular and (B) cortical bone surfaces. Images acquired at x10 magnification. Black 
bars equal to 50µm. 
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Figure 5.14. The effects of 28-day continuous PTH on gene expression within the 
femora of WT and Phospho1-/- mice. 
RT-qPCR analysis of the mRNA expression within the distal femora of WT and 
Phospho1-/- mice receiving continuous PTH for 28-days. (A) Phospho1 (B) Alpl (C) 
Smpd3 (D) Chkα (E) Chkβ (F) Enpp1 (G) Sost (H) Pth1r (I) Runx2 and (J) Trps1. 
Data are represented as mean ± S.E.M. N>5, *P<0.05, **P<0.01. 
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was significantly upregulated in Phospho1-/- mice but not in WT mice exposed to 
cPTH (P<0.05 Fig. 5.14.B & C). The continuous exposure to PTH did not affect the 
expression of Chkα, Chkβ, Enpp1, Pth1r, Runx2 or Trps1 in the distal femora of either 
genotype of mice. Surprisingly, Sost expression in WT femora was not affected by 
continuous PTH exposure. However, in Phospho1-/- mice continuously exposed to 
PTH, Sost expression within the distal femora was markedly enhanced (P<0.01, Fig. 
5.14.G).  
5.5.9. The effects of 28-day cPTH exposure on the bone microarchitecture and 
biomechanical properties in WT and Phospho1-/- mice. 
Male WT and Phospho1-/- mice exposed to 28-day cPTH displayed no changes in 
trabecular or cortical bone architecture within the tibia compared to vehicle treated 
control animals (Figs. 5.15., 5.16. & 5.17.). Not unsurprisingly, there were no 
differences observed in the biomechanical properties of the tibia in either genotype in 
response to this PTH exposure (Fig. 5.18.).  
5.5.10. Understanding the expression of components of systemic phosphate 
regulation within the bone and kidney. 
In an attempt to further investigate the potential mechanism regulating the altered 
response to iPTH in Phospho1-/- mice, the expression of known regulators of systemic 
phosphate homeostasis were assessed within the bone and kidney (i.e. the primary 
target organs of PTH). Within the kidney, the expression of Pth1r in Phospho1-/- mice 
was around 46% of that seen in WT kidneys (P<0.01, Fig. 5.19.A). The well-
established upregulation of Cyp27b1 (25-hydroxyvitamin D3 1α-hydroxylase) in 
response to PTH exposure was not observed in this 14-day intermittent model. Despite  
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Figure 5.15. Metaphyseal trabecular bone parameters in WT and Phospho1-/- 
mice receiving continuous PTH or vehicle control for 28-days. 
(A) Representative 3D µCT images of metaphyseal trabecular bone in WT and 
Phospho1-/- mice receiving continuous PTH or vehicle control for 28-days. Analysis 
of the trabecular bone parameters (B) trabecular bone volume/ total volume (BV/TV) 
(C) trabecular bone mineral density (BMD) (D) trabecular pattern factor (Tb.Pf) (E) 
trabecular thickness (Tb.Th.) (F) trabecular number (Tb.N.) and (G) trabecular 
separation (Tb.Sp.). Data are represented as mean ± S.E.M. N>5, *P<0.05. 
WT + cPTH 
cPTH 
WT  
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Figure 5.16. Cortical bone parameters at 37% tibial length in WT and 
Phospho1-/- mice receiving continuous PTH or vehicle control for 28-days.  
(A) Representative 3D micro-CT images of tibial cortical bone at 37% tibial length 
(Proximal to middle) in WT and Phospho1-/- mice receiving continuous PTH or 
vehicle control for 28-days. Analysis of the cortical bone parameters (B) cortical 
bone volume/ total volume (BV/TV) (C) cortical cross-sectional thickness (Ct.Th.) 
(D) cortical bone mineral density (BMD) (E) cortical tissue area (Tt.Ar.) (F) cortical 
bone area (Ct.Ar.) and (G) medullary area (Ma.Ar.). Data are represented as mean ± 
S.E.M. N>5, *P<0.05, **P<0.01. 
WT + cPTH 
cPTH 
WT  
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Figure 5.17. Cortical bone parameters at 50% tibial length in WT and 
Phospho1-/- mice receiving continuous PTH or vehicle control for 28-days.  
(A) Representative 3D micro-CT images of tibial cortical bone at 50% tibial length 
in WT and Phospho1-/- mice receiving continuous PTH or vehicle control for 28-
days. Analysis of the cortical bone parameters (B) cortical bone volume/ total 
volume (BV/TV) (C) cortical cross-sectional thickness (Ct.Th.) (D) cortical bone 
mineral density (BMD) (E) cortical tissue area (Tt.Ar.) (F) cortical bone area 
(Ct.Ar.) and (G) medullary area (Ma.Ar.). Data are represented as mean ± S.E.M. 
N>5, *P<0.05, **P<0.01, ***P<0.001. 
WT + cPTH 
cPTH 
WT  
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Figure 5.18. Three-point bending analysis of the tibia from WT and Phospho1-/- 
mice receiving cPTH or vehicle control for 28-days. 
Analysis of the biomechanical parameters (A) maximum load (B) work to maximum 
load (C) deflection at maximum load (D) load at rupture (E) work to rupture (F) 
deflection at rupture and (G) stiffness in the tibiae of WT and Phospho1-/- mice 
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Figure 5.19. Disturbed expression of components of phosphate regulation within 
the femora and kidney of  Phospho1-/- mice. 
RT-qPCR analysis of the mRNA expression within the kidney of WT and Phospho1-
/- mice receiving iPTH (80 µg/kg/day) for 14-days. (A) Pth1r (B) Cyp27b1 and  (C) 
Vdr.  RT-qPCR analysis of the mRNA expression within the distal femora of WT and 
Phospho1-/- mice receiving iPTH (80 µg/kg/day) for 14-days. (D) Fgf23 and (E) Vdr. 
Data are represented as mean ± S.E.M. N>4, *P<0.05, **P<0.01, ***P<0.001. 
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this, the basal levels of Cyp27b1 expression was decreased in Phospho1-/- kidneys 
compared to WT (P<0.05). The basal expression of  the vitamin D receptor (Vdr) was 
similarly found to exhibit reduced expression levels in Phospho1-/- kidney (P<0.05) 
but not in bone (Fig. 5.19.C & E). In the distal femora, PTH induced the upregulation 
of Fgf23 and Vdr expression in WT animals but not in Phospho1-/- mice. 
5.6. Discussion 
The pleiotropic effects of PTH on bone, which are dictated by the frequency of the 
exposure, have been progressively uncovered, aiding our understanding of the 
osteoanabolic effects of iPTH therapy and pathological bone loss associated with 
hyperparathyroidism. The mineralisation of osteoid, during both the initial formation 
of the skeleton and modelling and remodelling events, provides mechanical integrity 
to bone. The intravesicular phosphatase, PHOSPHO1 is essential for the initiation of 
MV-mediated HA formation, through the generation of Pi from the hydrolysis of 
phospholipid metabolites PCho and PEth (Roberts et al., 2004, Yadav et al., 2011). 
This Chapter sought to uncover the regulation of Phospho1 expression by PTH in vivo.   
In this study, I investigated several iPTH challenge models in order to assess the effects 
of acute (6 h) and chronic exposure (14 and 28 days) of PTH to provide a 
comprehensive analysis of the temporal effects of iPTH on Phospho1 expression and 
other gene markers of bone mineralisation. Phospho1 expression in the distal femur 
was enhanced in response to both a single, 6 h exposure to PTH and long term (14 day 
and 28 day) iPTH exposure in male WT mice. The genetic ablation of Phospho1 results 
in a disproportionate osteoid:bone volume ratio, greenstick fractures and bowing of 
long bones due to severe hypomineralisation (Yadav et al., 2011, Huesa et al., 2011, 
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Rodriguez-Florez et al., 2015). In addition, the biogenesis of MV is impaired in the 
absence of Phospho1 (Yadav et al., 2016). Despite this, the knowledge surrounding 
the effects of enhanced Phospho1 expression during ECM mineralisation are scant. In 
fact, the findings I presented in Chapter 3, in which the overexpression of Phospho1 
in MC3T3-C24 osteoblast-like cells enhanced ECM mineralisation compared to non-
transfected cell cultures (Huesa et al., 2015) appears to be the only available 
information on this subject. With this, albeit limited knowledge in mind, it is 
reasonable to propose that the iPTH-mediated enhancement of Phospho1 expression 
will lead to the enhancement of skeletal mineralisation. This hypothesis is bolstered 
by the fact that MVs (and thus potentially PHOSPHO1) have been shown to participate 
in the mineralisation of mature rat bone during the remodelling process (Hoshi and 
Ozawa, 2000). Furthermore, Phospho1 expression has been observed in the medullary 
bone of adult chickens. Medullary bone (a source of calcium for egg shell formation) 
is continually remodelled in 24 h cycles and as such, the presence of Phospho1 could 
indicate a potential involvement in the mineralisation of osteoid during bone 
remodelling (Stewart et al., 2006). Furthermore, immunohistochemical localisation 
studies on the chicken have shown that PHOSPHO1 expression is also associated with 
osteons in cortical bone that were actively mineralising their osteoid.  No 
immunoreactivity was observed in closed osteons (Stewart et al., 2006). These findings 
point towards a role for PHOSPHO1 throughout the lifespan of the skeleton. As 
nSMase2 is similarly implicated in the biogenesis of MV and indeed, more directly in 
the mineralisation process (through the generation of PCho as a substrate for 
PHOSPHO1) (Thouverey et al., 2011, Khavandgar et al., 2011, Khavandgar and 
Chapter 5                                   Examining the in vivo regulation of Phospho1 by parathyroid hormone 
 
~ 168 ~ 
 
Murshed, 2015), the upregulation of Smpd3 observed in this study in response to iPTH 
is likely to have facilitated the anabolic effects of iPTH. 
This present study additionally assessed the expression of the transcription factors 
Runx2 and Trps1 in the distal femur of male mice treated with PTH. Runx2 and Trps1 
mRNA expression was enhanced in WT mice in response to both a 6 h PTH exposure 
and a 14-day iPTH exposure but not in 28-day iPTH or continuously exposed mice. 
Trps1, a GATA transcription factor which primarily acts to repress the transcription of 
genes has recently been shown to be connected with the mineralisation process 
(Napierala et al., 2008, Kuzynski et al., 2014). Mutations in the Trps1 gene lead to the 
human condition tricho-rhino-phalangeal syndrome which is characterised by 
craniofacial and skeletal dysplasias (Momeni et al., 2000). The siRNA mediated 
knockdown of Trps1 in a pre-odontoblastic cell line leads to the suppression of 
Phospho1 and Smpd3 expression (Kuzynski et al., 2014). It is perhaps somewhat 
counterintuitive then that the same researchers found that the overexpression of Trps1 
results in decreased ECM mineralisation of these cell cultures (Kuzynski et al., 2014). 
Further studies will need to be performed to investigate the role of Trps1 in mediating 
Phospho1 expression. Although scarce, the research on Runx2 regulation of Phospho1 
is more convincing. The overexpression of Runx2 in mouse limb bud cultures leads to 
a 4-fold increase in Phospho1 expression (Nishimura et al., 2012). Runx2 directs 
mesenchymal precursors to the osteoblast lineage (Komori, 2010) and as such its 
expression precedes that of Phospho1. It is well stablished that Runx2 may be 
phosphorylated by PTH-directed activation of PKA (Franceschi and Xiao, 2003). 
Immunoprecipitation studies will be required to unequivocally confirm the ability of 
Runx2 to bind to the Phospho1 promoter. However, the data presented here alongside 
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that of Nishimura et al. (2012) certainly suggests a role for Runx2 in positively 
regulating Phospho1 expression.  
Despite the differential effects of iPTH observed between WT and Phospho1-/- mice, 
with respect to the expression of key mineralisation genes, there were only modest 
differences noted in their anabolic response to 28-day iPTH. In particular the 
osteoanabolic response to 28-day iPTH in trabecular bone was only moderately 
diminished in the absence of Phospho1. Interestingly however, there was an anabolic 
response noted in the cortical compartments of WT mice receiving 28-day iPTH but 
not in Phospho1-/-. In fact, Phospho1-/- mice actually displayed decreased cortical 
BMD with iPTH exposure. It is well established that the osteoanabolic effects of iPTH 
are more rapidly observed in cancellous as opposed to cortical bone (Rubin et al., 
2002). Moreover, reported BMD decreases during spaceflight are greater in the 
trabecular compartment (2.2-2.7%/ month) as opposed to the cortical compartment 
(0.4-0.5%/ month) (Lang et al., 2004). Of course, trabecular bone is more 
metabolically active than cortical bone due to its greater surface area (Clarke, 2008). 
The lack of induction of Runx2 in Phospho1-/- mice in response to iPTH, and therefore 
the potential reduced recruitment of osteoblasts from mesenchymal precursors, may 
have further slowed the remodelling rate of bone. It is therefore possible, that given an 
extended period of iPTH, Phospho1-/- mice would display anabolic features in the 
cortical compartment. Unfortunately this laboratory has struggled to successfully 
develop a method for detecting PHOSPHO1 in the mouse by immunohistochemistry. 
Personal communication with Dr Brian Foster (Ohio State University) has indicated 
that this current problem is not specific to our own laboratory despite their previous 
successful immunolocalisation of PHOSPHO1 in teeth (Zweifler et al., 2016). This 
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suggests a batch difference in the commercial production of the PHOSPHO1 antibody 
and this has hampered efforts to investigate any potential differences between 
trabecular and cortical bone PHOSPHO1 localisation. There were no obvious 
differences in the localisation or staining levels of TNAP within the cortical bone WT 
and Phospho1-/- mice exposed to 28-day iPTH (Fig. 5.13.).  
In this study, the continuous infusion of PTH over 28-days in male mice (from 4 weeks 
of age) did not induce any catabolic effects on bone microarchitecture as assessed by 
µCT. This was surprising as many previous studies have reported a catabolic effect on 
the skeleton of cPTH infusion (Hock and Gera, 1992, Uzawa et al., 1995, Iida-Klein 
et al., 2005).  Investigations into the lack of effect observed uncovered a recent study 
which similarly noted this lack of catabolism. Babey et al. (2015) infused PTH 1-34 
(60µg/kg/day) for 28-days into 12-week old male and female mice (similar to the 
protocol used in my studies) and detected decreased trabecular thickness, BMD and 
BV/TV in the distal femur of female mice only. This study additionally observed that 
osteoclast precursors derived from female mice were significantly more responsive to 
RANKL and macrophage colony stimulating factor compared to male mice. In 
contrast, bone marrow stromal cell cultures from male mice continuously exposed to 
PTH mineralised their ECM to a greater extent than cultures derived from female mice 
(Babey et al., 2015). This is not an isolated observation; trabecular bone preservation 
in male mice receiving cPTH infusion being noted previously (Cheng et al., 2013). 
Additional hints of gender specific differences in the response to chronic, high doses 
of PTH are available from the literature surrounding the human condition of 
hyperparathyroidism. Small scale studies from sample populations in Spain and India, 
revealed a more severe disease in women compared to men, with women exhibiting a 
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reduction in bone mass throughout the skeleton whereas men appear to have a bone 
sparing phenotype (Rico et al., 1994, Shah et al., 2012). Intriguingly, the results of my 
studies imply that the skeleton of male mice is responsive to the anabolic effects of 
iPTH but not to the catabolic effects of cPTH (the effects of iPTH and cPTH are 
summarised in Table 4). This to the best of my knowledge is a novel finding. Overall, 
the findings of my current work, alongside the research described herein, provide 
sufficient evidence to doubt the currently accepted dogma that cPTH exposure leads 
to bone loss under all conditions. Specifically, it highlights the importance of 
considering sex differences and the influence of the gonadal steroids in future 
endocrine experiments.   
 Table 4. Summary of the effects of iPTH and cPTH in WT and Phospho1-/- mice. 
 
The expression of genes which regulate the PTH-Vitamin D-FGF-23 axis within the 
kidney and bone were assessed after PTH exposure in both WT and Phospho1-/- mice. 
This was done in an attempt to explain the different response to PTH between WT and 
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al. (2011) did not report details on these key systemic regulators of phosphate despite 
observing severe hypomineralisation in the skeletons of the Phospho1-/- mice. It might 
be expected that Phospho1-/- mice would exhibit some sort of Pi sparing phenotype. 
Reduced Pth1r expression was observed in the bone of Phospho1-/- animals (6 week 
old male) compared to WT. However, the receptor exhibited similar reduced 
expression in the kidney of Phospho1-/- animals. These data point towards reduced 
bone resorption (through reduced remodelling) and reduced reabsorption of Pi at the 
proximal tubule of the kidney. These data on the expression of the Pth1r are in 
disagreement with previously published data which revealed that Phospho1-/- mice 
have high levels of the bone formation and resorption serum markers, N-terminal 
propeptide (P1NP) and C-terminal telopeptide of type I collagen (CTX), indicative of 
an increased remodelling rate (Huesa et al., 2011). Increased remodelling in the 
Phospho1-/- mouse is proposed to be a response to the pathological incidence of 
greenstick fractures exhibited in the bones of these mice (Huesa et al., 2011). Of 
course, PTH is not the only regulator of bone remodelling and the effects of other 
hormones (e.g. Insulin, Vitamin D) and growth factors (e.g. Insulin like growth factor 
1, BMPs) must be investigated in the Phospho1-/- mouse. For example, although the 
data concerning the effects of PTH on FGF-23 regulation are disparate (Franceschi 
and Xiao, 2003), I observed differences in the response of Fgf23 mRNA expression to 
PTH exposure between WT and Phospho1-/- mice. A comprehensive metabolomics 
study may be necessary to explain the differences between WT and Phospho1-/- mice 
in their skeletal response to PTH exposure.  
This Chapter has unequivocally confirmed the potent regulation of Phospho1 and 
Smpd3 by PTH in vivo. Stimulation of the expression of the genes by PTH, points 
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towards a role for these enzymes during bone modelling and remodelling. 
Additionally, these data highlight a role for Phospho1 in mediating the anabolic effects 
of iPTH, in particular in cortical bone. Studies modelling the continuous exposure to 
PTH add to the emerging body of evidence revealing that the osteocatabolic effects of 
this exposure may be limited to female mice. As a whole these data expand our 
knowledge of the regulation of key mineralisation genes which will be taken forward 
to benefit the pursuit of therapeutic agents to regulate biomineralisation.  
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Mineralisation of the ECM of bone and cartilage is an essential prerequisite to a 
functional skeleton. On the other hand, in soft tissues, mineralisation is typically 
pathologic, disrupting the normal physiology of the affected tissue. As such, this 
process is tightly regulated, both locally and systemically. The compartmentalisation 
of the initiation of mineralisation within specialised extracellular vesicles (MVs) 
provides an additionally regulatory element. The composition and function of the 
protein constituents are steadily being uncovered. PHOSPHO1, discovered in 1999 
within chick growth plate chondrocytes (Houston et al., 1999), is now known to be 
essential for the initiation of mineralisation within MV. The genetic ablation of 
Phospho1 results in severely hypomineralised and ductile bones (Yadav et al., 2011, 
Huesa et al., 2011, Rodriguez-Florez et al., 2015), reduced MV biogenesis and 
function (Yadav et al., 2016) and altered osteocytogenesis and lacunae morphology 
(Javaheri et al., 2015). Despite this knowledge of the skeletal phenotype associated 
with the absence of Phospho1, little is known about its genetic and molecular 
regulation, nor its interaction with other MV components. The work reported in this 
thesis aimed to provide an understanding of these unknowns through both in vitro and 
in vivo experimentation. 
The in vitro study of the essential phosphatases and phosphate transporters of MV 
mineralisation has to date been limited by the use of βGP to induce ECM 
mineralisation, a substrate for TNAP, the major MV phosphatase. The work presented 
in Chapter 3, highlighted that ECM mineralisation in the absence of βGP is achievable. 
Osteoblast cell cultures exposed to Ca2+ exhibited ECM mineralisation comparable to 
that observed in βGP treated cultures. Of course, this approach is not without 
limitations as Ca2+ is capable of inducing a number of cellular functions such as 
Chapter 6                                                                                                        Final discussion and future work 
 
~ 176 ~ 
 
differentiation, proliferation, adhesion and endo- and exo-cytosis amongst others. 
With further characterisation however, these phosphatase-substrate free mineralisation 
conditions will allow investigators to successfully investigate the mechanisms of 
endogenous Pi generation during mineralisation. Embryonic metatarsals displayed 
diaphyseal mineralisation when cultured in serum free conditions supplemented with 
ascorbic acid only. This represents the optimum conditions for analysis of phosphatase 
function (and endogenous Pi production). However, this model is limited to the study 
of chondrocyte directed cartilage mineralisation. Both these culture models were 
utilised to examine the temporal expression of key mineralisation enzymes during 
osteoblast and chondrocyte mineralisation. Of particular interest was the finding that 
PHOSPHO1 and nSMase2 appear to be simultaneously upregulated prior to the 
appearance of mineralisation. Furthermore, in the absence of PHOSPHO1, nSMase2 
expression is downregulated. These findings bolster the hypothesis that these enzymes 
work in tandem for the generation and processing of PCho during ECM mineralisation. 
However, the expression pattern of these enzymes alone is not confirmatory of 
cooperative function. Substrate and enzymatic product analysis should be performed 
by mass spectrometry within these models. Furthermore, the expression analysis 
experiments detailed in Chapter 3 should be performed with fro/fro calvarial 
osteoblasts and embryonic metatarsals. Although fro/fro skeletal tissues exhibit 
reduced ceramide levels (due to the lack of sphingomyelinase activity) the PCho levels 
have not been investigated. One might hypothesise that these would similarly be 
reduced, and as such PHOSPHO1 activity might be correspondingly reduced. It would 
be informative to generate and analyse the skeleton of fro/fro;Phospho1-/- compound 
homozygotes. If the osteomalacia of the double knock-out mouse was greater than 
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observed in either the Smpd3 or Phospho1 deficient mouse then it is likely that both 
gene products influence ECM mineralisation via independent mechanisms.  However 
as hypothesised in this work, if the osteomalacia of the double knock-out mouse was 
similar this would suggest that nSMase2 and PHOSPHO1 might act in the same 
pathway e.g. nSMase2 acts upstream of PHOSPHO1. 
As the skeleton of the fro/fro mice are severely hypomineralised, it is unlikely that 
other PCho generating enzymes (e.g. CK) are upregulated to provide PCho for Pi 
generation by PHOSPHO1. Perinatal lethality of the fro/fro mouse has limited its use 
as it is difficult (and expensive) to breed and accrue enough experimental animals. 
However, Alebrahim et al. (2014) recently generated a fro/fro mouse with tetracycline 
inducible-Smpd3 expression. The early embryonic expression of Smpd3 improves the 
survivability of the fro/fro mouse.  
The characterisation of the fro/fro (Khavandgar et al., 2011) and Chkβ-/- mice (Sher et 
al., 2006) and the striking skeletal mineralisation defects observed provided the 
impetus for the work of this thesis, which in part, sought to investigate the interplay 
between these enzymes (which both generate PCho) and PHOSPHO1. Of course, 
nSMase2 and CK activity are not the only mechanisms of PCho generation and 
furthermore, recombinant human PHOSPHO1 exhibits activity towards PCho and 
PEth (Roberts et al., 2004). Studies on the lipid composition of MV have shown that 
the PE, PC and SM content of MVs is reduced rapidly during mineralisation. MV 
mineralisation is also associated with a rise in diacylglycerols and monoacylglycerols 
indicative of phospholipase C and lysophospholipase C activity respectively (Mebarek 
et al., 2013). Interestingly, MV membranes are enriched in lysophosphospholipids 
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(LP) which contain only one fatty acid moiety (Wu et al., 2002). The generation of 
PCho from LPC is classically viewed as a three step process in vertebrates (Cole et al., 
2012). Recently, NPP6 was characterised as possessing choline-specific 
glycerophosphodiester phosphodiesterase activity, showing specificity towards LPC 
in in vitro assays (Sakagami et al., 2005). The direct generation of PCho from LPC by 
NPP6 could provide an alternative mechanism to provide PHOSPHO1 substrate within 
MVs. The data surrounding NPP6 is however limited, and to date its presence within 
MVs has not been established although data from this laboratory has confirmed it 
expression within bone by immunoblotting and immunohistochemistry (unpublished 
observations). Phospholipase C activity is often generically assumed to mean 
phosphatidylinositol-PLC activity which results in the generation of the established 
signalling molecule inositol 1,4,5, triphosphate. PC specific PLC isoforms have not 
been reported in vertebrates, but if identified the production of PCho and DAG from 
PC could, hypothetically, be yet another source of PCho within MVs.  
As alluded to earlier, to truly investigate the role of lipid metabolism in ECM 
mineralisation, analysis of lipid precursors and metabolites will be necessary. 
Moreover this analysis should be performed in transgenic mouse models. The analysis 
of MV lipid composition and fluctuation during biomineralisation by thin layer 
chromatography (carried out by Wu et al. (2002)) are limited by current standards. The 
advances in mass spectrometry techniques now allows for the extensive 
characterisation and quantification of lipids in biological samples. Despite this, MS 
still remains challenging in mineralised samples, with phosphate salts being particular 
problematic by affecting the ionisation of analytes and introducing significant noise 
into generated spectra. Despite this, MS-approaches to lipid analysis are being reported 
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in the literature (Gotliv et al., 2006, Dambach et al., 2004, Zhu et al., 2016). It was 
originally an aim of this studentship to characterise the ‘lipodomes’ of the in vitro 
model systems developed in Chapter 3 during ECM mineralisation but prohibitive 
costs of this approach made it impossible to make major progress towards this aim. 
Despite this, with the assistance and expertise of Prof. Phillip Whitfield of the 
Lipidomics research facility, University of the Highlands and Islands, Inverness, I have 
been able to obtain some preliminary lipidomic data from cultured embryonic 
metatarsal samples. Lipids were extracted from metatarsal samples (20 bones) after 
collagenase digestion using established methods (Folch et al., 1957) and described in 
section 2.6.1. The resultant lipid extracts underwent liquid chromatography-mass 
spectrometry as described in section 2.6.1. and performed by Prof. Whitfield. These 
preliminary experiments generated data about eight classes of phospholipids 
(Fig. 6.1.). These results are yet to be normalised to a yet to be determined variable, 
however they demonstrate the ability to obtain quantitative lipidomic data from 
embryonic metatarsal samples. Furthermore samples were spiked with non-
physiologic lipid species prior to analysis and acted as an internal standard from which 
to quantify the picomolar quantities of the lipids within the samples (Fig. 6.1.). As I 
and others have recently written about (Marino et al., 2016), embryonic metatarsals 
are a highly physiological model of endochondral ossification, in particular, the E15 
stage provides a means of investigating the initiation of mineralisation. In our 
lipidomic experiments, the final volume infused in the mass spectrometer was the 
equivalent of four metatarsals further emphasising the practicality of this approach for 
future studies. 
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Figure 6.1. Quantification of lipids extracted from cultured embryonic 
metatarsals.  
Total lipids were extracted from WT and Phospho1-/- E15 metatarsals cultured for 5 
days. Separation and quantification of lipid species was performed by HPLC-MS. (A) 
Phosphatidylcholine (PC) species (B) Lysophosphatidylcholine (LPC) species (C) 
Phosphatidylethanolamine (PE) species (D) Lysophosphatidylethanolamine (LPE) 
species (E) Sphingomyelin (SM) species (F) Phosphatidylserine (PS) species (G) 
Phosphatidylinositol (PI) species (H) Phosphatidylglycerol (PG) species. Data are 
presented as mean ± S.E.M for N=3 samples per genotype.      
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Primarily through the modulation of osteoblast recruitment, proliferation and 
apoptosis, iPTH exposure increases bone formation on periosteal, endocortical and 
trabecular bone surfaces (Kousteni and Bilezikian, 2008). Furthermore, PTH 
suppresses the expression of the Wnt antagonist, SOST from osteocytes. This thesis 
presents data revealing that PTH potently modulates the expression of Phospho1 and 
Smpd3, and that iPTH enhances the expression of these genes in vivo. The role of these 
two enzymes in skeletal mineralisation has been discussed in detail in this thesis. A 
schematic model of the actions of iPTH on the expression of Phospho1 and Smpd3, 
and the downstream effects of this on MVs are presented in Fig. 6.2. The genetic 
ablation or pharmacological inhibition of PHOSPHO1 or nSMase2 results in profound 
mineralisation defects and reduced MV release. The work of this thesis additionally 
found, that in the absence of Phospho1, Smpd3 expression was not induced by iPTH, 
and neither were there any anabolic effects of iPTH within cortical bone. Whilst this 
is preliminary data, it is tempting to propose that the enhancement of Phospho1 and 
Smpd3 expression provides an additional means of explaining the osteoanabolic 
effects of iPTH on the skeleton. To add weight to this hypothesis it must be first 
confirmed that upregulation of Phospho1 expression in adult bone results in an 
increase in BMD. C57Bl/6J mice overexpressing Phospho1 under the influence of the 
col1a1 promoter (i.e. bone specific) have been developed and are awaiting 
characterisation by this laboratory. These mice will be useful to investigate the effects 
of Phospho1 upregulation, however a mouse with inducible Phospho1 expression 
(perhaps through a tetracycline-dependent transcriptional control system) will be 
required to answer the aforementioned question, i.e. does the upregulation of 
Phospho1 in adult bone increase BMD. These mice may also be important to  
Chapter 6                                                                                                        Final discussion and future work 
 




Figure 6.2. Schematic model of the effects of PTH on Phospho1 and Smpd3. 
Results from this thesis have identified the cAMP/PKA signalling pathway as the key 
intracellular pathway regulating Phospho1 and Smpd3 expression. Furthermore, iPTH 
upregulates the expression of Phospho1 and Smpd3 in WT mouse femur. Based on 
current knowledge of the roles of PHOSPHO1 and nSMase2, this upregulation is 
proposed to have multifaceted roles on MVs including the increase in MV release and 
the upregulation of Pi generation within MVs. These roles are hypothesised to 
increases local mineralisation of the ECM. Adenylyl cylclase (AC), Adenosine 
triphosphate(ATP), cyclic adenosine monophosphate (cAMP), Protein kinase A 
(PKA), parathyroid hormone (PTH), parathyroid hormone 1 receptor (PTH1R), matrix 
vesicle (MV), plasma membrane (PM), nuclear membrane (NM), sphingomyelin 
(SM), phosphocholine (PCho), inorganic phosphate (Pi). 
Chapter 6                                                                                                        Final discussion and future work 
 
~ 183 ~ 
 
investigate the influence of PHOSPHO1 on fracture repair. A recent abstract at the 
ASBMR in 2015 from the laboratory of Monzur Murshed (McGill University, 
Montreal) indicated that long bones from Phospho1 deficient mice repaired their bones 
poorly after rod immobilised fracture surgery. This work suggests that PHOSPHO1 
plays an integral role during bone fracture repair and may be a therapeutic target to 
improve the fracture healing process. 
From the in vitro observation that cPTH exposure inhibited the expression of 
Phospho1 (Chapter 4 and (Houston et al., 2016)), in an osteoblast cell line it was 
hypothesised that the bone loss observed in hyperparathyroidism may be a result of 
reduced mineralisation gene expression by osteoblasts coupled with the enhanced 
osteoclastogenesis classically reported. Indeed hyperparathyroidism appears to affect 
bone mass in the cortical compartment whilst sparing cancellous bone mass and 
increasing osteoblast number (Dempster et al., 2007, Jilka et al., 2010). Intermittent 
PTH experiments have underscored a more important role for PHOSPHO1 in cortical 
bone. Unfortunately, the experiments performed in Chapter 5 to investigate the effects 
of cPTH on WT and Phospho1 deficient mice were performed in male mice which, I 
discovered after the completion of my studies, have been reported not to exhibit the 
well-established osteocatabolic effects of cPTH (Babey et al., 2015). These studies 
should be repeated in female mice to test the involvement, if any, of PHOSPHO1 
during cPTH induced bone loss. On first appearances, the observation that PTH 
positively and negatively regulates Phospho1 expression depending on the length of 
exposure, may seem inconsistent with the high bone mass phenotype of 
hypoparathyroidism. However, hypoparathyroidism is characterised by low bone 
turnover (parathyroidectomised rats exhibit reduced RANKL expression (Ueno et al., 
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2003)), and not excessive osteoblast activity. Indeed, OCN positive osteoblasts (i.e. 
mature osteoblasts) are reduced in hypoparathyroidism and SOST levels are high 
(Rubin et al., 2011), implying bone formation is slowed. Additionally, the regulation 
of Phospho1 by other endocrine and paracrine factors in the absence of PTH cannot 
be ruled out, for example, this study also identified BMP-2 as a positive regulator of 
Phospho1 expression (Chapter 4, Fig. 4.8.).  
The positive regulation of Phospho1 and Smpd3 by BMP-2 is certainly worthy of 
further investigation. BMP-2 is powerfully osteogenic and is used clinically to 
improve the repair of non-union fractures. BMP-2 upregulates the expression of the 
osteogenic transcription factor, Runx2, through the activation of Dlx5, a transcriptional 
activator of Runx2 (Lee et al., 2003, Samee et al., 2008). Induction of Runx2 
expression has been shown to enhance Phospho1 expression in mouse limb bud 
cultures (Nishimura et al., 2012). Thus it is possible that BMP-2 upregulates Phospho1 
expression through activation of Runx2. As a starting point, cycloheximide studies 
would be useful to determine if the action of BMP-2 on Phospho1 is a direct effect or 
one that requires a protein intermediary. With this in mind, a recent microarray study 
of Smad3 overexpressing MC3T3-E1 osteoblast like cells, revealed a 157-fold 
increase in Phospho1 transcript level (Hisa et al., 2011). Evidence is emerging that 
BMP-2 can activate the non-canonical BMP signalling pathways involving Smad2/3, 
albeit in murine gonadotrope-like cells (Wang et al., 2014).  
A variety of human conditions, characterised by disrupted mineralisation, have been 
shown to be the result of mutations within known and discrete genetic loci. For 
example, the pathogenesis of sclerosteosis, fibrodysplasia ossificans progressiva, HPP 
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and pseudoxanthoma elasticum has been linked to mutations within the SOST, ACVR1, 
ALPL and ABCC6 genes respectively (Balemans et al., 2001, Shore et al., 2006, 
Henthorn and Whyte, 1992, Nitschke et al., 2012). These conditions are typically 
severe albeit rare. In contrast, the aetiology of osteoporosis is multifactorial and may 
secondarily arise as a result of other complications. To date, no disorders of 
mineralisation have been linked to mutations in the PHOSPHO1 locus. However it is 
tantalising to speculate that inhibition of PHOSPHO1 function may be implicated in 
the high incidence of bone fractures amongst people taking acid-suppressive 
medications such as proton pump inhibitors (PPI).  Three recent large epidemiologic 
studies completed in Denmark, UK and Canada have reported an increased risk of 
osteoporosis related fractures including fractures of the hip with chronic PPI therapy 
(Yang et al., 2006, Vestergaard et al., 2006, Targownik et al., 2008). PPIs such as 
omeprazole, esomeprazole, pantoprazole and lansoprazole are commonly prescribed 
to control and prevent symptoms of chronic unrelenting conditions such as 
gastroesophageal reflux disease, ulcers and dyspepsia and patients are prescribed PPIs 
for protracted periods of time (Jacobson et al., 2003).  The commonly accepted 
explanation for the casual relationship between PPI use and bone fractures is the 
impairment of calcium absorption leading to secondary hyperparathyroidism and 
increased osteoclastic bone resorption (Vestergaard et al., 2006). This calcium 
malabsorption maybe a consequence of PPI induced reduction in acid production 
(hypochlorhydria) in the stomach and proximal duodenum leading to the retention of 
calcium in its food matrix and defective calcium absorption.  However, studies on the 
effects of hypochlorhydria on calcium absorption have been equivocal, suggesting a 
limited role of reduced acid secretion in the development of fractures (Bo-Linn et al., 
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1984, Marcinowska-Suchowierska et al., 1995). These, and other conflicting data, 
suggest that PPI use may increase fracture incidence by a mechanism that is in addition 
to, or independent of, its effect of calcium malabsorption and secondary 
hyperparathyroidism.  Previous studies in this laboratory have identified lansoprazole 
as a potent PHOSPHO1 inhibitor, which when tested in vivo can inhibit bone 
mineralisation (Roberts et al., 2007, MacRae et al., 2010). Further studies are required 
to evaluate if PHOSPHO1 mediates the bones response to PPI administration.    
Furthermore, methylation of the PHOSPHO1 locus has been associated with future 
risk of developing type II diabetes (Chambers et al., 2015, Dayeh et al., 2016) and 
consistent with this observation, work from this laboratory has shown that   Phospho1-
/- mice exhibit improved glucose and insulin tolerance and resist high-fat-diet induced 
obesity and diabetes. Surprisingly, this protective phenotype was manifested in the 
absence of altered levels of undercarboxylated osteocalcin, the principal bone 
endocrine hormone (Oldknow et al. unpublished) 
The results of Chapter 5 of this thesis has provided preliminary evidence for a role of 
PHOSPHO1 in eliciting the anabolic effects of PTH in bone, which are worthy of 
further investigation. To explore a potential role for PHOSPHO1 in human bone 
mineralisation, it would be beneficial to first investigate its role in a large animal 
model. Despite the advantages of rodents in the study of protein function and disease 
pathogenesis, the morphological, anatomical and mechanical properties of rodent bone 
do not accurately model the human situation (Aerssens et al., 1998). Pigs, like humans 
exhibit Haversian remodelling and growth plate fusion and have similar femoral cross 
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sectional diameters, making them an attractive candidate to more appropriately study 
the regulation of bone mineralisation (Bagi et al., 2011, Li et al., 2015).  
The recent sequencing and annotation of the Sus scrofa (domestic pig) genome 
improves the practicality of the pig as a model species (Groenen et al., 2012). This, in 
combination with the emergence of engineered nuclease technologies such as the 
clustered, regularly interspaced, short palindromic repeats (CRISPR)/Cas9 systems, 
allows the rapid, and relatively easy, generation of genome edited pigs. In brief, 
CRISPR associated protein 9 (Cas9) is a double stranded nuclease derived from 
Streptococcus pyogenes which may be targeted to cut the genome via an RNA-guide 
molecule. Double strand cleavage through the activity of Cas9 stimulated non-
homologous end joining, a DNA repair mechanisms which is particularly prone to the 
introduction of insertion and deletion mutations (Sander and Joung, 2014). During my 
PhD, three pairs of CRISPR guides were designed against the pig PHOSPHO1 gene.  
The guides were designed to target a region within pig PHOSPHO1, homologous to 
exon 3 of the murine Phospho1 gene. This is the same region containing an adenine to 
thymine substitution which generates the stop codon and thus loss of functional 
PHOSPHO1 within the Phospho1-/- mouse. To date these guides have been cloned into 
Cas9 containing, mammalian expression vectors and transfected into a pig fibroblast 
cell line. Due to time constraints the ability of these constructs to cleave at the target 
site has yet to be tested. If successful, these constructs may be used to generate genome 
edited founder pigs through the method of Lillico et al. (2013). Characterisation of the 
skeleton of PHOSPHO1-/- pigs will provide a more reliable insight into its potential 
role in humans. 
                                                                                                                                                                References 





Addison, W. N., Azari, F., Sørensen, E. S., Kaartinen, M. T. & Mckee, M. D. 2007. 
Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-
regulating osteopontin, and inhibiting alkaline phosphatase activity. Journal of Biological 
Chemistry, 282, 15872-15883. 
 
Addison, W. N., Nakano, Y., Loisel, T., Crine, P. & Mckee, M. D. 2008. MEPE-ASARM peptides 
control extracellular matrix mineralization by binding to hydroxyapatite: An inhibition 
regulated by PHEX cleavage of ASARM. Journal of Bone and Mineral Research, 23, 1638-1649. 
 
Addison, W. N., Masica, D. L., Gray, J. J. & Mckee, M. D. 2010. Phosphorylation-dependent 
inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. 
Journal of Bone and Mineral Research, 25, 695-705. 
 
Addison, W. N., Nelea, V., Chicatun, F., Chien, Y. C., Tran-Khanh, N., Buschmann, M. D., 
Nazhat, S. N., Kaartinen, M. T., Vali, H., Tecklenburg, M. M., Franceschi, R. T. & Mckee, M. D. 
2015. Extracellular matrix mineralization in murine MC3T3-E1 osteoblast cultures: An 
ultrastructural, compositional and comparative analysis with mouse bone. Bone, 71, 244-
256. 
 
Aerssens, J., Boonen, S., Lowet, G. & Dequeker, J. 1998. Interspecies Differences in Bone 
Composition, Density, and Quality: Potential Implications for in Vivo Bone Research. 
Endocrinology, 139, 663-670. 
 
Agarwal, R. & Garcia, A. J. 2015. Biomaterial strategies for engineering implants for enhanced 
osseointegration and bone repair. Advanced Drug Delivery Reviews, 94, 53-62. 
 
Alebrahim, S., Khavandgar, Z., Marulanda, J. & Murshed, M. 2014. Inducible transient 
expression of Smpd3 prevents early lethality in fro/fro mice. Genesis, 52, 408-16. 
 
Ali, S. Y., Sajdera, S. W. & Anderson, H. C. 1970. Isolation and Characterization of Calcifying 
Matrix Vesicles from Epiphyseal Cartilage. Proceedings of the National Academy of Sciences, 
67, 1513-1520. 
 
Amin, A. K., Huntley, J. S., Bush, P. G., Simpson, H. R. W. & Hall, A. C. 2009. Chondrocyte Death 
in Mechanically Injured Articular Cartilage-The Influence of Extracellular Calcium. Journal of 
Orthopaedic Research, 27, 778-784. 
 
Anderson, H. C. 1967. Electron microscopic studies of induced cartilage development and 
calcification. Journal of Cellular Biology, 35, 81-101. 
 
Anderson, H. C. 1969. Vesicles Associated with Calcification in Matrix of Epiphyseal Cartilage. 
Journal of Cell Biology, 41, 59-&. 
 
Anderson, H. C. 1995. Molecular biology of matrix vesicles. Clin Orthop Relat Res, 266-280. 
 
 
                                                                                                                                                               References 
 
~ 189 ~ 
 
Anderson, H. C., Hsu, H. H., Morris, D. C., Fedde, K. N. & Whyte, M. P. 1997. Matrix vesicles 
in osteomalacic hypophosphatasia bone contain apatite-like mineral crystals. American 
Journal of Pathology, 151, 1555-1561. 
 
Anderson, H. C. 2003. Matrix vesicles and calcification. Current Rheumatology Reports, 5, 
222-6. 
 
Anderson, H. C., Sipe, J. B., Hessle, L., Dhamyamraju, R., Atti, E., Camacho, N. P. & Millan, J. 
L. 2004. Impaired calcification around matrix vesicles of growth plate and bone in alkaline 
phosphatase-deficient mice. American Journal of Pathology, 164, 841-847. 
 
Anderson, H. C., Garimella, R. & Tague, S. E. 2005a. The role of matrix vesicles in growth plate 
development and biomineralization. Frontiers in Bioscience, 10, 822-37. 
 
Anderson, H. C., Harmey, D., Camacho, N. P., Garimella, R., Sipe, J. B., Tague, S., Bi, X., 
Johnson, K., Terkeltaub, R. & Millán, J. L. 2005b. Sustained osteomalacia of long bones despite 
major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific 
alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient 
mice. American Journal of Pathology, 166, 1711-1720. 
 
Andrade, A. C., Chrysis, D., Audi, L. & Nilsson, O. 2011. Methods to study cartilage and bone 
development. Endocrinology and Development, 21, 52-66. 
 
Aoyama, C., Liao, H. & Ishidate, K. 2004. Structure and function of choline kinase isoforms in 
mammalian cells. Progress in Lipid Research, 43, 266-281. 
 
Aslan, D., Andersen, M. D., Gede, L. B., De Franca, T. K., Jørgensen, S. R., Schwarz, P. & 
Jørgensen, N. R. 2012. Mechanisms for the bone anabolic effect of parathyroid hormone 
treatment in humans. Scandinavian Journal of Clinical and Laboratory Investigation, 72, 14-
22. 
 
Aspden, R. M. 2003. Mechanical testing of bone ex vivo. Bone Research Protocols, 80, 369-
379. 
 
Aukhil, I., Cui, C., Yunhong, B. & Cooper, L. F. 2000. Identification and characterization of a 
novel gene in developing bone, cartilage and cardiac muscle. Molecular Biology of the Cell, 
11, 163A. 
 
Babey, M., Wang, Y., Kubota, T., Fong, C., Menendez, A., Elalieh, H. Z. & Bikle, D. D. 2015. 
Gender-Specific Differences in the Skeletal Response to Continuous PTH in Mice Lacking the 
IGF1 Receptor in Mature Osteoblasts. Journal of Bone and Mineral Research, 30, 1064-1076. 
 
Bagi, C. M., Berryman, E. & Moalli, M. R. 2011. Comparative Bone Anatomy of Commonly 
Used Laboratory Animals: Implications for Drug Discovery. Comparative Medicine, 61, 76-85. 
 
Balcerzak, M., Hamade, E., Zhang, L., Pikula, S., Azzar, G., Radisson, J., Bandorowicz-Pikula, J. 
& Buchet, R. 2003. The roles of annexins and alkaline phosphatase in mineralization process. 
Acta Biochimica Polonica, 50, 1019-1038. 
 
                                                                                                                                                               References 
 
~ 190 ~ 
 
Balemans, W., Ebeling, M., Patel, N., Van Hul, E., Olson, P., Dioszegi, M., Lacza, C., Wuyts, W., 
Van Den Ende, J., Willems, P., Paes-Alves, A. F., Hill, S., Bueno, M., Ramos, F. J., Tacconi, P., 
Dikkers, F. G., Stratakis, C., Lindpaintner, K., Vickery, B., Foernzler, D. & Van Hul, W. 2001. 
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein 
(SOST). Human Molecular Genetics, 10, 537-543. 
 
Baron, R. & Hesse, E. 2012. Update on bone anabolics in osteoporosis treatment: rationale, 
current status, and perspectives. Journal of Clinical Endocrinology and Metabolism, 97, 311-
25. 
 
Beck, L., Leroy, C., Beck-Cormier, S., Forand, A., Salaun, C., Paris, N., Bernier, A., Urena-Torres, 
P., Prie, D., Ollero, M., Coulombel, L. & Friedlander, G. 2010. The Phosphate Transporter PiT1 
(Slc20a1) Revealed As a New Essential Gene for Mouse Liver Development. Plos One, 5. 
 
Bellido, T., Ali, A. A., Plotkin, L. I., Fu, Q., Gubrij, I., Roberson, P. K., Weinstein, R. S., O'brien, 
C. A., Manolagas, S. C. & Jilka, R. L. 2003. Proteasomal degradation of Runx2 shortens 
parathyroid hormone-induced anti-apoptotic signaling in osteoblasts - A putative 
explanation for why intermittent administration is needed for bone anabolism. Journal of 
Biological Chemistry, 278, 50259-50272. 
 
Bellows, C. G., Heersche, J. N. M. & Aubin, J. E. 1992. Inorganic-phosphate added Exogenously 
or released from Beta-glycerophosphate Initiates Mineralization of Osteoid Nodules in vitro. 
Bone and Mineral, 17, 15-29. 
 
Bellows, C. G., Ishida, H., Aubin, J. E. & Heersche, J. N. M. 1990. Parathyroid Hormone 
Reversibly Suppresses the Differentiation of Osteoprogenitor Cells into Functional 
Osteoblasts. Endocrinology, 127, 3111-3116. 
 
Bernard, G. W. & Pease, D. C. 1969. An electron microscopic study of initial intramembranous 
osteogenesis. American  Journal of Anatomy, 125, 271-90. 
 
Best, J. L., Amezcua, C. A., Mayr, B., Flechner, L., Murawsky, C. M., Emerson, B., Zor, T., 
Gardner, K. H. & Montminy, M. 2004. Identification of small-molecule antagonists that inhibit 
an activator:coactivator interaction. Proceedings of the National Academy of Sciences, 101, 
17622-17627. 
 
Bo-Linn, G. W., Davis, G. R., Buddrus, D. J., Morawski, S. G., Santa Ana, C. & Fordtran, J. S. 
1984. An evaluation of the importance of gastric acid secretion in the absorption of dietary 
calcium. Journal of Clinical Investigation, 73, 640-647. 
 
Bollen, M., Gijsbers, R., Ceulemans, H., Stalmans, W. & Stefan, C. 2000. Nucleotide 
pyrophosphatases/phosphodiesterases on the move. Critical Reviews in Biochemistry and 
Molecular Biology, 35, 393-432. 
 
Bonewald, L. F. 2011. The Amazing Osteocyte. Journal of Bone and Mineral Research, 26, 229-
238. 
 
Bonewald, L. F. & Wacker, M. J. 2013. FGF23 Production by Osteocytes. Pediatric nephrology 
(Berlin, Germany), 28, 563-568. 
                                                                                                                                                               References 
 
~ 191 ~ 
 
Bonucci, E. 1967. Fine structure of early cartilage calcification. Journal of Ultrastructural 
Research, 20, 33-50. 
 
Boskey, A. L. & Roy, R. 2008. Cell Culture Systems for Studies of Bone and Tooth 
Mineralization. Chemical Reviews, 108, 4716-4733. 
 
Bourgine, A., Pilet, P., Diouani, S., Sourice, S., Lesoeur, J., Beck-Cormier, S., Khoshniat, S., 
Weiss, P., Friedlander, G., Guicheux, J. & Beck, L. 2013. Mice with Hypomorphic Expression 
of the Sodium-Phosphate Cotransporter PiT1/Slc20a1 Have an Unexpected Normal Bone 
Mineralization. Plos One, 8. 
 
Brandi, M. L. 2009. Microarchitecture, the key to bone quality. Rheumatology, 48, iv3-iv8. 
 
Britto, J. M., Fenton, A. J., Holloway, W. R. & Nicholson, G. C. 1994. Osteoblasts mediate 
thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology, 134, 169-76. 
 
Brown, E. M. 2015. Chapter 6 - Control of Parathyroid Hormone Secretion by its Key 
Physiological Regulators A2 - Bilezikian, John P. The Parathyroids (Third Edition). San Diego: 
Academic Press. 
 
Calbet, L. J. A., Moysi, S. J., Dorado, C. & Rodríguez, P. L. 1998. Bone Mineral Content and 
Density in Professional Tennis Players. Calcified Tissue International, 62, 491-496. 
 
Canalis, E. & Delany, A. M. 2002. Mechanisms of glucocorticoid action in bone. Annals of the 
New York Academy of Science, 966, 73-81. 
 
Carter, D. R., Van Der Meulen, M. C. H. & Beaupré, G. S. 1996. Mechanical factors in bone 
growth and development. Bone, 18, S5-S10. 
 
Chae, Y.-M., Heo, S.-H., Kim, J.-Y., Lee, J.-M., Ryoo, H.-M. & Cho, J.-Y. 2009. Upregulation of 
smpd3 via BMP2 stimulation and Runx2. Bmb Reports, 42, 86-90. 
 
Chambers, J. C., Loh, M., Lehne, B., Drong, A., Kriebel, J., Motta, V., Wahl, S., Elliott, H. R., 
Rota, F., Scott, W. R., Zhang, W., Tan, S. T., Campanella, G., Chadeau-Hyam, M., Yengo, L., 
Richmond, R. C., Adamowicz-Brice, M., Afzal, U., Bozaoglu, K., Mok, Z. Y., Ng, H. K., Pattou, F., 
Prokisch, H., Rozario, M. A., Tarantini, L., Abbott, J., Ala-Korpela, M., Albetti, B., Ammerpohl, 
O., Bertazzi, P. A., Blancher, C., Caiazzo, R., Danesh, J., Gaunt, T. R., De Lusignan, S., Gieger, 
C., Illig, T., Jha, S., Jones, S., Jowett, J., Kangas, A. J., Kasturiratne, A., Kato, N., Kotea, N., 
Kowlessur, S., Pitkaniemi, J., Punjabi, P., Saleheen, D., Schafmayer, C., Soininen, P., Tai, E. S., 
Thorand, B., Tuomilehto, J., Wickremasinghe, A. R., Kyrtopoulos, S. A., Aitman, T. J., Herder, 
C., Hampe, J., Cauchi, S., Relton, C. L., Froguel, P., Soong, R., Vineis, P., Jarvelin, M. R., Scott, 
J., Grallert, H., Bollati, V., Elliott, P., Mccarthy, M. I. & Kooner, J. S. 2015. Epigenome-wide 
association of DNA methylation markers in peripheral blood from Indian Asians and 
Europeans with incident type 2 diabetes: a nested case-control study. Lancet Diabetes 
Endocrinol, 3, 526-34. 
 
Chang, M. K., Raggatt, L.-J., Alexander, K. A., Kuliwaba, J. S., Fazzalari, N. L., Schroder, K., 
Maylin, E. R., Ripoll, V. M., Hume, D. A. & Pettit, A. R. 2008. Osteal tissue macrophages are 
                                                                                                                                                               References 
 
~ 192 ~ 
 
intercalated throughout human and mouse bone lining tissues and regulate osteoblast 
function in vitro and in vivo. Journal of Immunology, 181, 1232-1244. 
Chang, Y. L., Stanford, C. M. & Keller, J. C. 2000. Calcium and phosphate supplementation 
promotes bone cell mineralization: Implications for hydroxyapatite (HA)-enhanced bone 
formation. Journal of Biomedical Materials Research, 52, 270-278. 
 
Charles, J. F. & Aliprantis, A. O. 2014. Osteoclasts: more than just 'bone eaters'. Trends in 
Molecular Medicine, 20, 449-459. 
 
Chen, Q., Bei, J. J., Liu, C., Feng, S. B., Zhao, W. B., Zhou, Z., Yu, Z. P., Du, X. J. & Hu, H. Y. 2016. 
HMGB1 Induces Secretion of Matrix Vesicles by Macrophages to Enhance Ectopic 
Mineralization. Plos One, 11. 
 
Cheng, Z., Liang, N., Chen, T.-H., Li, A., Maria, C. S., You, M., Ho, H., Song, F., Bikle, D., Tu, C., 
Shoback, D. & Chang, W. 2013. Sex and Age Modify Biochemical and Skeletal Manifestations 
of Chronic Hyperparathyroidism by Altering Target Organ Responses to Ca(2+) and PTH in 
Mice. Journal of bone and mineral research : the official journal of the American Society for 
Bone and Mineral Research, 28, 1087-1100. 
 
Chung, C.-H., Golub, E. E., Forbes, E., Tokuoka, T. & Shapiro, I. M. 1992. Mechanism of action 
of β-glycerophosphate on bone cell mineralization. Calcified Tissue International, 51, 305-
311. 
 
Ciancaglini, P., Yadav, M. C., Sper Simao, A. M., Narisawa, S., Pizauro, J. M., Farquharson, C., 
Hoylaerts, M. F. & Millan, J. L. 2010. Kinetic Analysis of Substrate Utilization by Native and 
TNAP-, NPP1-, or PHOSPHO1-Deficient Matrix Vesicles. Journal of Bone and Mineral 
Research, 25, 716-723. 
 
Clarke, B. 2008. Normal Bone Anatomy and Physiology. Clinical Journal of the American 
Society of Nephrology, 3, S131-S139. 
 
Clarke, C. J., Cloessner, E. A., Roddy, P. l. & Hannun, Y. A. 2011. Neutral sphingomyelinase 2 
(nSMase2) is the primary neutral sphingomyelinase isoform activated by tumour necrosis 
factor-α in MCF-7 cells. Biochemical Journal, 435, 381-390. 
 
Cole, L. K., Vance, J. E. & Vance, D. E. 2012. Phosphatidylcholine biosynthesis and lipoprotein 
metabolism. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1821, 
754-761. 
 
Cotmore, J. M., Nichols, G. & Wuthier, R. E. 1971. Phospholipid—Calcium Phosphate 
Complex: Enhanced Calcium Migration in the Presence of Phosphate. Science, 172, 1339-
1341. 
 
Coxam, V., Miller, M. A., Bowman, M. B. & Miller, S. C. 1996. Ontogenesis of IGF regulation 
of longitudinal bone growth in rat metatarsal rudiments cultured in serum-free medium. 
Archives of Physiology and Biochemistry, 104, 173-9. 
 
Cui, L., Houston, D. A., Farquharson, C. & Macrae, V. E. 2016. Characterisation of matrix 
vesicles in skeletal and soft tissue mineralisation. Bone, 87, 147-158. 
                                                                                                                                                               References 
 
~ 193 ~ 
 
Dallas, S. L., Prideaux, M. & Bonewald, L. F. 2013. The Osteocyte: An Endocrine Cell … and 
More. Endocrine Reviews, 34, 658-690. 
 
Dambach, S., Fartmann, M., Kriegeskotte, C., Bruning, C., Hellweg, S., Wiesmann, H. P., 
Lipinsky, D. & Arlinghaus, H. F. 2004. ToF-SIMS and laser-SNMS analysis of apatite formation 
in extracellular protein matrix of osteoblasts in vitro. Surface and Interface Analysis, 36, 711-
715. 
 
Dayeh, T., Tuomi, T., Almgren, P., Perfilyev, A., Jansson, P. A., De Mello, V. D., Pihlajamaki, J., 
Vaag, A., Groop, L., Nilsson, E. & Ling, C. 2016. DNA methylation of loci within ABCG1 and 
PHOSPHO1 in blood DNA is associated with future type 2 diabetes risk. Epigenetics, 11, 482-
8. 
 
Dempster, D. W., Parisien, M., Silverberg, S. J., Liang, X. G., Schnitzer, M., Shen, V., Shane, E., 
Kimmel, D. B., Recker, R., Lindsay, R. & Bilezikian, J. P. 1999. On the mechanism of cancellous 
bone preservation in postmenopausal women with mild primary hyperparathyroidism. 
Journal of Clinical Endocrinology & Metabolism, 84, 1562-1566. 
 
Dempster, D. W., Hughes-Begos, C. E., Plavetic-Chee, K., Brandao-Burch, A., Cosman, F., 
Nieves, J., Neubort, S., Lu, S. S., Iida-Klein, A., Arnett, T. & Lindsay, R. 2005. Normal human 
osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are 
stimulated by PTH in the absence of osteoblasts. Journal of Cellular Biochemistry, 95, 139-48. 
 
Dempster, D. W., Müller, R., Zhou, H., Kohler, T., Shane, E., Parisien, M., Silverberg, S. J. & 
Bilezikian, J. P. 2007. Preserved three-dimensional cancellous bone structure in mild primary 
hyperparathyroidism. Bone, 41, 19-24. 
 
Dobnig, H. & Turner, R. T. 1995. Evidence that Intermittent Treatment with Parathyroid-
Hormone Increases Bone-Formation in Adult-Rats by Activation of Bone Lining Cells. 
Endocrinology, 136, 3632-3638. 
 
Ducy, P., Schinke, T. & Karsenty, G. 2000. The Osteoblast: A Sophisticated Fibroblast under 
Central Surveillance. Science, 289, 1501-1504. 
 
Eaton, S. L., Roche, S. L., Hurtado, M. L., Oldknow, K. J., Farquharson, C., Gillingwater, T. H. & 
Wishart, T. M. 2013. Total Protein Analysis as a Reliable Loading Control for Quantitative 
Fluorescent Western Blotting. Plos One, 8. 
 
Epker, B. N. & Frost, H. M. 1966. Periosteal appositional bone growth from age two to age 
seventy in man. A tetracycline evaluation. The Anatomical Record, 154, 573-577. 
 
Eriksen, E. F. 2002. Primary hyperparathyroidism: Lessons from bone histomorphometry. 
Journal of Bone and Mineral Research, 17, N95-N97. 
 
Farquharson, C. & Jefferies, D. 2000. Chondrocytes and longitudinal bone growth: The 
development of tibial dyschondroplasia. Poultry Science, 79, 994-1004. 
 
Farquharson, C. & Staines, K. 2011. The skeleton: no bones about it. Journal of Endocrinology, 
211, 107-108. 
                                                                                                                                                               References 
 
~ 194 ~ 
 
Fisher, L. W. & Fedarko, N. S. 2003. Six genes expressed in bones and teeth encode the 
current members of the SIBLING family of proteins. Connective Tissue Research, 44, 33-40. 
Folch, J., Lees, M. & Sloane Stanley, G. H. 1957. A simple method for the isolation and 
purification of total lipides from animal tissues. Journal of Biological Chemistry, 226, 497-509. 
 
Franceschi, R. T. & Xiao, G. Z. 2003. Regulation of the osteoblast-specific transcription factor, 
runx2: Responsiveness to multiple signal transduction pathways. Journal of Cellular 
Biochemistry, 88, 446-454. 
 
Franz-Odendaal, T. A. 2011. Induction and patterning of intramembranous bone. Frontiers in 
Bioscience (Landmark Ed), 16, 2734-46. 
 
Gallego-Ortega, D., De Molina, A. R., Ramos, M. A., Valdes-Mora, F., Barderas, M. G., 
Sarmentero-Estrada, J. & Lacal, J. C. 2009. Differential Role of Human Choline Kinase alpha 
and beta Enzymes in Lipid Metabolism: Implications in Cancer Onset and Treatment. Plos 
One, 4. 
 
Gardella, T. J. 2015. Chapter 4 - Interactions of PTH with Receptors and Signaling A2 - 
Bilezikian, John P. The Parathyroids (Third Edition). San Diego: Academic Press. 
 
Genge, B. R., Wu, L. N. Y. & Wuthier, R. E. 2003. Separation and quantification of chicken and 
bovine growth plate cartilage matrix vesicle lipids by high-performance liquid 
chromatography using evaporative light scattering detection. Analytical Biochemistry, 322, 
104-115. 
 
Giachelli, C. M. 2005. Inducers and inhibitors of biomineralization: lessons from pathological 
calcification. Orthodontics & Craniofacial Research, 8, 229-231. 
 
Gibellini, F. & Smith, T. K. 2010. The Kennedy pathway—De novo synthesis of 
phosphatidylethanolamine and phosphatidylcholine. IUBMB Life, 62, 414-428. 
 
Glanemann, C., Loos, A., Gorret, N., Willis, L. B., O'brien, X. M., Lessard, P. A. & Sinskey, A. J. 
2003. Disparity between changes in mRNA abundance and enzyme activity in 
Corynebacterium glutamicum: implications for DNA microarray analysis. Applied 
Microbiology and Biotechnology, 61, 61-68. 
 
Glimcher, M. J. 1987. The nature of the mineral component of bone and the mechanism of 
calcification. Instructional course lectures, 36, 49-69. 
 
Golub, E. E. 2011. Biomineralization and matrix vesicles in biology and pathology. Seminars 
in Immunopathology, 33, 409-417. 
 
Gotliv, B. A., Robach, J. S. & Veis, A. 2006. The composition and structure of bovine 
peritubular dentin: Mapping by time of flight secondary ion mass spectroscopy. Journal of 
Structural Biology, 156, 320-333. 
 
Groenen, M. a. M., Archibald, A. L., Uenishi, H., Tuggle, C. K., Takeuchi, Y., Rothschild, M. F., 
Rogel-Gaillard, C., Park, C., Milan, D., Megens, H.-J., Li, S., Larkin, D. M., Kim, H., Frantz, L. a. 
F., Caccamo, M., Ahn, H., Aken, B. L., Anselmo, A., Anthon, C., Auvil, L., Badaoui, B., Beattie, 
                                                                                                                                                               References 
 
~ 195 ~ 
 
C. W., Bendixen, C., Berman, D., Blecha, F., Blomberg, J., Bolund, L., Bosse, M., Botti, S., Bujie, 
Z., Bystrom, M., Capitanu, B., Carvalho-Silva, D., Chardon, P., Chen, C., Cheng, R., Choi, S.-H., 
Chow, W., Clark, R. C., Clee, C., Crooijmans, R. P. M. A., Dawson, H. D., Dehais, P., De Sapio, 
F., Dibbits, B., Drou, N., Du, Z.-Q., Eversole, K., Fadista, J., Fairley, S., Faraut, T., Faulkner, G. 
J., Fowler, K. E., Fredholm, M., Fritz, E., Gilbert, J. G. R., Giuffra, E., Gorodkin, J., Griffin, D. K., 
Harrow, J. L., Hayward, A., Howe, K., Hu, Z.-L., Humphray, S. J., Hunt, T., Hornshoj, H., Jeon, 
J.-T., Jern, P., Jones, M., Jurka, J., Kanamori, H., Kapetanovic, R., Kim, J., Kim, J.-H., Kim, K.-W., 
Kim, T.-H., Larson, G., Lee, K., Lee, K.-T., Leggett, R., Lewin, H. A., Li, Y., Liu, W., Loveland, J. 
E., Lu, Y., Lunney, J. K., Ma, J., Madsen, O., Mann, K., Matthews, L., Mclaren, S., Morozumi, 
T., Murtaugh, M. P., Narayan, J., Truong Nguyen, D., Ni, P., Oh, S.-J., Onteru, S., Panitz, F., 
Park, E.-W., et al. 2012. Analyses of pig genomes provide insight into porcine demography 
and evolution. Nature, 491, 393-398. 
 
Gronowicz, G., Woodiel, F. N., Mccarthy, M.-B. & Raisz, L. G. 1989. In vitro mineralization of 
fetal rat parietal bones in defined serum-free medium: Effect of β-glycerol phosphate. 
Journal of Bone and Mineral Research, 4, 313-324. 
 
Haaijman, A., Dsouza, R. N., Bronckers, A., Goei, S. W. & Burger, E. H. 1997. OP-1 (BMP-7) 
affects mRNA expression of type 1, II, X collagen, and matrix Gla protein in ossifying long 
bones in vitro. Journal of Bone and Mineral Research, 12, 1815-1823. 
 
Haaijman, A., Karperien, M., Lanske, B., Hendriks, J., Löwik, C. W. G. M., Bronckers, A. L. J. J. 
& Burger, E. H. 1999. Inhibition of terminal chondrocyte differentiation by bone 
morphogenetic protein 7 (OP-1) in vitro depends on the periarticular region but is 
independent of parathyroid hormone-related peptide. Bone, 25, 397-404. 
 
Hadjidakis, D. J. & Androulakis, I. I. 2006. Bone Remodeling. Annals of the New York Academy 
of Sciences, 1092, 385-396. 
 
Hahn, M., Vogel, M., Pompesius-Kempa, M. & Delling, G. 1992. Trabecular bone pattern 
factor—a new parameter for simple quantification of bone microarchitecture. Bone, 13, 327-
330. 
 
Hajjawi, M. O. R., Macrae, V. E., Huesa, C., Boyde, A., Millan, J. L., Arnett, T. R. & Orriss, I. R. 
2014. Mineralisation of collagen rich soft tissues and osteocyte lacunae in Enpp1(-/-) mice. 
Bone, 69, 139-147. 
 
Hakim, F. T., Cranley, R., Brown, K. S., Eanes, E. D., Harne, L. & Oppenheim, J. J. 1984. 
Hereditary joint disorder in progressive ankylosis (ank/ank) mice I. association of calcium 
hydroxyapatite deposition with inflammatory arthropathy. Arthritis & Rheumatism, 27, 
1411-1420. 
 
Harmey, D., Hessle, L., Narisawa, S., Johnson, K. A., Terkeltaub, R. & Millan, J. L. 2004. 
Concerted regulation of inorganic pyrophosphate and osteopontin by Akp2, Enpp1, and Ank 
- An integrated model of the pathogenesis of mineralization disorders. American Journal of 
Pathology, 164, 1199-1209. 
 
                                                                                                                                                               References 
 
~ 196 ~ 
 
Heilig, J., Paulsson, M. & Zaucke, F. 2016. Insulin-like growth factor 1 receptor (IGF1R) 
signaling regulates osterix expression and cartilage matrix mineralization during 
endochondral ossification. Bone, 83, 48-57. 
 
Henthorn, P. S. & Whyte, M. P. 1992. Missense mutations of the tissue-nonspecific alkaline 
phosphatase gene in hypophosphatasia. Clinical Chemistry, 38, 2501-2505. 
 
Hewison, M., Zehnder, D., Bland, R. & Stewart, P. 2000. 1alpha-Hydroxylase and the action 
of vitamin D. Journal of Molecular Endocrinology, 25, 141-148. 
 
Hisa, I., Inoue, Y., Hendy, G. N., Canaff, L., Kitazawa, R., Kitazawa, S., Komori, T., Sugimoto, T., 
Seino, S. & Kaji, H. 2011. Parathyroid Hormone-responsive Smad3-related Factor, Tmem119, 
Promotes Osteoblast Differentiation and Interacts with the Bone Morphogenetic Protein-
Runx2 Pathway. Journal of Biological Chemistry, 286, 9787-9796. 
 
Ho, A. M., Johnson, M. D. & Kingsley, D. M. 2000. Role of the Mouse ank Gene in Control of 
Tissue Calcification and Arthritis. Science, 289, 265-270. 
 
Hock, J. M. & Gera, I. 1992. Effects of continuous and intermittent administration and 
inhibition of resorption on the anabolic response of bone to parathyroid hormone. Journal 
of Bone and Mineral Research, 7, 65-72. 
 
Hogan, B. L. 1996. Bone morphogenetic proteins: multifunctional regulators of vertebrate 
development. Genes and Development, 10, 1580-94. 
 
Hoshi, K. & Ozawa, H. 2000. Matrix vesicle calcification in bones of adult rats. Calcified Tissue 
International, 66, 430-434. 
 
Houston, B., Seawright, E., Jefferies, D., Hoogland, E., Lester, D., Whitehead, C. & 
Farquharson, C. 1999. Identification and cloning of a novel phosphatase expressed at high 
levels in differentiating growth plate chondrocytes. Biochimica Et Biophysica Acta-Molecular 
Cell Research, 1448, 500-506. 
 
Houston, B., Stewart, A. J. & Farquharson, C. 2004. PHOSPHO1 - A novel phosphatase 
specifically expressed at sites of mineralisation in bone and cartilage. Bone, 34, 629-637. 
 
Houston, D. A., Myers, K., Macrae, V. E., Staines, K. A. & Farquharson, C. 2016. The Expression 
of PHOSPHO1, nSMase2 and TNAP is Coordinately Regulated by Continuous PTH Exposure in 
Mineralising Osteoblast Cultures. Calcified Tissue International, In press. 
 
Huesa, C., Yadav, M. C., Finnila, M. a. J., Goodyear, S. R., Robins, S. P., Tanner, K. E., Aspden, 
R. M., Milian, J. L. & Farquharson, C. 2011. PHOSPHO1 is essential for mechanically 
competent mineralization and the avoidance of spontaneous fractures. Bone, 48, 1066-1074. 
 
Huesa, C., Houston, D., Kiffer-Moreira, T., Yadav, M. C., Luis Millan, J. & Farquharson, C. 2015. 
The functional co-operativity of tissue-nonspecific alkaline phosphatase (TNAP) and 
PHOSPHO1 during initiation of skeletal mineralization. Biochemistry and Biophysics Reports, 
4, 196-201. 
                                                                                                                                                               References 
 
~ 197 ~ 
 
Iida-Klein, A., Lu, S. S., Kapadia, R., Burkhart, M., Moreno, A., Dempster, D. W. & Lindsay, R. 
2005. Short-term continuous infusion of human parathyroid hormone 1-34 fragment is 
catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in 
C57BL/J6 mice. Journal of Endocrinology, 186, 549-557. 
 
Irving, J. T. 1959. A histological staining method for sites of calcification in teeth and bone. 
Archives of Oral Biology, 1, 89-IN2. 
 
Ishizuya, T., Yokose, S., Hori, M., Noda, T., Suda, T., Yoshiki, S. & Yamaguchi, A. 1997. 
Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on 
exposure time in rat osteoblastic cells. Journal of Clinical Investigation, 99, 2961-2970. 
 
Isogai, Y., Akatsu, T., Ishizuya, T., Yamaguchi, A., Hori, M., Takahashi, N. & Suda, T. 1996. 
Parathyroid hormone regulates osteoblast differentiation positively or negatively depending 
on the differentiation stages. Journal of Bone and Mineral Research, 11, 1384-1393. 
 
Jacobson, B. C., Ferris, T. G., Shea, T. L., Mahlis, E. M., Lee, T. H. & Wang, T. C. 2003. Who is 
using chronic acid suppression therapy and why? American Journal of Gastroenterology, 98, 
51-8. 
 
James, A. W. 2013. Review of Signaling Pathways Governing MSC Osteogenic and Adipogenic 
Differentiation. Scientifica, 2013, 17. 
 
Jang, M.-G., Lee, J. Y., Yang, J.-Y., Park, H., Kim, J. H., Kim, J.-E., Shin, C. S., Kim, S. Y. & Kim, S. 
W. 2015. Intermittent PTH treatment can delay the transformation of mature osteoblasts 
into lining cells on the periosteal surfaces. Journal of Bone and Mineral Metabolism, 1-8. 
 
Jansen, R. S., Küçükosmanoğlu, A., De Haas, M., Sapthu, S., Otero, J. A., Hegman, I. E. M., 
Bergen, A. a. B., Gorgels, T. G. M. F., Borst, P. & Van De Wetering, K. 2013. ABCC6 prevents 
ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide 
release. Proceedings of the National Academy of Sciences, 110, 20206-20211. 
 
Javaheri, B., Carriero, A., Staines, K. A., Chang, Y. M., Houston, D. A., Oldknow, K. J., Millan, J. 
L., Kazeruni, B. N., Salmon, P., Shefelbine, S., Farquharson, C. & Pitsillides, A. A. 2015. 
Phospho1 deficiency transiently modifies bone architecture yet produces consistent 
modification in osteocyte differentiation and vascular porosity with ageing. Bone, 81, 277-
291. 
 
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M. & Manolagas, S. C. 1999. 
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. 
Journal of Clinical Investigation, 104, 439-446. 
 
Jilka, R. L., O'brien, C. A., Bartell, S. M., Weinstein, R. S. & Manolagas, S. C. 2010. Continuous 
Elevation of PTH Increases the Number of Osteoblasts via Both Osteoclast-Dependent and -
Independent Mechanisms. Journal of Bone and Mineral Research, 25, 2427-2437. 
 
 
                                                                                                                                                               References 
 
~ 198 ~ 
 
Jonason, J. H. & O’keefe, R. J. 2014. Isolation and Culture of Neonatal Mouse Calvarial 
Osteoblasts. In: HILTON, J. M. (ed.) Skeletal Development and Repair: Methods and Protocols. 
Totowa, NJ: Humana Press. 
 
Kakoi, H., Maeda, S., Shinohara, N., Matsuyama, K., Imamura, K., Kawamura, I., Nagano, S., 
Setoguchi, T., Yokouchi, M., Ishidou, Y. & Komiya, S. 2014. Bone Morphogenic Protein (BMP) 
Signaling Up-regulates Neutral Sphingomyelinase 2 to Suppress Chondrocyte Maturation via 
the Akt Protein Signaling Pathway as a Negative Feedback Mechanism. Journal of Biological 
Chemistry, 289, 8135-8150. 
 
Kaneki, H., Takasugi, I., Fujieda, M., Kiriu, M., Mizuochi, S. & Ide, H. 1999. Prostaglandin E-2 
stimulates the formation of mineralized bone nodules by a cAMP-independent mechanism 
in the culture of adult rat calvarial osteoblasts. Journal of Cellular Biochemistry, 73, 36-48. 
 
Kano, J., Sugimoto, T., Fukase, M. & Chihara, K. 1994. Direct Involvement of cAMP-Dependent 
Protein Kinase in the Regulation of Alkaline Phosphatase Activity by Parathyroid Hormone 
(PTH) and PTH-Related Peptide in Osteoblastic UMR-106 Cells. Biochemical and Biophysical 
Research Communiations, 199, 271-276. 
 
Kapustin, A. N., Davies, J. D., Reynolds, J. L., Mcnair, R., Jones, G. T., Sidibe, A., Schurgers, L. 
J., Skepper, J. N., Proudfoot, D., Mayr, M. & Shanahan, C. M. 2011. Calcium Regulates Key 
Components of Vascular Smooth Muscle Cell-Derived Matrix Vesicles to Enhance 
Mineralization. Circulation Research, 109, E1-U41. 
 
Kapustin, A. N., Chatrou, M. L. L., Drozdov, I., Zheng, Y., Davidson, S. M., Soong, D., Furmanik, 
M., Sanchis, P., De Rosales, R. T. M., Alvarez-Hernandez, D., Shroff, R., Yin, X., Muller, K., 
Skepper, J. N., Mayr, M., Reutelingsperger, C. P., Chester, A., Bertazzo, S., Schurgers, L. J. & 
Shanahan, C. M. 2015. Vascular Smooth Muscle Cell Calcification Is Mediated by Regulated 
Exosome Secretion. Circulation Research, 116, 1312-1323. 
 
Karsenty, G. 2006. Convergence between bone and energy homeostases: Leptin regulation 
of bone mass. Cell Metabolism, 4, 341-348. 
 
Kato, K., Nishimasu, H., Okudaira, S., Mihara, E., Ishitani, R., Takagi, J., Aoki, J. & Nureki, O. 
2012. Crystal structure of Enpp1, an extracellular glycoprotein involved in bone 
mineralization and insulin signaling. Proceedings of the National Academy of Sciences, 109, 
16876-81. 
 
Kato, Y., Shimazu, A., Nakashima, K., Suzuki, F., Jikko, A. & Iwamoto, M. 1990. Effects of 
Parathyroid Hormone and Calcitonin on Alkaline Phosphatase Activity and Matrix 
Calcification in Rabbit Growth-Plate Chondrocyte Cultures. Endocrinology, 127, 114-118. 
 
Keller, H. & Kneissel, M. 2005. SOST is a target gene for PTH in bone. Bone, 37, 148-158. 
 
Khavandgar, Z., Poirier, C., Clarke, C. J., Li, J. J., Wang, N., Mckee, M. D., Hannun, Y. A. & 
Murshed, M. 2011. A cell-autonomous requirement for neutral sphingomyelinase 2 in bone 
mineralization. Journal of Cell Biology, 194, 277-289. 
                                                                                                                                                               References 
 
~ 199 ~ 
 
Khavandgar, Z., Alebrahim, S., Eimar, H., Tamimi, F., Mckee, M. D. & Murshed, M. 2013. Local 
Regulation of Tooth Mineralization by Sphingomyelin Phosphodiesterase 3. Journal of Dental 
Research, 92, 358-364. 
 
Khavandgar, Z. & Murshed, M. 2015. Sphingolipid metabolism and its role in the skeletal 
tissues. Cellular and Molecular Life Sciences, 72, 959-969. 
 
Khouja, H. I., Bevington, A., Kemp, G. J. & Russell, R. G. G. 1990. Calcium and orthophosphate 
deposits in vitro do not imply osteoblast-mediated mineralization: Mineralization by 
betaglycerophosphate in the absence of osteoblasts. Bone, 11, 385-391. 
 
Kiffer-Moreira, T., Yadav, M. C., Zhu, D., Narisawa, S., Sheen, C., Stec, B., Cosford, N. D., Dahl, 
R., Farquharson, C., Hoylaerts, M. F., Macrae, V. E. & Millan, J. L. 2013. Pharmacological 
Inhibition of PHOSPHO1 Suppresses Vascular Smooth Muscle Cell Calcification. Journal of 
Bone and Mineral Research, 28, 81-91. 
 
Kim, K. M. 1976. Calcification of matrix vesicles in human aortic valve and aortic media. 
Federation Proceedings, 35, 156-62. 
 
Kim, S. W., Pajevic, P. D., Selig, M., Barry, K. J., Yang, J. Y., Shin, C. S., Baek, W. Y., Kim, J. E. & 
Kronenberg, H. M. 2012. Intermittent parathyroid hormone administration converts 
quiescent lining cells to active osteoblasts. Journal of Bone and Mineral Research, 27, 2075-
2084. 
 
Kirsch, T., Wang, W. & Pfander, D. 2003. Functional differences between growth plate 
apoptotic bodies and matrix vesicles. Journal of Bone and Mineral Research, 18, 1872-1881. 
 
Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, 
R. T., Gao, Y. H., Inada, M., Sato, M., Okamoto, R., Kitamura, Y., Yoshiki, S. & Kishimoto, T. 
1997. Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation owing to 
Maturational Arrest of Osteoblasts. Cell, 89, 755-764. 
 
Komori, T. 2010. Regulation of bone development and extracellular matrix protein genes by 
RUNX2. Cell and Tissue Research, 339, 189-195. 
 
Kousteni, S. & Bilezikian, J. P. 2008. The cell biology of parathyroid hormone in osteoblasts. 
Current Osteoporosis Reports, 6, 72-6. 
 
Kozhemyakina, E., Lassar, A. B. & Zelzer, E. 2015. A pathway to bone: signaling molecules and 
transcription factors involved in chondrocyte development and maturation. Development, 
142, 817-831. 
 
Kramer, I., Keller, H., Leupin, O. & Kneissel, M. 2010. Does osteocytic SOST suppression 
mediate PTH bone anabolism? Trends in Endocrinology and Metabolism, 21, 237-244. 
 
Krishnan, V., Moore, T. L., Ma, Y. F. L., Helvering, L. M., Frolik, C. A., Valasek, K. M., Ducy, P. 
& Geiser, A. G. 2003. Parathyroid hormone bone anabolic action requires Bbfa1/Runx2-
dependent signaling. Molecular Endocrinology, 17, 423-435. 
 
                                                                                                                                                               References 
 
~ 200 ~ 
 
Kronenberg, H. M. 2003. Developmental regulation of the growth plate. Nature, 423, 332-
336. 
 
Kronenberg, H.M. 2005. How PTHrP controls growth plate chondrocytes. BoneKEy-
Osteovision, 2, 7-15. 
 
Kronenberg, H.M. 2006. PTHrP and Skeletal Development. Annals of the New York Academy 
of Sciences, 1068, 1-13. 
 
Krug, H.E., Mahowald M.L. & Clark C. 1989. Progressive ankylosis (ank/ank) in mice: an animal 
model of spondyloarthropathy. III. Proliferative spleen cell response to T cell mitogens. 
Clinical and Experimental Immunology, 78, 97-101. 
 
Kular, J., Tickner, J. C., Pavlos, N. J., Viola, H. M., Abel, T., Lim, B. S., Yang, X., Chen, H., Cook, 
R., Hool, L. C., Zheng, M. H. & Xu, J. 2015. Choline Kinase beta Mutant Mice Exhibit Reduced 
Phosphocholine, Elevated Osteoclast Activity, and Low Bone Mass. Journal of Biological 
Chemistry, 290, 1729-1742. 
 
Kuzynski, M., Goss, M., Bottini, M., Yadav, M. C., Mobley, C., Winters, T., Poliard, A., 
Kellermann, O., Lee, B., Millan, J. L. & Napierala, D. 2014. Dual Role of the Trps1 Transcription 
Factor in Dentin Mineralization. Journal of Biological Chemistry, 289, 27481-27493. 
 
Landis, W. J., Song, M. J., Leith, A., Mcewen, L. & Mcewen, B. F. 1993. Mineral and organic 
matrix interaction in normally calcifying tendon visualized in three dimensions by high-
voltage electron microscopic tomography and graphic image reconstruction. Journal of 
Structural Biology, 110, 39-54. 
 
Landis, W. J. 1999. An overview of vertebrate mineralization with emphasis on collagen-
mineral interaction. Gravitational and Space Biology Bulletin, 12, 15-26. 
 
Landis, W. J. & Silver, F. H. 2008. Mineral Deposition in the Extracellular Matrices of 
Vertebrate Tissues: Identification of Possible Apatite Nucleation Sites on Type I Collagen. 
Cells, Tissues, Organs, 189, 20-24. 
 
Landis, W. J. & Jacquet, R. 2013. Association of Calcium and Phosphate Ions with Collagen in 
the Mineralization of Vertebrate Tissues. Calcified Tissue International, 93, 329-337. 
 
Lang, T., Leblanc, A., Evans, H., Lu, Y., Genant, H. & Yu, A. 2004. Cortical and trabecular bone 
mineral loss from the spine and hip in long-duration spaceflight. Journal of Bone and Mineral 
Research, 19, 1006-1012. 
 
Langdahl, B. L. & Harsløf, T. 2011. Medical treatment of osteoporotic vertebral fractures. 
Therapeutic Advances in Musculoskeletal Disease. 
 
Lee, M.-H., Kim, Y.-J., Kim, H.-J., Park, H.-D., Kang, A.-R., Kyung, H.-M., Sung, J.-H., Wozney, J. 
M., Kim, H.-J. & Ryoo, H.-M. 2003. BMP-2-induced Runx2 Expression Is Mediated by Dlx5, and 
TGF-β1 Opposes the BMP-2-induced Osteoblast Differentiation by Suppression of Dlx5 
Expression. Journal of Biological Chemistry, 278, 34387-34394. 
 
                                                                                                                                                               References 
 
~ 201 ~ 
 
Li, J. J., Manickam, G., Ray, S., Oh, C. D., Yasuda, H., Moffatt, P. & Murshed, M. 2016. Smpd3 
expression in both chondrocytes and osteoblasts is required for normal endochondral bone 
development Molecular and Cellular Biology, In press. 
 
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E. & Wu, D. 2005. Sclerostin Binds 
to LRP5/6 and Antagonizes Canonical Wnt Signaling. Journal of Biological Chemistry, 280, 
19883-19887. 
 
Li, Y., Chen, S.-K., Li, L., Qin, L., Wang, X.-L. & Lai, Y.-X. 2015. Bone defect animal models for 
testing efficacy of bone substitute biomaterials. Journal of Orthopaedic Translation, 3, 95-
104. 
 
Li, Z., Wu, G., Sher, R. B., Khavandgar, Z., Hermansson, M., Cox, G. A., Doschak, M. R., 
Murshed, M., Beier, F. & Vance, D. E. 2014a. Choline kinase beta is required for normal 
endochondral bone formation. Biochimica Et Biophysica Acta-General Subjects, 1840, 2112-
2122. 
 
Li, Z., Wu, G., Van Der Veen, J. N., Hermansson, M. & Vance, D. E. 2014b. Phosphatidylcholine 
metabolism and choline kinase in human osteoblasts. Biochimica Et Biophysica Acta-
Molecular and Cell Biology of Lipids, 1841, 859-867. 
 
Lillico, S. G., Proudfoot, C., Carlson, D. F., Stverakova, D., Neil, C., Blain, C., King, T. J., Ritchie, 
W. A., Tan, W., Mileham, A. J., Mclaren, D. G., Fahrenkrug, S. C. & Whitelaw, C. B. 2013. Live 
pigs produced from genome edited zygotes. Scientific Reports, 3, 2847. 
 
Lindsay, R., Krege, J. H., Marin, F., Jin, L. & Stepan, J. J. 2016. Teriparatide for osteoporosis: 
importance of the full course. Osteoporosis International, 27, 2395-2410. 
 
Liu, Q., Wan, Q., Yang, R., Zhou, H. & Li, Z. 2012. Effects of intermittent versus continuous 
parathyroid hormone administration on condylar chondrocyte proliferation and 
differentiation. Biochemical Biophysical Research Communications, 424, 182-188. 
 
Livak, K. J. & Schmittgen, T. D. 2001. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(T)(-Delta Delta C) method. Methods, 25, 402-408. 
 
Locklin, R. M., Khosla, S., Turner, R. T. & Riggs, B. L. 2003. Mediators of the biphasic responses 
of bone to intermittent and continuously administered parathyroid hormone. Journal of 
Cellular Biochemistry, 89, 180-190. 
 
Lorenz-Depiereux, B., Schnabel, D., Tiosano, D., Häusler, G. & Strom, T. M. 2010. Loss-of-
Function ENPP1 Mutations Cause Both Generalized Arterial Calcification of Infancy and 
Autosomal-Recessive Hypophosphatemic Rickets. American Journal of Human Genetics, 86, 
267-272. 
 
Lotinun, S., Sibonga, J. D. & Turner, R. T. 2002. Differential effects of intermittent and 
continuous administration of parathyroid hormone on bone histomorphometry and gene 
expression. Endocrine, 17, 29-36. 
 
                                                                                                                                                               References 
 
~ 202 ~ 
 
Ma, B., Leijten, J. C. H., Wu, L., Kip, M., Van Blitterswijk, C. A., Post, J. N. & Karperien, M. 2013. 
Gene expression profiling of dedifferentiated human articular chondrocytes in monolayer 
culture. Osteoarthritis and Cartilage, 21, 599-603. 
 
Ma, Y. F. L., Cain, R. L., Halladay, D. L., Yang, X. H., Zeng, Q. Q., Miles, R. R., Chandrasekhar, 
S., Martin, T. J. & Onyia, J. E. 2001. Catabolic effects of continuous human PTH (1-38) in vivo 
is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and 
gene-associated bone formation. Endocrinology, 142, 4047-4054. 
 
Mackenzie, N. C. W., Huesa, C., Rutsch, F. & Macrae, V. E. 2012a. New insights into NPP1 
function: Lessons from clinical and animal studies. Bone, 51, 961-968. 
 
Mackenzie, N. C. W., Zhu, D., Milne, E. M., Van 'T Hof, R., Martin, A., Quarles, D. L., Millan, J. 
L., Farquharson, C. & Macrae, V. E. 2012b. Altered Bone Development and an Increase in FGF-
23 Expression in Enpp1(-/-) Mice. Plos One, 7. 
 
Mackie, E. J., Ahmed, Y. A., Tatarczuch, L., Chen, K. S. & Mirams, M. 2008. Endochondral 
ossification: How cartilage is converted into bone in the developing skeleton. International 
Journal of Biochemistry & Cell Biology, 40, 46-62. 
 
Mackie, E. J., Tatarczuch, L. & Mirams, M. 2011. The skeleton: a multi-functional complex 
organ. The growth plate chondrocyte and endochondral ossification. Journal of 
Endocrinology, 211, 109-121. 
 
Macnabb, C., Patton, D. & Hayes, J. S. 2016. Sclerostin Antibody Therapy for the Treatment 
of Osteoporosis: Clinical Prospects and Challenges. Journal of Osteoporosis. 
 
Macrae, V. E., Farquharson, C. & Ahmed, S. F. 2006. The restricted potential for recovery of 
growth plate chondrogenesis and longitudinal bone growth following exposure to pro-
inflammatory cytokines. Journal of Endocrinology, 189, 319-328. 
 
Macrae, V. E., Davey, M. G., Mcteir, L., Narisawa, S., Yadav, M. C., Millan, J. L. & Farquharson, 
C. 2010. Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during 
limb development of the chick. Bone, 46, 1146-1155. 
 
Maes, C., Kobayashi, T. & Kronenberg, H. M. 2007. A Novel Transgenic Mouse Model to Study 
the Osteoblast Lineage in Vivo. Annals of the New York Academy of Sciences, 1116, 149-164. 
 
Mannstadt, M., Juppner, H. & Gardella, T. J. 1999. Receptors for PTH and PTHrP: their 
biological importance and functional properties. American Journal of Physiology-Renal 
Physiology, 277, F665-F675. 
 
Marcinowska-Suchowierska, E. B., Talalaj, M. J., Wlodarcyzk, A. W., Bielecki, K., Zawadzki, J. 
J. & Brzozowski, R. 1995. Calcium/phosphate/vitamin D homeostasis and bone mass in 
patients after gastrectomy, vagotomy, and cholecystectomy. World Journal of Surgery, 19, 
597-601; discussion 601-2. 
 
Marino, S., Staines, K. A., Brown, G., Howard-Jones, R. A. & Adamczyk, M. 2016. Models of ex 
vivo explant cultures: applications in bone research. BoneKEy Reports, 5. 
                                                                                                                                                               References 
 
~ 203 ~ 
 
Martin, A., David, V., Laurence, J. S., Schwarz, P. M., Lafer, E. M., Hedge, A. M. & Rowe, P. S. 
N. 2008. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): 
ASARM-Peptide(s) are directly responsible for defective mineralization in HYP. 
Endocrinology, 149, 1757-1772. 
 
Mckee, M. D., Yadav, M. C., Foster, B. L., Somerman, M. J., Farquharson, C. & Millán, J. L. 
2013. Compounded PHOSPHO1/ALPL Deficiencies Reduce Dentin Mineralization. Journal of 
Dental Research. 
 
Mcmahon, D. 1975. Cycloheximide is not a Specific Inhibitor of Protein-Synthesis In vivo. 
Plant Physiology, 55, 815-821. 
 
Mcnally, E. A., Schwarcz, H. P., Botton, G. A. & Arsenault, A. L. 2012. A model for the 
ultrastructure of bone based on electron microscopy of ion-milled sections. Plos One, 7, 
e29258. 
 
Mebarek, S., Abousalham, A., Magne, D., Le Duy, D., Bandorowicz-Pikula, J., Pikula, S. & 
Buchet, R. 2013. Phospholipases of Mineralization Competent Cells and Matrix Vesicles: 
Roles in Physiological and Pathological Mineralizations. International Journal of Molecular 
Sciences, 14, 5036-5129. 
 
Merrill, A. H., Sullards, M. C., Allegood, J. C., Kelly, S. & Wang, E. 2005. Sphingolipidomics: 
High-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid 
chromatography tandem mass spectrometry. Methods, 36, 207-224. 
 
Merrill, A. H. 2011. Sphingolipid and Glycosphingolipid Metabolic Pathways in the Era of 
Sphingolipidomics. Chemical Reviews, 111, 6387-6422. 
 
Millan, J. L. 2006. Alkaline Phosphatases : Structure, substrate specificity and functional 
relatedness to other members of a large superfamily of enzymes. Purinergic Signalling, 2, 
335-41. 
 
Millán, J. 2012. The Role of Phosphatases in the Initiation of Skeletal Mineralization. Calcified 
Tissue International, 1-8. 
 
Millán, J. L. & Whyte, M. P. 2015. Alkaline Phosphatase and Hypophosphatasia. Calcified 
Tissue International, 1-19. 
 
Momeni, P., Glockner, G., Schmidt, O., Von Holtum, D., Albrecht, B., Gillessen-Kaesbach, G., 
Hennekam, R., Meinecke, P., Zabel, B., Rosenthal, A., Horsthemke, B. & Ludecke, H. J. 2000. 
Mutations in a new gene, encoding a zinc-finger protein, cause tricho-rhino-phalangeal 
syndrome type I. Nature Genetics, 24, 71-4. 
 
Muriel, M. P., Bonaventure, J., Stanescu, R., Maroteaux, P., Guénet, J. L. & Stanescu, V. 1991. 
Morphological and biochemical studies of a mouse mutant (fro/fro) with bone fragility. Bone, 
12, 241-248. 
 
Nakashima, T., Hayashi, M., Fukunaga, T., Kurata, K., Oh-Hora, M., Feng, J. Q., Bonewald, L. 
F., Kodama, T., Wutz, A., Wagner, E. F., Penninger, J. M. & Takayanagi, H. 2011. Evidence for 
                                                                                                                                                               References 
 
~ 204 ~ 
 
osteocyte regulation of bone homeostasis through RANKL expression. Nature Medicine, 17, 
1231-4. 
 
Napierala, D., Sam, K., Morello, R., Zheng, Q., Munivez, E., Shivdasani, R. A. & Lee, B. 2008. 
Uncoupling of chondrocyte differentiation and perichondrial mineralization underlies the 
skeletal dysplasia in tricho-rhino-phalangeal syndrome. Human Molecular Genetics, 17, 
2244-2254. 
 
Narisawa, S., Frohlander, N. & Millan, J. L. 1997. Inactivation of two mouse alkaline 
phosphatase genes and establishment of a model of infantile hypophosphatasia. 
Developmental Dynamics, 208, 432-446. 
 
Narisawa, S., Yadav, M. C. & Millán, J. L. 2013. In Vivo Overexpression of Tissue-Nonspecific 
Alkaline Phosphatase Increases Skeletal Mineralization and Affects the Phosphorylation 
Status of Osteopontin. Journal of Bone and Mineral Research, 28, 1587-1598. 
 
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J. Y., Hodsman, 
A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., Wang, O. H. & Mitlak, B. H. 2001. Effect of 
parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal 
women with osteoporosis. New England Journal of Medicine, 344, 1434-1441. 
 
Nishimura, R., Wakabayashi, M., Hata, K., Matsubara, T., Honma, S., Wakisaka, S., Kiyonari, 
H., Shioi, G., Yamaguchi, A., Tsumaki, N., Akiyama, H. & Yoneda, T. 2012. Osterix Regulates 
Calcification and Degradation of Chondrogenic Matrices through Matrix Metalloproteinase 
13 (MMP13) Expression in Association with Transcription Factor Runx2 during Endochondral 
Ossification. Journal of Biological Chemistry, 287, 33179-33190. 
 
Nitschke, Y., Baujat, G., Botschen, U., Wittkampf, T., Du Moulin, M., Stella, J., Le Merrer, M., 
Guest, G., Lambot, K., Tazarourte-Pinturier, M. F., Chassaing, N., Roche, O., Feenstra, I., 
Loechner, K., Deshpande, C., Garber, S. J., Chikarmane, R., Steinmann, B., Shahinyan, T., 
Martorell, L., Davies, J., Smith, W. E., Kahler, S. G., Mcculloch, M., Wraige, E., Loidi, L., Höhne, 
W., Martin, L., Hadj-Rabia, S., Terkeltaub, R. & Rutsch, F. 2012. Generalized arterial 
calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either 
ENPP1 or ABCC6. American Journal of Human Genetics, 90, 25-39. 
 
Nudelman, F., Pieterse, K., George, A., Bomans, P. H. H., Friedrich, H., Brylka, L. J., Hilbers, P. 
a. J., De With, G. & Sommerdijk, N. a. J. M. 2010. The role of collagen in bone apatite 
formation in the presence of hydroxyapatite nucleation inhibitors. Nature Materials, 9, 1004-
1009. 
 
Okawa, A., Nakamura, I., Goto, S., Moriya, H., Nakamura, Y. & Ikegawa, S. 1998. Mutation in 
Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. 
Nature Genetics, 19, 271-273. 
 
Oldknow, K. J., Macrae, V. E. & Farquharson, C. 2015. Endocrine role of bone: recent and 
emerging perspectives beyond osteocalcin. Journal of Endocrinology, 225, R1-R19. 
 
Onyia, J. E., Helvering, L. M., Gelbert, L., Wei, T., Huang, S. G., Chen, P. N., Dow, E. R., Maran, 
A., Zhang, M. Z., Lotinun, S., Lin, X., Halladay, D. L., Miles, R. R., Kulkarni, N. H., Ambrose, E. 
                                                                                                                                                               References 
 
~ 205 ~ 
 
M., Ma, Y. L., Frolik, C. A., Sato, M., Bryant, H. U. & Turner, R. T. 2005. Molecular profile of 
catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An 
analysis by DNA microarray. Journal of Cellular Biochemistry, 95, 403-418. 
 
Orimo, H. & Shimada, T. 2006. Effects of phosphates on the expression of tissue-nonspecific 
alkaline phosphatase gene and phosphate-regulating genes in short-term cultures of human 
osteosarcoma cell lines. Molecular and Cellular Biochemistry, 282, 101-108. 
 
Pazianas, M. 2015. Anabolic effects of PTH and the ‘anabolic window’. Trends in 
Endocrinology & Metabolism, 26, 111-113. 
 
Pioszak, A. A. & Xu, H. E. 2008. Molecular recognition of parathyroid hormone by its G 
protein-coupled receptor. Proceedings of the National Academy of Sciences, 105, 5034-5039. 
 
Poole, K. E. S. & Reeve, J. 2005. Parathyroid hormone - a bone anabolic and catabolic agent. 
Current Opinion in Pharmacology, 5, 612-617. 
 
Potts Jr, J. T., Kronenberg, H. M. & Rosenblatt, M. 1982. Parathyroid Hormone: Chemistry, 
Biosynthesis, and Mode of Action. In: C.B. ANFINSEN, J. T. E. & FREDERIC, M. R. (eds.) 
Advances in Protein Chemistry. Academic Press. 
 
Potts, J. T. 2005. Parathyroid hormone: past and present. Journal of Endocrinology, 187, 311-
325. 
 
Prideaux, M., Loveridge, N., Pitsillides, A. A. & Farquharson, C. 2012. Extracellular Matrix 
Mineralization Promotes E11/gp38 Glycoprotein Expression and Drives Osteocytic 
Differentiation. Plos One, 7, e36786. 
 
Provot, S. & Schipani, E. 2005. Molecular mechanisms of endochondral bone development. 
Biochemical Biophysical Research Communications, 328, 658-665. 
 
Qin, L., Qiu, P., Wang, L. Q., Li, X., Swarthout, J. T., Soteropoulos, P., Tolias, P. & Partridge, N. 
C. 2003. Gene expression profiles and transcription factors involved in parathyroid hormone 
signaling in osteoblasts revealed by microarray and bioinformatics. Journal of Biological 
Chemistry, 278, 19723-19731. 
 
Qin, L., Raggatt, L. J. & Partridge, N. C. 2004. Parathyroid hormone: a double-edged sword for 
bone metabolism. Trends in Endocrinology and Metabolism, 15, 60-65. 
 
Rashid, F., Shiba, H., Mizuno, N., Mouri, Y., Fujita, T., Shinohara, H., Ogawa, T., Kawaguchi, H. 
& Kurihara, H. 2003. The effect of extracellular calcium ion on gene expression of bone-
related proteins in human pulp cells. Journal of Endodontics, 29, 104-107. 
 
Reeve, J., Hesp, R., Williams, D., Hulme, P., Klenerman, L., Zanelli, J., Darby, A. J., Tregear, G. 
W. & Parsons, J. A. 1976a. Anabolic effect of low doses of a fragment of human parathyroid 
hormone on the skeleton in postmenopausal osteoporosis. The Lancet, 307, 1035-1038. 
 
                                                                                                                                                               References 
 
~ 206 ~ 
 
Reeve, J., Tregear, G. W. & Parsons, J. A. 1976b. Preliminary trial of low-doses of human 
parathyroid-hormone 1-34 peptide in treatment of osteoporosis. Calcified Tissue Research, 
21, 469-477. 
 
Register, T. C., Mclean, F. M., Low, M. G. & Wuthier, R. E. 1986. Roles of Alkaline-Phosphatase 
and Labile Internal Mineral in Matrix Vesicle-Mediated Calcification - Effect of Selective 
Release of Membrane-Bound Alkaline-Phosphatase and Treatment with Isosmotic pH-6 
Buffer. Journal of Biological Chemistry, 261, 9354-9360. 
 
Reinholt, F. P. & Wernerson, A. 1988. Septal distribution and the relationship of matrix vesicle 
size to cartilage mineralization. Bone and Mineral, 4, 63-71. 
 
Revollo, L. & Civitelli, R. 2015. Chapter 7 - Molecular Actions of Parathyroid Hormone A2 - 
Bilezikian, John P. The Parathyroids (Third Edition). San Diego: Academic Press. 
 
Rey, A., Manen, D., Rizzoli, R., Ferrari, S. L. & Caverzasio, J. 2007. Evidences for a role of p38 
MAP kinase in the stimulation of alkaline phosphatase and matrix mineralization induced by 
parathyroid hormone in osteoblastic cells. Bone, 41, 59-67. 
 
Rico, H., Revilla, M., Arribas, I., Villa, L. F. & Debuergo, M. A. 1994. Total and regional bone-
mineral content in primary hyperparathyroidism - sex-differences. Mineral and Electrolyte 
Metabolism, 20, 112-116. 
 
Roach, H. I., Aigner, T. & Kouri, J. B. 2004. Chondroptosis: a variant of apoptotic cell death in 
chondrocytes? Apoptosis, 9, 265-77. 
 
Roberts, S., Narisawa, S., Harmey, D., Millan, J. L. & Farquharson, C. 2007. Functional 
involvement of PHOSPHO1 in matrix vesicle-mediated skeletal mineralization. Journal of 
Bone and Mineral Research, 22, 617-627. 
 
Roberts, S. J., Stewart, A. J., Sadler, P. J. & Farquharson, C. 2004. Human PHOSPH01 exhibits 
high specific phosphoethanolamine and phosphocholine phosphatase activities. Biochemical 
Journal, 382, 59-65. 
 
Robison, R. 1923. The possible significance of hexosephosphoric esters in ossification. 
Biochemical Journal, 17, 286-293. 
 
Robling, A. G., Niziolek, P. J., Baldridge, L. A., Condon, K. W., Allen, M. R., Alam, I., Mantila, S. 
M., Gluhak-Heinrich, J., Bellido, T. M., Harris, S. E. & Turner, C. H. 2008. Mechanical 
stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. Journal of 
Biological Chemistry, 283, 5866-75. 
 
Rodriguez-Florez, N., Garcia-Tunon, E., Mukadam, Q., Saiz, E., Oldknow, K. J., Farquharson, 
C., Millan, J. L., Boyde, A. & Shefelbine, S. J. 2015. An Investigation of the Mineral in Ductile 
and Brittle Cortical Mouse Bone. Journal of Bone and Mineral Research, 30, 786-795. 
 
Rowe, P. S. N. 2012. The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled. Cell 
Biochemistry and Function, 30, 355-375. 
 
                                                                                                                                                               References 
 
~ 207 ~ 
 
Rubin, R. M., Cosman, F., Lindsay, R. & Bilezikian, P. J. 2002. The Anabolic Effects of 
Parathyroid Hormone. Osteoporosis International, 13, 267-277. 
 
Rubin, M. R., Manavalan, J. S., Dempster, D. W., Shah, J., Cremers, S., Kousteni, S., Zhou, H., 
Mcmahon, D. J., Kode, A., Sliney, J., Shane, E., Silverberg, S. J. & Bilezikian, J. P. 2011. 
Parathyroid Hormone Stimulates Circulating Osteogenic Cells in Hypoparathyroidism. The 
Journal of Clinical Endocrinology and Metabolism, 96, 176-186. 
 
Russell, R. G. G. & Fleisch, H. 1975. Pyrophosphate and Diphosphonates in Skeletal 
Metabolism - Physiological, Clinical and Therapeutic Aspects. Clinical Orthopaedic Related 
Research, 241-263. 
 
Rutsch, F., Schauerte, P., Kalhoff, H., Petrarulo, M., August, C. & Diekmann, L. 2000. Low 
levels of urinary inorganic pyrophosphate indicating systemic pyrophosphate deficiency in a 
boy with idiopathic infantile arterial calcification. Acta Paediatrica, International Journal of 
Paediatrics, 89, 1265-1269. 
 
Sakagami, H., Aoki, J., Natori, Y., Nishikawa, K., Kakehi, Y., Natori, Y. & Arai, H. 2005. 
Biochemical and Molecular Characterization of a Novel Choline-specific 
Glycerophosphodiester Phosphodiesterase Belonging to the Nucleotide 
Pyrophosphatase/Phosphodiesterase Family. Journal of Biological Chemistry, 280, 23084-
23093. 
 
Samee, N., Geoffroy, V., Marty, C., Schiltz, C., Vieux-Rochas, M., Levi, G. & De Vernejoul, M.-
C. 2008. Dlx5, a Positive Regulator of Osteoblastogenesis, is Essential for Osteoblast-
Osteoclast Coupling. The American Journal of Pathology, 173, 773-780. 
 
Sander, J. D. & Joung, J. K. 2014. CRISPR-Cas systems for editing, regulating and targeting 
genomes. Nature Biotechnology, 32, 347-355. 
 
Sayegh, F. S., Solomon, G. C. & Davis, R. W. 1974. Ultrastructure of intracellular mineralization 
in the deer's antler. Clinical Orthopaedic Related Research, 267-84. 
 
Scheven, B. A. & Hamilton, N. J. 1991. Longitudinal bone growth in vitro: effects of insulin-
like growth factor I and growth hormone. Acta Endocrinology (Copenh), 124, 602-7. 
 
Schindeler, A., Mcdonald, M. M., Bokko, P. & Little, D. G. 2008. Bone remodeling during 
fracture repair: The cellular picture. Seminars in Cell and Developmental Biology, 19, 459-66. 
 
Schluter, K. D. 1999. PTH and PTHrP: Similar structures but different functions. News in 
Physiological Sciences, 14, 243-249. 
 
Sela, J. & Bab, I. A. 1979. The relationship between extracellular matrix vesicles and 
calcospherities in primary mineralization of neoplastic bone tissue. TEM and SEM studies on 
osteosarcoma. Virchows Archive A. Pathological Anatomy and Histology, 382, 1-9. 
 
Shah, V. N., Bhadada, S. K., Bhansali, A., Behera, A., Mittal, B. R. & Bhavin, V. 2012. Influence 
of age and gender on presentation of symptomatic primary hyperparathyroidism. Journal of 
Postgraduate Medicine, 58, 107-111. 
                                                                                                                                                               References 
 
~ 208 ~ 
 
Sher, R. B., Aoyama, C., Huebsch, K. A., Ji, S., Kerner, J., Yang, Y., Frankel, W. N., Hoppel, C. L., 
Wood, P. A., Vance, D. E. & Cox, G. A. 2006. A Rostrocaudal Muscular Dystrophy Caused by a 
Defect in Choline Kinase Beta, the First Enzyme in Phosphatidylcholine Biosynthesis. Journal 
of Biological Chemistry, 281, 4938-4948. 
 
Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., 
Tomizuka, K. & Yamashita, T. 2004. Targeted ablation of Fgf23 demonstrates an essential 
physiological role of FGF23 in phosphate and vitamin D metabolism. Journal of Clinical 
Investigation, 113, 561-8. 
 
Shore, E. M., Xu, M., Feldman, G. J., Fenstermacher, D. A., Cho, T.-J., Choi, I. H., Connor, J. M., 
Delai, P., Glaser, D. L., Lemerrer, M., Morhart, R., Rogers, J. G., Smith, R., Triffitt, J. T., 
Urtizberea, J. A., Zasloff, M., Brown, M. A. & Kaplan, F. S. 2006. A recurrent mutation in the 
BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans 
progressiva. Nature Genetics, 38, 525-527. 
 
Silva, B. C. & Bilezikian, J. P. 2015. Parathyroid hormone: anabolic and catabolic actions on 
the skeleton. Current Opinion in Pharmacology, 22, 41-50. 
 
Silva, B. C. & Kousteni, S. 2015. Chapter 8 - Cellular Actions of PTH: Osteoblasts, Osteoclasts, 
and Osteocytes A2 - Bilezikian, John P. The Parathyroids (Third Edition). San Diego: Academic 
Press. 
 
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Lüthy, R., Nguyen, H. Q., 
Wooden, S., Bennett, L., Boone, T., Shimamoto, G., Derose, M., Elliott, R., Colombero, A., Tan, 
H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., 
Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R. & Boyle, W. J. 
1997. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density. 
Cell, 89, 309-319. 
 
Sisca, R. F. & Provenza, D. V. 1972. Initial dentin formation in human deciduous teeth. An 
electron microscope study. Calcified Tissue Research, 9, 1-16. 
 
Sommerfeldt, D. W. & Rubin, C. T. 2001. Biology of bone and how it orchestrates the form 
and function of the skeleton. European Spine Journal, 10 Suppl 2, S86-95. 
 
Sousa, S. B., Jenkins, D., Chanudet, E., Tasseva, G., Ishida, M., Anderson, G., Docker, J., Ryten, 
M., Sa, J., Saraiva, J. M., Barnicoat, A., Scott, R., Calder, A., Wattanasirichaigoon, D., 
Chrzanowska, K., Simandlová, M., Van Maldergem, L., Stanier, P., Beales, P. L., Vance, J. E. & 
Moore, G. E. 2014. Gain-of-function mutations in the phosphatidylserine synthase 1 (PTDSS1) 
gene cause Lenz-Majewski syndrome. Nature Genetics, 46, 70-76. 
 
Speer, M. Y., Mckee, M. D., Guldberg, R. E., Liaw, L., Yang, H. Y., Tung, E., Karsenty, G. & 
Giachelli, C. M. 2002. Inactivation of the osteopontin gene enhances vascular calcification of 
matrix Gla protein-deficient mice: Evidence for osteopontin as an inducible inhibitor of 
vascular calcification in vivo. Journal of Experimental Medicine, 196, 1047-1055. 
 
St John, H. C., Meyer, M. B., Benkusky, N. A., Carlson, A. H., Prideaux, M., Bonewald, L. F. & 
Pike, J. W. 2015. The parathyroid hormone-regulated transcriptome in osteocytes: Parallel 
                                                                                                                                                               References 
 
~ 209 ~ 
 
actions with 1,25-dihydroxyvitamin D-3 to oppose gene expression changes during 
differentiation and to promote mature cell function. Bone, 72, 81-91. 
 
Staines, K. A., Mackenzie, N. C. W., Clarkin, C. E., Zelenchuk, L., Rowe, P. S., Macrae, V. E. & 
Farquharson, C. 2012. MEPE is a novel regulator of growth plate cartilage mineralization. 
Bone, 51, 418-430. 
 
Staines, K. A., Prideaux, M., Allen, S., Buttle, D. J., Pitsillides, A. A. & Farquharson, C. 2016. 
E11/Podoplanin Protein Stabilization Through Inhibition of the Proteasome Promotes 
Osteocyte Differentiation in Murine in Vitro Models. Journal of Cellular Physiology, 231, 
1392-1404. 
 
Stenbeck, G. & Horton, M. A. 2004. Endocytic trafficking in actively resorbing osteoclasts. 
Journal of Cell Science, 117, 827-836. 
 
Stern, P. H. & Vance, D. E. 1987. Phosphatidylcholine metabolism in neonatal mouse calvaria. 
Biochemical Journal, 244, 409-415. 
 
Stewart, A. J., Schmid, R., Blindauer, C. A., Paisey, S. J. & Farquharson, C. 2003. Comparative 
modelling of human PHOSPHO1 reveals a new group of phosphatases within the haloacid 
dehalogenase superfamily. Protein Engineering, 16, 889-895. 
 
Stewart, A. J., Roberts, S. J., Seawright, E., Davey, M. G., Fleming, R. H. & Farquharson, C. 
2006. The presence of PHOSPHO1 in matrix vesicles and its developmental expression prior 
to skeletal mineralization. Bone, 39, 1000-1007. 
 
Stoffel, W., Jenke, B., Block, B., Zumbansen, M. & Koebke, J. 2005. Neutral sphingomyelinase 
2 (smpd3) in the control of postnatal growth and development. Proceedings of the National 
Academy of Sciences, 102, 4554-4559. 
 
Stoffel, W., Jenke, B., Holz, B., Binczek, E., Guenter, R. H., Knifka, J., Koebke, J. & Niehoff, A. 
2007. Neutral sphingomyelinase (SMPD3) deficiency causes a novel form of chondrodysplasia 
and dwarfism that is rescued by Col2A1-driven smpd3 transgene expression. American 
Journal of Pathology, 171, 153-161. 
 
Sudo, H., Kodama, H. A., Amagai, Y., Yamamoto, S. & Kasai, S. 1983. In vitro differentiation 
and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. 
Journal of Cellular Biology, 96, 191-198. 
 
Sugiyama, T., Saxon, L. K., Zaman, G., Moustafa, A., Sunters, A., Price, J. S. & Lanyon, L. E. 
2008. Mechanical loading enhances the anabolic effects of intermittent parathyroid 
hormone (1–34) on trabecular and cortical bone in mice. Bone, 43, 238-248. 
 
Suzuki, A., Ghayor, C., Guicheux, J., Magne, D., Quillard, S., Kakita, A., Ono, Y., Miura, Y., Oiso, 
Y., Itoh, M. & Caverzasio, J. 2006. Enhanced expression of the inorganic phosphate 
transporter Pit-1 is involved in BMP-2-Induced matrix mineralization in osteoblast-like cells. 
Journal of Bone and Mineral Research, 21, 674-683. 
 
                                                                                                                                                               References 
 
~ 210 ~ 
 
Targownik, L. E., Lix, L. M., Metge, C. J., Prior, H. J., Leung, S. & Leslie, W. D. 2008. Use of 
proton pump inhibitors and risk of osteoporosis-related fractures. Canadian Medical 
Association Journal, 179, 319-26. 
 
Teitelbaum, S. L. 2000. Bone Resorption by Osteoclasts. Science, 289, 1504-1508. 
 
Terakado, A., Tagawa, M., Goto, S., Yamazaki, M., Moriya, H. & Fujimura, S. 1995. Elevation 
of alkaline phosphatase activity induced by parathyroid hormone in osteoblast-like cells from 
the spinal hyperostotic mouse TWY (twy/twy). Calcified Tissue International, 56, 135-139. 
 
Terkeltaub, R. 2006. Physiologic and pathologic functions of the NPP nucleotide 
pyrophosphatase/phosphodiesterase family focusing on NPP1 in calcification. Purinergic 
Signalling, 2, 371-377. 
 
Thouverey, C., Malinowska, A., Balcerzak, M., Strzelecka-Kiliszek, A., Buchet, R., Dadlez, M. & 
Pikula, S. 2011. Proteomic characterization of biogenesis and functions of matrix vesicles 
released from mineralizing human osteoblast-like cells. Journal of Proteomics, 74, 1123-1134. 
Thouverey, C., Strzelecka-Kiliszek, A., Balcerzak, M., Buchet, R. & Pikula, S. 2009. Matrix 
vesicles originate from apical membrane microvilli of mineralizing osteoblast-like Saos-2 
cells. Journal of Cellular Biochemistry, 106, 127-138. 
 
Tintut, Y., Parhami, F., Le, V., Karsenty, G. & Demer, L. L. 1999. Inhibition of Osteoblast-
specific Transcription Factor Cbfa1 by the cAMP Pathway in Osteoblastic Cells: 
Ubiquitin/Proteosome-dependent regulation. Journal of Biological Chemistry, 274, 28875-
28879. 
 
Uchida, T. 1994. Regulation of choline kinase r: Analyses of alternatively spliced choline 
kinases and the promoter region. Journal of Biochemistry, 116, 508-518. 
 
Ueno, Y., Shinki, T., Nagai, Y., Murayama, H., Fujii, K. & Suda, T. 2003. In vivo administration 
of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of 
thyroparathyroidectomized rats constantly infused with PTH. Journal of Cellular 
Biochemistry, 90, 267-77. 
 
Uzawa, T., Hori, M., Ejiri, S. & Ozawa, H. 1995. Comparison of the effects of intermittent and 
continuous administration of human parathyroid hormone(1–34) on rat bone. Bone, 16, 477-
484. 
 
Valentin-Opran, A., Wozney, J., Csimma, C., Lilly, L. & Riedel, G. E. 2002. Clinical evaluation of 
recombinant human bone morphogenetic protein-2. Clin Orthop Relat Res, 110-20. 
 
Van Der Horst, G., Farih-Sips, H., Lowik, C. & Karperien, M. 2005. Multiple mechanisms are 
involved in inhibition of osteoblast differentiation by PTHrP and PTH in KS483 cells. Journal 
of Bone and Mineral Research, 20, 2233-2244. 
 
Vestergaard, P., Rejnmark, L. & Mosekilde, L. 2006. Proton pump inhibitors, histamine H2 
receptor antagonists, and other antacid medications and the risk of fracture. Calcified Tissue 
Interntional, 79, 76-83. 
 
                                                                                                                                                               References 
 
~ 211 ~ 
 
Walsh, J. S. 2015. Normal bone physiology, remodelling and its hormonal regulation. Surgery 
(Oxford), 33, 1-6. 
 
Wan, M., Yang, C. Z., Li, J., Wu, X. W., Yuan, H. L., Ma, H. R., He, X., Nie, S. Y., Chang, C. B. & 
Cao, X. 2008. Parathyroid hormone signaling through low-density lipoprotein-related protein 
6. Genes & Development, 22, 2968-2979. 
 
Wang, D., Christensen, K., Chawla, K., Xiao, G. Z., Krebsbach, P. H. & Franceschi, R. T. 1999. 
Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and 
in vivo differentiation mineralization potential. Journal of Bone and Mineral Research, 14, 
893-903. 
 
Wang, W., Xu, J., Du, B. & Kirsch, T. 2005. Role of the Progressive Ankylosis Gene (ank) in 
Cartilage Mineralization. Molecular and Cellular Biology, 25, 312-323. 
 
Wang, Y., Ho, C. C., Bang, E., Rejon, C. A., Libasci, V., Pertchenko, P., Hébert, T. E. & Bernard, 
D. J. 2014. Bone Morphogenetic Protein 2 Stimulates Noncanonical SMAD2/3 Signaling via 
the BMP Type 1A Receptor in Gonadotrope-Like Cells: Implications for FSH Synthesis. 
Endocrinology, 155, 1970-1981. 
 
Weiss, M. J., Cole, D. E., Ray, K., Whyte, M. P., Lafferty, M. A., Mulivor, R. A. & Harris, H. 1988. 
A missense mutation in the human liver/bone/kidney alkaline phosphatase gene causing a 
lethal form of hypophosphatasia. Proceedings of the National Academy of Sciences, 85, 7666-
7669. 
 
White, A. P., Vaccaro, A. R., Hall, J. A., Whang, P. G., Friel, B. C. & Mckee, M. D. 2007. Clinical 
applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. International 
Orthopaedics, 31, 735-41. 
 
Whyte, M. P. 2010. Physiological role of alkaline phosphatase explored in hypophosphatasia. 
In: ZAIDI, M. (ed.) Skeletal Biology and Medicine. 
 
Whyte, M. P., Zhang, F., Wenkert, D., Mcalister, W. H., Mack, K. E., Benigno, M. C., Coburn, 
S. P., Wagy, S., Griffin, D. M., Ericson, K. L. & Mumm, S. 2015. Hypophosphatasia: Validation 
and expansion of the clinical nosology for children from 25 years experience with 173 
pediatric patients. Bone, 75, 229-239. 
 
Williams, G. R. 2013. Thyroid Hormone Actions in Cartilage and Bone. European Thyroid 
Journal, 2, 3-13. 
 
Wolf, M., Jaeger, A., Abuduwali, N., Goetz, W. & Lossdoerfer, S. 2013. Continuous PTH 
modulates alkaline phosphatase activity in human PDL cells via protein kinase C dependent 
pathways in vitro. Annals of Anatomy-Anatomischer Anzeiger, 195, 455-460. 
 
Woo, S. M., Rosser, J., Dusevich, V., Kalajzic, I. & Bonewald, L. F. 2011. Cell Line IDG-SW3 
Replicates Osteoblast-to-Late-Osteocyte Differentiation In Vitro and Accelerates Bone 
Formation In Vivo. Journal of Bone and Mineral Research, 26, 2634-2646. 
 
                                                                                                                                                               References 
 
~ 212 ~ 
 
Wu, G., Aoyama, C., Young, S. G. & Vance, D. E. 2008. Early Embryonic Lethality Caused by 
Disruption of the Gene for Choline Kinase α, the First Enzyme in Phosphatidylcholine 
Biosynthesis. Journal of Biological Chemistry, 283, 1456-1462. 
 
Wu, G., Sher, R. B., Cox, G. A. & Vance, D. E. 2010. Differential expression of choline kinase 
isoforms in skeletal muscle explains the phenotypic variability in the rostrocaudal muscular 
dystrophy mouse. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 
1801, 446-454. 
 
Wu, L. N. Y., Genge, B. R., Kang, M. W., Arsenault, A. L. & Wuthier, R. E. 2002. Changes in 
phospholipid extractability and composition accompany mineralization of chicken growth 
plate cartilage matrix vesicles. Journal of Biological Chemistry, 277, 5126-5133. 
 
Wu, L. N. Y., Genge, B. R. & Wuthier, R. E. 2009. Differential effects of zinc and magnesium 
ions on mineralization activity of phosphatidylserine calcium phosphate complexes. Journal 
of Inorganic Biochemistry, 103, 948-962. 
 
Wuthier, R. E. & Lipscomb, G. F. 2011. Matrix vesicles: structure, composition, formation and 
function in calcification. Frontiers in Bioscience, 16, 2812-+. 
 
Xiao, Y. T., Xiang, L. X. & Shao, J. Z. 2007. Bone morphogenetic protein. Biochemical and 
Biophysical Research Communications, 362, 550-3. 
 
Xiao, Z., Blonder, J., Zhou, M. & Veenstra, T. D. 2009. Proteomic analysis of extracellular 
matrix and vesicles. Journal of Proteomics, 72, 34-45. 
 
Yadav, M. C., Simao, A. M. S., Narisawa, S., Huesa, C., Mckee, M. D., Farquharson, C. & Millan, 
J. L. 2011. Loss of Skeletal Mineralization by the Simultaneous Ablation of PHOSPHO1 and 
Alkaline Phosphatase Function: A Unified Model of the Mechanisms of Initiation of Skeletal 
Calcification. Journal of Bone and Mineral Research, 26, 286-297. 
 
Yadav, M. C., De Oliveira, R. C., Foster, B. L., Fong, H., Cory, E., Narisawa, S., Sah, R. L., 
Somerman, M., Whyte, M. P. & Millan, J. L. 2012. Enzyme replacement prevents enamel 
defects in hypophosphatasia mice. Journal of Bone and Mineral Research, 27, 1722-1734. 
 
Yadav, M. C., Huesa, C., Narisawa, S., Hoylaerts, M. F., Moreau, A., Farquharson, C. & Millan, 
J. L. 2014. Ablation of osteopontin improves the skeletal phenotype of phospho1(-/-) mice. 
Journal of Bone and Mineral Research, 29, 2369-81. 
 
Yadav, M. C., Bottini, M., Cory, E., Bhattacharya, K., Kuss, P., Narisawa, S., Sah, R. L., Beck, L., 
Fadeel, B., Farquharson, C. & Millán, J. L. 2016. Skeletal Mineralization Deficits and Impaired 
Biogenesis and Function of Chondrocyte-Derived Matrix Vesicles in Phospho1-/- and 
Phospho1/Pit1 Double Knockout Mice. Journal of Bone and Mineral Research, n/a-n/a. 
 
Yamashita, T., Takahashi, N. & Udagawa, N. 2012. New roles of osteoblasts involved in 
osteoclast differentiation. World Journal of Orthopedics, 3, 175-181. 
 
Yang, Y. X., Lewis, J. D., Epstein, S. & Metz, D. C. 2006. Long-term proton pump inhibitor 
therapy and risk of hip fracture. Journal of the American Medical Association, 296, 2947-53. 
                                                                                                                                                               References 
 
~ 213 ~ 
 
Yee, J. A. 1985. Stimulation of alkaline phosphatase activity in cultured neonatal mouse 
calvarial bone cells by parathyroid hormone. Calcified Tissue International, 37, 530-538. 
 
Yoshiko, Y., Candeliere, G. A., Maeda, N. & Aubin, J. E. 2007. Osteoblast Autonomous Pi 
Regulation via Pit1 Plays a Role in Bone Mineralization. Molecular and Cellular Biology, 27, 
4465-4474. 
 
Zaidi, M., Blair, H. C., Moonga, B. S., Abe, E. & Huang, C. L. H. 2003. Osteoclastogenesis, Bone 
Resorption, and Osteoclast-Based Therapeutics. Journal of Bone and Mineral Research, 18, 
599-609. 
 
Zerega, B., Cermelli, S., Bianco, P., Cancedda, R. & Cancedda, F. D. 1999. Parathyroid hormone 
PTH(1-34) and parathyroid hormone-related protein PTHrP(1-34) promote reversion of 
hypertrophic chondrocytes to a prehypertrophic proliferating phenotype and prevent 
terminal differentiation of osteoblast-like cells. Journal of Bone and Mineral Research, 14, 
1281-1289. 
 
Zhu, D., Mackenzie, N. C., Shanahan, C. M., Shroff, R. C., Farquharson, C. & Macrae, V. E. 
2015. BMP-9 regulates the osteoblastic differentiation and calcification of vascular smooth 
muscle cells through an ALK1 mediated pathway. Journal of Cellular and Molecular Medicine, 
19, 165-74. 
 
Zhu, W., Chen, T., Ding, S., Yang, G., Xu, Z., Xu, K., Zhang, S., Ma, T. & Zhang, J. 2016. 
Metabolomic study of the bone trabecula of osteonecrosis femoral head patients based on 
UPLC–MS/MS. Metabolomics, 12, 1-14. 
 
Zweifler, L. E., Ao, M., Yadav, M., Kuss, P., Narisawa, S., Kolli, T. N., Wimer, H. F., Farquharson, 
C., Somerman, M. J., Millan, J. L. & Foster, B. L. 2016. Role of PHOSPHO1 in Periodontal 
Development and Function. Journal of Dental Research, 95, 742-51. 
                                                                                                                                                                  Appendix 
















Appendix I                                                                                                                            Buffers and solutions 
~ 215 ~ 
 
 
Appendix I – Buffers and solutions 
Cell and organ culture media 
Maintenance medium  
αMEM supplemented with 10% foetal bovine serum (FBS) and 0.05mg/mL 
gentamicin. 
  
MC3T3 mineralisation medium  
αMEM supplemented with: 10% FBS; 0.05mg/mL gentamicin; 50µg/mL L-ascorbic 
acid; 1.5mM calcium chloride. 
 
Primary osteoblast mineralisation medium  
αMEM supplemented with: 10% FBS; 0.05mg/mL gentamicin; 50µg/mL L-ascorbic 
acid; 6.0mM calcium chloride. 
 
Human osteoblast culture medium  
DMEM supplemented with: 20% FBS; 0.6mg/mL L-glutamine; 100U/mL / 
100µg/mL penicillin-streptomycin; 1.25μg/ml fungizone. 
 
IDG-SW3 proliferation medium 
αMEM supplemented with: 10% FBS; 0.05mg/mL gentamicin; 25U/mL recombinant 
mouse Interferon-γ. 
 
IDG-SW3 differentiation medium  
αMEM supplemented with: 10% FBS; 0.05mg/mL gentamicin; 50µg/mL L-ascorbic 
acid; 4mM βGP. 
 
Metatarsal preparation medium  
0.8ml αMEM medium (without ribonucleosides), 10.45ml sterile PBS, 22.5mg BSA 
(Fraction V)  
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Metatarsal culture medium/ Calvariae culture media 
αMEM medium (without ribonucleosides) supplemented with: 0.2% w/v BSA 








1.92g/L citric acid in dH2O at pH 6.0 
 
Western Blotting  
RIPA buffer 
20mM Tris-HCl (pH8), 135mM NaCl, 10% Glycerol, 1% IGEPAL, 0.1% SDS, 0.5% 
Na Deoxycholate, 2mM EDTA  
 
LDS Sample reducing agent  
40% glycerol, 4% LDS, 4% Ficoll*-400, 0.8 M triethanolamine-Cl pH 7.6, 0.025% 
phenol red, 0.025% coomassie G250, 2mM EDTA disodium 
 
1X Transfer buffer 
100ml 10X transfer buffer, 200ml 98% Ethanol, 700ml dH2O.  
 
10X Transfer buffer 
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MOPS running buffer  
5% v/v MOPS (50mM MOPS, 50mM Tris, 0.1% SDS, 1mM EDTA, pH 7.7) in 
dH2O 
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Appendix II - qPCR primers 
Gene Source   Sequence (5'-3') 








Smpd3 MWG Eurofins 
F CTAACCACCCACTCCCACTT 
R CCAATAGACTCCAAACCTGAAGA 
Alpl MWG Eurofins 
F GGGACGAATCTCAGGGTACA 
R AGTAACTGGGGTCTCTCTCTTT 
Chkα Primer Design 
F TTCTCATTTCGGATGCCAACA 
R TGAGGATGCGGCGGAATAA 
Chkβ Primer Design 
F GATGCCACTAGAGCGAGAAG 
R TCAGAAGTTACGAGACAAGACC 
Enpp1 MWG Eurofins 
F GCTAATCATCAGGAGGTCAAG 
R GCTAATCATCAGGAGGTCAAG 
Pth1r MWG Eurofins 
F CCAACCCTAAGCATCCCAAA 
R TCCTCGGAGACTGGTAATGG 
Runx2 MWG Eurofins 
F TTCTTCACACGCATTCCATCT 
R GCCAACAGTAAAGTCACAATCC 
Sp7 MWG Eurofins 
F CGGTTTGGGTCAGACGATG 
R GCTTGCCTTTCTTCTTCTTC 
Atf4 MWG Eurofins 
F ACTGGTATTTGAGGATTTTGCTAAC 
R TGTTGTTGACGGTAACTGACTC 
Sost Primer Design 
F ATACCACAATACTGAATCTGAAAGC 
R CACTATTTGCCTGTCCCTCTG 
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Gene Source   Sequence (5'-3') 
Atp5b Primer Design 
F Not disclosed 
R Not disclosed 
Gapdh Primer Design 
F Not disclosed 




F Not disclosed 
R Not disclosed 
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Appendix III - Antibodies 
Primary antibodies 
Antibody Species  Source Use Dilution  
PHOSPHO1 Human Abd Serotec, Bio-
Rad 
Western blotting 1:1000 
nSMase2 Rabbit Santa Cruz 
Biotech 








β-actin Rabbit Cell signalling 
technology 
Western blotting 1:1000 
   
Secondary antibodies 
Antibody Source Use Dilution  
Goat anti-rat Dako Immunohistochemistry 1:100 
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Appendix IV – Genotyping 
DNA extraction solutions 
Solution 1 
100mL dH2O, 40µL of 0.5M EDTA, 0.1g NaOH. 
Solution 2 
96mL dH2O, 4mL of 1M Tris, pH 5.5. 
Genotyping primers 
Genotyping assay Source  Sequence (5’-3’) 














Phospho1-/- : T 
Phospho1 genotyping PCR thermal conditions 
1. 94°C for 3 min 
2. (94°C for 30s, 61°C for 30s 72°C for 90s) x 2 
3. (94°C for 30s, 59°C for 30s, 72°C for 30s) x 2 
4. (94°C for 30s, 57°C for 30s, 72°C for 90s) x 2 
5. (94°C for 30s, 55°C for 30s, 72°C for 30s) x 28 
6. 94°C for 30s, 61°C for 30s and 72°C for 10 min 
 
Appendix IV                                                                                                                                           Genotyping 
~ 222 ~ 
 
Restriction digest master mix 
0.15µL BSA (purified, 100x), 1.5µL NEB buffer 2, 2.85µL dH2O, 0.5µL BsrD1 
restriction enzyme 
To 10µL of PCR reaction add 5µL of the restriction digest master mix and incubate 
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Appendix V – Mass spectrometry chromatograms 





































































746.6084 820.3082679.5134 774.5665718.5770644.4278 800.5820 838.5644692.5612664.5298631.1897
NL: 1.31E6
Pos_Metatarsal_WT1#875
-1021  RT: 12.01-13.99  
AV: 147 T: FTMS {1,1}  + 




-1021  RT: 12.00-13.99  
AV: 147 T: FTMS {1,1}  + 
p ESI Full ms 
[250.00-2000.00] 






Appendix V                                                                                                                                                                                                            Mass spectrometry chromatograms 
~ 224 ~ 
 
ii) Sphingomyelins 


















































































1-1095  RT: 13.99-15.01  
AV: 75 T: FTMS {1,1}  + p 




2-1095  RT: 14.01-15.00  
AV: 74 T: FTMS {1,1}  + p 
ESI Full ms 
[250.00-2000.00] 
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iii) Phosphatidylethanolaines/ Lysophosphatidylethanolamines 
 





















































































2-837  RT: 9.51-11.50  
AV: 146 T: FTMS {1,1}  - 




2-837  RT: 9.51-11.50  
AV: 146 T: FTMS {1,1}  - 
p ESI Full ms 
[250.00-2000.00] 
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861.5514733.4287 876.2515692.4525677.4980 759.5197637.4096 655.4437 809.5353
NL: 5.63E4
Neg_Metatarsal_WT1#43
7-655  RT: 6.00-9.00  AV: 
219 T: FTMS {1,1}  - p 




7-655  RT: 6.00-9.00  AV: 
219 T: FTMS {1,1}  - p 
ESI Full ms 
[250.00-2000.00] 
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4-946  RT: 10.50-13.00  
AV: 183 T: FTMS {1,1}  - p 




4-946  RT: 10.50-13.00  
AV: 183 T: FTMS {1,1}  - p 
ESI Full ms 
[250.00-2000.00] 
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9-1382  RT: 14.00-19.00  
AV: 364 T: FTMS {1,1}  - p 




9-1382  RT: 14.00-19.00  
AV: 364 T: FTMS {1,1}  - p 
ESI Full ms 
[250.00-2000.00] 
WT sample 1 
Phospho1
-/- 
sample 1 
